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Abstract 
 
In  Chapter  1,  I  introduce  ischaemic  stroke,  thrombolytic  therapy, 
thrombolysis  trials  and  then  discuss  the  rationale  for  exclusion  criteria  in 
stroke thrombolysis guidelines.   
 
In Chapter 2, I describe methods for examining outcomes in patients that are 
currently  recommended  for  exclusions  from  receiving  alteplase  for  acute 
ischaemic stroke.     
 
In  Chapter  3,  I  examine  Virtual  International  Stroke Trials Archive  (VISTA) 
data to test whether current European recommendation suggesting exclusion 
of  elderly  patients  (older  than  80  years)  from  thrombolysis  for  acute 
ischaemic  stroke  is  justified.  Employing  non randomised  controlled 
comparison of outcomes, I show better outcomes amongst all patients (P < 
0.0001; OR, 1.39; 95% CI, 1.26 to 1.54), young patients (P < 0.0001; OR, 1.42; 
95% CI, 1.26 to 1.59) and the elderly patients (P = 0.002; OR, 1.34; 95% CI, 
1.05 to 1.70). Odds Ratios are consistent across all age deciles > 30 years. 
Outcomes assessed by National Institutes of Health Scale (NIHSS) score and 
dichotomised modified Rankin Scale score are consistently similar.  
 
In  Chapter  4,  I  compare  thrombolysed  patients  in  Safe  Implementation  of 
Thrombolysis in Stroke International Stroke Thrombolysis Register (SITS ISTR) 
with VISTA non thrombolysed patients ("comparators" or "controls") and test 
exactly similar question as in Chapter 3.  Distribution of scores on modified 
Rankin scale are better amongst all thrombolysis patients than controls (odds 
ratio  1.6,  95%  confidence  interval  1.5  to  1.7;  Cochran Mantel Haenszel 
P<0.001).  Association  occurs  independently  amongst  patients  aged  ≤80  (0R 
1.6, 95%CI1.5 to 1.7; P<0.001; n=25,789) and in those aged >80 (OR 1.4, 95% 
CI 1.3 to 1.6; P<0.001; n=3439). Odds ratios are consistent across all 10 year 
age  ranges  above  30,  and  benefit  is  significant  from  age  41  to  90; 
dichotomised outcomes (score on modified Rankin scale 0 1 v 2 6; 0 2 v 3 6; 
and 6 (death) versus rest) are consistent with the results of ordinal analysis. 
These findings are consistent with results from VISTA reported in Chapter 3.                                   15 
 
Age  alone  should  not  be  a  criterion  for  excluding  patients  from  receiving 
thrombolytic therapy. 
 
In  Chapter  5,  I  employ  VISTA  data  to  examine  whether  patients  having 
diabetes and previous stroke have improved outcomes from use of alteplase 
in  acute  ischaemic  stroke.  Employing  a  non randomised  controlled 
comparison, I show that the functional outcomes are better for thrombolysed 
patients  versus  nonthrombolysed  comparators  amongst  non diabetic  (P  < 
0.0001; OR 1.4 [95% CI 1.3 1.6]) and diabetic (P = 0.1; OR 1.3 [95% CI1.05 
1.6])  patients.  Similarly,  outcomes  are  better  for  thrombolysed  versus 
nonthrombolysed patients who have not had a prior stroke (P < 0.0001; OR 
1.4 [95% CI1.2 1.6]) and those who have (P = 0.02; OR 1.3 [95% CI1.04 1.6]). 
There is no interaction of diabetes and prior stroke with treatment (P = 0.8). 
Neurological  outcomes  (NIHSS)  are  consistent  with  functional  outcomes 
(mRS).  
 
In Chapter 6, I undertake a non randomised controlled comparison of SITS 
ISTR data with VISTA controls and examine whether patients having diabetes 
and previous stroke have improved outcomes from use of alteplase in acute 
ischaemic  stroke.  I  show  that  adjusted  mRS  outcomes  are  better  for 
thrombolysed  versus  non thrombolysed  comparators  amongst  patients  with 
diabetes  mellitus  (OR  1.45[95%  CI1.30 1.62],  N=5354),  previous  stroke  (OR 
1.55[95%  CI1.40 1.72],  N=4986),  or  concomitant  diabetes  mellitus  and 
previous  stroke  (OR  1.23  [95%  CI  0.996 1.52],  P=0.05,  N=1136),  all  CMH 
p<0.0001.  These  are  comparable  to  outcomes  between  thrombolysed  and 
non thrombolysed  comparators  amongst  patients  suffering  neither  diabetes 
mellitus nor previous stroke: OR=1.53(95%CI 1.42 1.63), p<0.0001, N=19339. 
There are no interaction between diabetes mellitus and previous stroke with 
alteplase  treatment  (t PA*DM*PS,  p=0.5).  Present  data  supports  results 
obtained from the analyses of VISTA data in chapter 5. There is no statistical 
evidence  to  recommend  exclusion  of  patients  with  diabetes  and  previous 
stroke from receiving alteplase.  
 
In  Chapter  7,  I  examine  VISTA  data  to  test  whether  exclusion  of  patients 
having  a  mild  or  severe  stroke  at  baseline  would  be  justified.  Stratifying                                   16 
 
baseline stroke severity for quintiles of NIHSS scores, I observe that there are 
significant  associations  of  use  of  alteplase  with  improved  outcomes  for 
baseline NIHSS levels from 5 to 24 (p<0.05). This association lose significance 
for baseline NIHSS categories 1 to 4 (P = 0.8; OR, 1.1; 95% CI, 0.3 4.4; N = 
8/161) or ≥ 25 (P = 0.08; OR, 1.1; 95% CI, 0.7 1.9; N = 64/179) when sample 
sizes are small and confidence interval wide. These findings fail to provide 
robust evidence to support the use of alteplase in the mild or severe stroke 
patients, though potential for benefit appears likely. 
 
In Chapter 8, I present a meta analysis of trials that investigated mismatch 
criteria for patients’ selection to examine whether present evidence supports 
delayed  thrombolysis  amongst  patients  selected  according  to  mismatch 
criteria. I collate outcome data for patients who were enrolled after 3 hours 
of  stroke  onset  in  thrombolysis  trials  and  had  mismatch  on  pre treatment 
imaging. I compare favourable outcome, reperfusion and/or recanalisation, 
mortality,  and  symptomatic  intracerebral  haemorrhage  between  the 
thrombolysed and non thrombolysed groups of patients and the probability of 
a favourable outcome among patients with successful reperfusion and clinical 
findings  for  3  to  6  versus  6  to  9  hours  from  post  stroke  onset.  I  identify 
articles  describing  the  DIAS,  DIAS  II,  DEDAS,  DEFUSE,  and  EPITHET  trials, 
giving a total of 502 mismatch patients thrombolysed beyond 3 hours. The 
combined adjusted odds ratios (a ORs) for favourable outcomes are greater 
for patients who had successful reperfusion (a OR=5.2; 95% CI, 3 to 9; I
2=0%). 
Favourable clinical outcomes are not significantly improved by thrombolysis 
(a OR=1.3; 95% CI, 0.8 to 2.0; I
2=20.9%). Odds for reperfusion/recanalisation 
are  increased  amongst  patients  who  received  thrombolytic  therapy  (a 
OR=3.0; 95% CI, 1.6 to 5.8; I
2=25.7%). The combined data show a significant 
increase in mortality after thrombolysis (a OR=2.4; 95% CI, 1.2 to 4.9; I
2=0%), 
but this is not confirmed when I exclude data from desmoteplase doses that 
are abandoned in clinical development (a OR=1.6; 95% CI, 0.7 to 3.7; I
2=0%). 
Symptomatic  intracerebral  haemorrhage  is  significantly  increased  after 
thrombolysis (a OR=6.5; 95% CI, 1.2 to 35.4; I
2=0%) but not significant after 
exclusion of abandoned doses of desmoteplase (a OR=5.4; 95% CI, 0.9 to 31.8; 
I
2=0%).  Delayed  thrombolysis  amongst  patients  selected  according  to 
mismatch  imaging  is  associated  with  increased  reperfusion/recanalisation.                                   17 
 
Recanalisation/reperfusion is associated with improved outcomes. However, 
delayed  thrombolysis  in  mismatch  patients  was  not  confirmed  to  improve 
clinical  outcome,  although  a  useful  clinical  benefit  remains  possible. 
Thrombolysis  carries  a  significant  risk  of  symptomatic  intracerebral 
haemorrhage and possibly increased mortality. Criteria to diagnose mismatch 
are still evolving. Validation of the mismatch selection paradigm is required 
with  a  phase  III  trial.  Pending  these  results,  delayed  treatment,  even 
according to mismatch selection, cannot be recommended as part of routine 
care. 
 
In Chapter 9, I summarise the findings of my research, discuss its impact on 
the  research  community,  and  discuss  weaknesses  inherent in  registry  data 
and limitation of statistical methods. Then, I elaborate the future directions I 
may take to further research on the theme of this thesis.  
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1  Introduction 
1.1 Background 
Stroke is defined as a ‘rapidly developing clinical signs of focal (or global) 
disturbance of cerebral function with symptoms lasting 24 hours or longer or 
leading to death, with no apparent cause other than vascular origin’.
1 It is 
classified into ischaemic stroke and haemorrhagic stroke. Ischaemic stroke 
occurs  after  reduction  in  cerebral  blood  flow  leading  to  loss  of  neuronal 
functions.
2  Symptoms correspond to the vascular territory involved. If hypo 
perfusion  persists,  the  involved  tissue  gradually  undergoes  infarction. 
Haemorrhagic  stroke  occurs  due  to  rupture  of  a  blood  vessel  in  brain 
parenchyma.
3 
Stroke  is  the  third  leading  cause  of  death.
4  Survivors  lead  a  life  that  is 
characterised  by  physical  dependence  and  suffering  due  to  several 
neurological  symptoms  (like  cognitive  decline,  dementia,  depression  or 
seizures).
5 7 Every year approximately 15 million people suffer from stroke. Of 
these,  about  5  million  die  and  another  5  million  are  left  with  residual 
disability.
8 Costs involved in providing curative, preventive and rehabilitative 
measures to these patients are significant.
9,10 The United States of America 
spends about 17 billion dollars a year in caring for these patients.
11,12  For 
example, in 2000, Medicare for Stroke hospitalisations cost $7.04 billion, the 
average being $15,818 per person.
11 Europe is subject to suffer similar major 
costs.
13,14 Developing (emerging) economies are no less affected. Here, stroke 
incidence  is  7 10  times  greater  than  the  developed  countries.
15  Urgent 
measures to control the stroke epidemic are needed.
16 18,19 22  
A patient who presents with an acute onset of ischaemic stroke is offered a 
therapy  called  thrombolytic  therapy.  At  present,  alteplase  is  the  only 
thrombolytic  agent  that  is  licensed  for  use  in  ischaemic  stroke.
23  As  per
 
guidelines, this drug should be given only to a selected group of patients.
23,24  
Table  1.1  shows  that  there  are  differences  in  the  wordings  of 
contraindications  for  alteplase  use  across  different  jurisdictions.
25                                   20 
 
 
 
 
 
 
 
 
 
Figure    1-1Loss  of  Disability  Adjusted  Life  Years  (above)  and  mortality  rate  (below) 
attributed to stroke within European Union (above)  
 
 
Source: www.who.int (Permissions obtained from World Health Organization Press  
WHP  (Permissions Management and Reprint Rights) 20 Avenue Appia,  Office 4152  
CH 1211 Genève 27,  Switzerland; ID number 82115)
13,14  
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Table   1-1  Contraindications to the use of alteplase in acute ischaemic stroke in European Union, United States and Canada 
 
List of contraindications 
European License for t-
PA use in Stroke
23 
United States  
Guidelines
26  Canadian Guidelines
27 
If Brain imaging shows  intracranial 
haemorrhage 
Contraindicated  Contraindicated  Contraindicated 
Age group <18 years or >80 years of age  Contraindicated     
If onset of symptoms occurred >4.5  
hours
1 
Contraindicated  Contraindicated  Contraindicated 
Severe stroke (e.g. NIHSS >25)  Contraindicated     
If patient has a minor deficit or 
symptoms rapidly improving 
Contraindicated  Contraindicated  Contraindicated 
If heparin was given  ≤48 hours ago and  
patient has an elevated APTT 
Contraindicated  Contraindicated  Contraindicated 
                                                
1    Use of rtPA in the time period of 3 to 4.5 hours after stroke has received a Class I Recommendation, Level of Evidence B by the American Heart Association. In these patients, 
exclusion criteria include (a) those that are  employed for treatment in 0-3 hours and (b) those incorporated within ECASS III trial: age > 80 years, patients receiving anticoagulant with 
an INR of >1.7 baseline NIHSS >25 or presence of diabetes mellitus and previous stroke
28.  Del Zoppo GJ, Saver JL, Jauch EC, Adams HP, Jr. Expansion of the time window for 
treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association. Stroke 
2009;40:2945-8.  
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List of contraindications 
European License for t-
PA use in Stroke
23 
United States  
Guidelines
26  Canadian Guidelines
27 
If platelet count ≤100 000/mm3  Contraindicated  Contraindicated  Contraindicated 
If patient is  receiving oral 
anticoagulants 
Contraindicated  and if  INR >1.7, then 
contraindicated 
and if INR >1.7,then 
contraindicated 
If a severe stroke is demonstrated by 
brain imaging 
Contraindicated  Contraindicated in case of  
>1/3 cerebral hemisphere 
Contraindicated in case 
of >1/3 MCA territory 
If seizure occurred  at stroke onset  Contraindicated  Contraindicated  Contraindicated 
If patient has a manifest or recent 
severe or dangerous bleeding 
Contraindicated  If it occured in prior 21 
days, then alteplase is 
contraindicated 
If it occured in prior 21 
days, then alteplase is 
contraindicated 
If there is a history of intracranial 
haemorrhage 
Contraindicated  Contraindicated  Contraindicated 
If there is a suspected subarachnoid 
haemorrhage 
Contraindicated  Contraindicated  Contraindicated 
Prior stroke within the last 3 months  Contraindicated  Contraindicated  Contraindicated 
Bacterial endocarditis  Contraindicated     
Myocardial infarction in the past 3 
months 
  Contraindicated  Contraindicated  
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List of contraindications 
European License for t-
PA use in Stroke
23 
United States  
Guidelines
26  Canadian Guidelines
27 
Pericarditis  Contraindicated    If post myocardial, then 
t PA is contraindicated 
If patient has a history of recent 
puncture of a non compressible blood 
vessel 
Contraindicated  If in past 7 days, then t PA 
is contraindicated 
If in past 7 days, then t 
PA is contraindicated. 
If patient underwent a major surgery  If in past 3 months, t PA 
is contraindicated 
If in past 14 days, then t 
PA is contraindicated 
If in past 14 days, t PA 
is contraindicated. 
If patient’s systolic blood pressure >185 
or diastolic >110 mm Hg or if there is a 
need of aggressive management to 
reduce blood pressure to these limits 
t PA is contraindicated  t PA  is contraindicated  t PA is contraindicated 
Prior stroke and concomitant diabetes  Contraindicated     
Intracranial neoplasm, arteriovenous 
malformation, or aneurysm 
Any history of CNS 
damage, then t PA is 
contraindicated 
t PA is contraindicated  t PA is contraindicated 
If patient suffered a significant trauma 
in past 3 months 
contraindicated  If head trauma, t PA is 
contraindicated 
If head trauma, t PA is 
contraindicated  
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List of contraindications 
European License for t-
PA use in Stroke
23 
United States  
Guidelines
26  Canadian Guidelines
27 
Acute pancreatitis  Contraindicated     
Blood glucose levels (mmol/L)  Contraindicated if levels 
are <2.7 or >22.2 
Contraindicated if levels 
are <2.7 
Contraindicated if 
levels are <3 or >22 
Ulcerative gastrointestinal disease 
during the last 3 months, oesophageal 
varices, arterial aneurysm, 
arterial/venous malformations 
Contraindicated     
History of Obstetrical delivery  Contraindicated     
Neoplasm with increased bleeding risk  Contraindicated     
Severe liver disease, including hepatic 
failure, cirrhosis, portal hypertension 
(oesophageal varices) and active 
hepatitis 
Contraindicated     
Recent (<10 days) traumatic external 
heart massage 
Contraindicated     
Other illness that could limit 
effectiveness or increase risk of 
    Contraindicated  
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List of contraindications 
European License for t-
PA use in Stroke
23 
United States  
Guidelines
26  Canadian Guidelines
27 
bleeding in the judgment of the 
physician 
 
Adapted from Jacques De Keyser, Zuzana Gdovinová, Maarten Uyttenboogaart, Patrick C. Vroomen, Gert Jan Luijckx Intravenous Alteplase for Stroke: Beyond the 
Guidelines and in Particular Clinical Situations, Stroke 2007 38(9):2612 2618 (Permissions obtained from Wolters Kluwer Health, License Number 2783781278803)
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1.2 Pathophysiology of Ischaemic Stroke 
Ischaemic  stroke  occurs  following  occlusion  of  vessel(s)  that  supply  blood  to 
brain tissue. Clots destined to occlude the cerebral blood vessel originate either 
in circulation and then reach the brain vessels, e.g., from an artery or heart in 
case of artery to artery embolism or cardio embolism respectively, or develop 
locally  (like  an  atheroma)  and  reduce  the  distal  cerebral  blood  flow  (e.g., 
following arterial stenosis due to the occlusion of arteries or the arterioles).
3   
Occlusion  of  the  brain  vessels  results  in  an  abrupt  reduction  of  cerebral 
perfusion which then results a mismatch of the brain’s requirement of oxygen 
and the amount that is actually available.
29  
Normal rate of blood flow in grey matter is 0.8 ml/g/minute. Brain functions are 
preserved as long as blood flows at a rate above 0.25 ml/g/minute. When it falls 
below 0.15 ml/g/minute, neurons enter a phase of irreversible morphological 
change leading to their death.
29,30 As a result, at stroke onset, there is often an 
ischaemic core (that is irreversibly damaged) which is surrounded by an area of 
hypo perfused brain parenchyma (“penumbra”; that is not yet infarcted). The 
penumbra is an ischaemic tissue that is functionally impaired and is likely to 
undergo an infarction if it is not salvaged before  a certain duration by using 
reperfusion or/and other strategies. If it is not salvaged, penumbra undergoes 
progressive recruitment into  an infarct core. In  a  time dependent manner, it 
expands and approximates the maximal volume that was originally at risk.
29,30 
Penumbra may derive some blood supply from surrounding collateral circulation, 
such as the Circle of Willis, ophthalmic artery or the leptomeningeal arteries. 
However,  because  these  patients  differ  in  the  amount  of  possible  collateral 
circulation,  a  similar  degree/type  of  occlusion  of  brain  vessels  leads  to  a 
variable amount of ischaemic insult. Penumbra is present in most patients until 3 
hours  of  stroke  onset,  and  then,  the  proportion  of  patients  with  penumbra 
diminishes to about 40% by 23 hours.
31 
Cerebral  ischaemia  also  results  in  a  time dependent  cascade  of  events  at 
molecular level leading to cell death.
32  
  Nishant Kumar Mishra, 2011    Chapter 1, 27 
 
 
1.3 Preclinical studies on thrombolytic therapy for acute 
ischaemic stroke 
Meyer et al showed successful thrombolysis in embolic stroke models of cats and 
monkeys. 
33  They used intravenous or intra arterial bovine or human plasmin for 
thrombolysis. 
33  Here,  the  thrombolysis  was  not  associated  with  excess 
haemorrhagic infarctions.
33  
 
Del  Zoppo  studied  neurological  outcomes  (defined  by  a  neurological  function 
measured  quantitatively  by  employing  a  neurologic  scale,  computerised 
tomography  based  estimation  of  cerebral  infarction  volume  and  carotid 
angiography) after the intracarotid administration of urokinase in baboons that 
suffered  stroke  in  the  right  corpus  striatum. 
34  In  these  models,  stroke  was 
induced  by  compression  of  the  right  middle  cerebral  artery  (just  before  the 
branching of the lenticulostriate arteries) lasting 3 hours. Also, six animals were 
employed as concurrent untreated controls. 
34 The controls underwent occlusion 
of middle cerebral artery but did not receive the urokinase infusion. 
34The study 
demonstrated improved neurologic outcomes and reduction in infarction volume 
amongst  those  baboons  that  received  urokinase  compared  to  those  that  did 
not.
34 The study was significant because it showed that “thrombolytic therapy 
given  within  3  hours  of  experimental  thrombotic  occlusion  may  salvage 
neurologic  function  and  reduce  cerebral  infarction  volume  without  CT  scan 
detectable intracranial bleeding.” 
34 
 
Zivin et al studied neurological outcomes in embolic stroke models of rabbits 
that were first injected with numerous small clots in their carotids and then 
given tissue plasminogen activator. 
35  Use of tissue plasminogen activator was 
associated with significant improvement in neurological outcomes. 
35   Further, it 
was also shown that the concentrations used in in vitro lysis of clots were similar 
to those that were anticipated in vivo situations. 
35   No haemorrhages related to 
the use of the drug were seen. 
35   In summary, the study showed that the tissue 
plasminogen activator could be used early after the stroke onset.
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Experiments indicated that the use of thrombolytic therapy was associated with 
excess haemorrhages if thrombolysis was given in delayed time after the stroke 
onset; and the rates were lower if it was given within 3.5 hours.
36,37 But, Lyden 
et  al  showed  that  there  were  no  differences  in  the  rates  of  cerebral 
haemorrhage if rabbits were thrombolysed with alteplase at 10 minutes, 8 hours 
or 24 hours.
38 Therefore, they concluded that “tPA treatment successfully causes 
thrombolysis of cerebral emboli without causing an increase in the incidence of 
cerebral haemorrhage in rabbits”. 
38 Later, Lyden et al also showed that the 
streptokinase (and not the t PA) was associated with significantly higher rates 
(and also size) of ICH. 
39  Sundt et al showed that ischaemia could be tolerated 
for 3 hours, and maybe longer and vascular occlusion did not immediately lead 
to death of all neurons fed by the supplying artery. 
40 Similarly, Harvey et al 
showed that in case of monkeys, it takes about 50 minutes for ischaemia to last 
so that it leads to the infarction of the entirely affected parenchyma.
41 
 
These  preclinical  experiments  indicated  that  the use  of  thrombolytic  therapy 
was an option to treat ischaemic stroke patients, and that the treatment should 
be offered as soon as possible after the onset of cerebral ischaemia. Therefore, 
when Brott et al
42 undertook to pursue a dose finding study for t PA in humans, 
they decided to treat patients as soon as possible. 
  
1.4 Thrombolytic therapy in acute ischaemic stroke 
From  the  previous  discussion,  it  is  apparent  that  recruitment  of  ischaemic 
penumbra into the core of cerebral ischaemia progresses in a time dependent 
manner.
29,32,40,41 If this progression is to be halted, a logical treatment would be 
to achieve rapid reperfusion of ischaemic tissue before it gets fully infarcted. By 
achieving this, one expects to see better outcomes in these patients.  
1.5 Thrombolytic agents  
Thrombolytic agents include recombinant tissue plasminogen activator (rt PA), 
desmoteplase,  urokinase,  anisoylated  plasminogen  streptokinase  activator Nishant Kumar Mishra, 2011    Chapter 1, 29 
 
complex,  staphylokinase,  streptokinase,  recombinant  pro Urokinase  and 
tenecteplase.
43  
Amongst these, only rt PA, also referred to as alteplase, activase or actilyse, is 
licensed for use in acute ischaemic stroke.
23  
Some physicians also use desmoteplase, urokinase or alteplase in an extended 
time window based on their local experience or in the settings of clinical trial.
44 
47  Streptokinase  was  investigated  in  the  past  and  the  trials  had  to  be 
prematurely  terminated  because  the  drug  was  associated  with  excess 
complications.
48 50 To date, alteplase is the only thrombolytic agent that has a 
proven efficacy in patients suffering acute ischaemic stroke; desmoteplase has 
potential, and is being investigated in delayed time windows. 
1.5.1 Tissue Plasminogen Activator (t-PA) 
Tissue  Plasminogen  Activator  (t PA)  is  an  endogenous  fibrin  specific  serine 
protease  that  releases  plasmin  from  plasminogen  by  lysing  arginine valine 
bond.
51 In addition to a thrombolytic effect, t PA also has various pleiotropic 
effects:  excitotoxicity,
52,53  proteolysis  of  extracellular  matrix  (  contributes  in  
neuronal  migration,  e.g.  by  neurite  and  axonal  extension),
54 57  long  term 
potentiation (enhanced memory formation),
58 61 vasoactive effect (vasodilation 
at lower concentrations of t PA and vice versa),
62, 
63 and enhanced expression of 
metalloproteinases (like MMP 9).
64 71   
Before stroke physicians began to use it, alteplase was already in use for the 
treatment of acute myocardial infarction (AMI). A clot can occlude the coronary 
arteries  and  lead  to  AMI.  Thrombolytic  agents  are  used  in  these  patients  to 
recanalise the occluded blood vessels.. Patients that suffer AMI are treated with 
either  a  3-hour  infusion  regimen
72 75  or  an  accelerated  regimen.
76 78      In  the 
former regimen, a dose of 100mg (6 10% of dose administered bolus, followed by 
50 54% as infusion over one hour and then 20% over each succeeding hour) is 
given to the patients (Dose is 1.25 mg/kg if the patients weight is less than 65 
kg).
72 75 In case of the latter regimen, dose is 100mg for those weighing more 
than 67 kg (15mg intra venous bolus, then 50mg in half an hour infusion and then 
35mg over the next hour).
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used is 15mg bolus, then  0.75 mg/kg in half an hour infusion and finally 0.5 
mg/kg during next one hour.
77,78  In case of AMI, aim of the thrombolytic therapy 
is to achieve recanalisation of the coronaries and salvage the ischaemic cardiac 
parenchyma. This leads to improved outcomes.
23 
Hoping  for  a  similar  phenomenon  to  occur  in  ischaemic  stroke  patients  and 
guided  by  findings  from  animal  models  (see  section  1.5)  NINDS  investigators 
initiated dose finding studies  for t PA in ischaemic stroke patients (NINDS pilot 
study part 1 and part 2).
79 In part 1 of the study, 74 patients were investigated 
within 90 minutes of symptoms onset after the administration of alteplase in 
doses ranging from 0.35 mg/kg (maximum dose of 25 mg) to 1.08 mg/kg. Here, 
none of the 58 patients treated with a dose </= 0.85 mg/kg developed cerebral 
haematoma.
42 In part 2 of study, patients were treated between 90 minutes and 
180 minutes of symptoms onset with alteplase at a dose of 0.6 mg/kg (maximum 
dose:  60  mg,  N=8),  0.85  mg/kg  (maximum  dose:  90  mg,  N=6)  or 0.95  mg/kg 
(maximum dose: 90 mg, N=6). Here, the risk of cerebral haematoma was 17% for 
patients receiving a dose >/=0.85 mg/kg.
80   
1.5.2 Urokinase (u-PA) 
Urokinase is a trypsin like enzyme that is produced in the kidney and excreted in 
human urine. It acts as a plasminogen activator (Molecular Weight 54000). 
81 84  
Several investigators have examined outcomes from its use in ischaemic stroke 
patients either in a non randomised design or by comparing outcomes with the 
use of other thrombolytic agents,
44,47,85 92 or in a randomised controlled trials 
design.
93-98 
 
In  a  double  blind  study  design,  Abe  et  al  (1981)  randomised  patients  that 
suffered from presumed thrombotic strokes within 2 weeks. Those that suffered 
presumed  embolic  stroke  or  severe  stroke  were  excluded.  Patients  received 
urokinase at the dose 60000 units/day for 7 days (n=57) or received a placebo 
(n=56). Outcomes were measured at 4 weeks after the start of treatment and 
included  measurement  of  global  improvement  rating  and  safety  assessment. 
Patients underwent a CT scan at baseline and a repeat CT examination if they 
suffered  neurological  worsening.  Clinical  improvement  occurred  in  70.4% Nishant Kumar Mishra, 2011    Chapter 1, 31 
 
thrombolysed  patients  compared  to  56%  non thrombolysed  patients. 
Haemorrhages did not occur in both arms.
99  
Atarashi  et  al  (1985)  examined  outcomes  in  patients  that  had  a  presumed 
diagnosis  of  cerebral  arterial  thrombosis  of  5  days. 
94    Patients  received 
urokinase (n=191, two groups comprising high dose urokinase 240 000 u/day IV 
for 7 days and low dose urokinase 60 000 u/day for 7 days) or placebo (n=94) in a 
double  blind  design. 
94    Where  possible,  the  patients  also  underwent  an 
angiography. 
94    Those  that  suffered  a  presumed  embolic  stroke  or  a  severe 
neurological deficit were excluded from enrolment. Outcome measures included 
clinical improvement described as per a final global improvement rating (done at 
4 weeks after the treatment was begun) and safety (defined by absence of any 
side effects). 
94  Thrombolysis was offered in a 120 hours’ time window. Rates of 
clinical improvement were similar in both arms: 45% in the thrombolysis group 
and 43.6% in placebo group. Rates of haemorrhage were 1% and 1.1% the two 
arms respectively.
94  
Australasian  Urokinase  Stroke  Study  (AUST)  was  a  multicentre  randomised 
controlled  trial  that  investigated  outcomes  from  the  use  of  intra arterial 
urokinase  in  patients  suffering  posterior  circulation  stroke.
95  Patients  were 
either given urokinase (in increments of 10
5 IU to a maximum dose of 10
6 IU) 
within 24 hours of symptoms onset or entered into the control arm. 20 patients 
were  screened,  16  randomised,  8  received  urokinase.  Primary  outcome  at  6 
months  (defined  by  combined  morbidity  (Barthel  Index  and  Rankin  Score)) 
occurred in 7/8 of the patients that received only anticoagulation and 4/8 of the 
patients  that  also  received  urokinase(OR  0.14,  95%CI  0.02 1.43).
95  Odds  for 
disability free survival were 1.33 (95% CI 0.07 26.62). Outcome data are shown 
in figure 1.2.
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Figure    1-2  Figure  showing  outcomes  in  patients  enrolled  in  AUST  trial  that 
randomised  patients  with  urokinase  and  anticoagulants  (heparin  and 
warfarin) or only the anticoagulants  
 
(Source: Modified from Macleod MR, Davis SM, Mitchell PJ, Gerraty RP, Fitt G, Hankey 
GJ,  Stewart-Wynne  EG,  Rosen  D,  McNeil  JJ, Bladin  CF,  Chambers  BR,  Herkes  GK, 
Young  D,  Donnan  GA.  Results  of  a  multicentre,  randomised  controlled  trial  of  intra-
arterial  urokinase  in  the  treatment  of  acute  posterior  circulation  ischaemic  stroke. 
Cerebrovasc  Dis.  2005;  20(1):12-7;  Permissions  for  use  obtained  from  S.  Karger  AG, 
Basel) 
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Middle  Cerebral  Artery  Embolism  Local  Fibrinolytic  Intervention  Trial  (MELT) 
selected  114  patients  (intra arterial  urokinase  N=57  or  placebo  N=57)  with 
symptoms of ischaemic stroke for last 6 hours and a demonstrable occlusion of 
middle  cerebral  artery  (M1/M2)  on  CT  angiography.
97  The  study  had  to  be 
stopped  when  tissue  plasminogen  activator  received  approval  for  use  in 
ischaemic stroke in Japan. Non significantly higher rates of favourable outcomes 
(m RS 0 2) were observed on day 90 in the group that received thrombolytic 
therapy  compared  to  the  placebo  arm  (49.1%  vs.  38.6%,  p=0.3).  Secondary 
outcome defined by m RS 0 1 on day 90 was achieved by 42.1% and 22.8% of the 
patients in the respective treatment arms (p=0.045). Neurological improvement 
(NIHSS  0 1  at  day  90)  occurred  more  frequently  after  the  use  of  urokinase 
(p=0.02). The study reported mortality rates of 5.3% and 3.5% in thrombolysis 
and control arm (p=1.000). Rates of intracerebral haemorrhage at 24 hours of 
treatment occurred in 9% and 2% of the patients (p=0.2).
97 
1.5.3 Prolyse  
Prolyse (nasaruplase), a glycosylated 411 amino acid single chain molecule (r 
proUK), is a precursor of urokinase. In the presence of fibrin associated plasmin, 
it gets activated into double chain urokinase (UK) on the surface of a thrombus. 
Heparin enhances the thrombolytic effect of urokinase, either by the release of 
tPA  from  the  endothelium  or  by  neutralisation  of  thrombin.  Urokinase  is  an 
endogenous plasminogen activator (t1/2= 9 to 12 minutes).
100 103 
Prolyse was investigated in two intra arterial thrombolysis trials called Prolyse in 
acute cerebral thromboembolism (PROACT) I and II in a 6 hour time window.
104,105 
The drug was administered intra arterially in the proximal 1/3
rd (or close to the 
proximal tip) of the clot in the middle cerebral artery (MCA 1 or MCA 2).  Prolyse 
was used at a dose of 6 mg in PROACT I and 9 mg in PROACT II; low dose iv 
heparin was given to all patients for four hours at the start of angiography in 
both PROACT I and PROACT II. PROACT I, a phase II randomised study, showed 
recanalisation efficacy (2P=0.02) and the safety (SICH rates, 2P=0.6) from the 
use of intra arterial thrombolysis in a 6 hour time window.
104  Later, PROACT II 
study showed significantly better functional outcomes in thrombolysed patients 
compared to the controls (90 day m RS 0 2 was achieved by 40% of the patients Nishant Kumar Mishra, 2011    Chapter 1, 34 
 
in treatment arm compared to 25% in the control arm, p=0.04; N=180, patients 
randomised in  proportions of 2:1 between treatment and control arms). Rates of 
recanalisation were 66% vs. 18%, p<0.05 and SICH within 24 hours 10% vs. 2%, 
p=0.06 between the two groups respectively. Despite showing an improvement in 
functional  outcomes,  the  therapy  failed  to  obtain  approval  from  regulatory 
authorities.
105  
 
1.5.4 Desmoteplase 
Desmoteplase  is  a  novel  plasminogen  activator  that  is  derived  from  saliva  of 
Desmodus rotundus.  It differs from alteplase in that it lacks the 2
nd kringle site 
in its molecular structure; does not need to be cleaved by plasmin and is active 
in its single chain form. It has reduced neurotoxicity and limited passage through 
the  blood brain barrier. DSMA  has  a  theoretical  advantage  over  rt PA  as  it  is 
almost non functional if fibrin is absent.
106 108 Investigators have been examining 
its efficacy and safety for use in acute ischaemic stroke patients in a delayed 
time window.
108  
Desmoteplase in Acute Ischaemic Stroke (DIAS) was a placebo controlled double 
blind dose finding phase II study which enrolled patients (baseline stroke severity 
on  NIHSS 4 20) for thrombolysis in 3 to 9 hours’ time window (Total patients: 
104  patients).  After  treating  47  patients  with  a  fixed  dose  regimen  (25  mg, 
37.5mg  or  50  mg)  of  desmoteplase  or  placebo  (part  1),  dosing  pattern  were 
modified  because  there  occurred  excessive  symptomatic  intracerebral 
haemorrhages  (26.7%).  Investigators  switched  over  to  part  II  of  the  study  in 
which a lower weight adjusted dose of 62.5 microgram/kg, 90 microgram/kg and 
125 microgram/kg were used. In the part II of the study, rates of symptomatic 
intracerebral haemorrhages were 2.2%; no SICH occurred in the placebo arm. 
Reperfusion  rates  were  71.4%  in  patients  treated  with  125microgram/kg 
compared  to  19.2%  in  the  placebo  arm.  Favourable  90%  clinical  outcome 
occurred in  60%  of patients  treated  with 125 microgram/kg  of desmoteplase, 
13.3% patients with a dose of 62.5microgram/kg of desmoteplase and 22.2% of 
placebo  treated  patients.  The  study  showed  a  strong  correlation  of  early 
reperfusion with improved clinical outcomes (P=0.0028).
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Dose Escalation of Desmoteplase for Acute Ischaemic Stroke (DEDAS) study was 
another  placebo controlled  double  blind  dose  escalation  phase  II  randomised 
study. It employed weight adjusted doses similar to DIAS and treated patients in 
a 3 to 9 hour time window. In this study, 8 patients received placebo and 29 
received desmoteplase (90 microgram/kg: n=14). No symptomatic intracerebral 
haemorrhage occurred. Rate of reperfusion was 37.5% in the placebo arm, 18.2% 
in  the  desmoteplase  arm  that  used  a  dose  of  90microgram/kg  and  53.3%  in 
desmoteplase  arm  that  used  a  dose  of  125  microgram/kg  arm.  25%  of  the 
placebo arm patients, 28.6% of 90 microgram/kg arm patients and 60% of 125 
microgram/kg  desmoteplase  had  good  clinical  outcomes  on  day  90.
110 
Desmoteplase  at  doses  of  90  and  125  microgram  per  kg  was  shown  to  be 
associated with a strong dose response relationship in a phase II design. 
109,110 
Between 2005 and 2007, Hacke et al randomised 193 patients in a dose ranging 
double blind placebo controlled trial in which patients that suffered acute stroke 
were selected based on presence of tissue at risk visible on either CT or MRI.
111 
123 patients entered the desmoteplase arm (n=57 for dose 90 microgram/kg and 
n= 66 microgram/kg) and 63 received placebo.
111 Median NIHSS at baseline was 
6(IQR  6 14)  and  only  30%  patients  had  a  visible  occlusion  at  baseline  brain 
imaging.
111 In the three groups of patients that received desmoteplase at dose of 
90microgram/kg, 120 microgram/kg or placebo, the respective clinical response 
rates on day 90 (defined by composite NIHSS improvement of 8 or more points, 
or NIHSS of 0 or 1, m RS of 0 2 points, Barthel Index  75 100) were 47%,36% and 
46%; change in lesion volume between baseline and day 30 were 14%,10.8% and  
10%;  rates  of  symptomatic  intracerebral  haemorrhage  were  3.5%,4.5%  and0%; 
and mortality rates were 5%,21% and 6%. The study failed to show benefit.
111 
Dose finding studies allow investigators to select a dose for further investigation 
in randomised controlled settings. 
1.5.5  Tenecteplase 
Tenecteplase is a mutant form of plasminogen activator which is characterised 
by  delayed  clearance,  longer  half life,  greater  fibrin  selectivity,  greater 
resistance  to  plasminogen  activator  inhibitor  and  greater  ability  to  lyse  a 
thrombus compared to alteplase. This drug appears to be safe for use in acute Nishant Kumar Mishra, 2011    Chapter 1, 36 
 
ischaemic stroke.
112 114 Chapman et al undertook to compare thrombolysis from 
use of wild t PA and tenecteplase. 
114 They used a model of New Zealand White 
rabbits who suffered ischaemic stroke due to injection of radio labelled blood 
clots. 
114 t PA was administered to 57 animals, tenecteplase to 70 animals (43 
received a dose of 0.6mg/kg, the rest received a dose of 1.5 mg/kg) and 37 
animals were used as controls. The study found recanalisation rates that were 
similar  between  the  animals  that  received  tenecteplase  or  alteplase.
114  The 
study  concluded:  “while  tPA  increases  haemorrhage  rate,  the  haemorrhage 
associated  with  TNK  treatment  is  not  statistically  different  compared  with 
controls or the tPA group.”
114 
In a pilot dose escalation study, Haley et al showed that tenecteplase at a dose 
of 0.1 0.4 mg/kg could safely be used in the acute ischaemic stroke patients: 
there  occurred  no  symptomatic  intracranial  haemorrhages  in  these  dose 
ranges.
115  A  phase  IIb/III  trial  of  tenecteplase  had  to  be  prematurely 
terminated.
116  The  study  involved  an  “adaptive,  sequential  dose  selection 
procedure that used major neurological improvement at 24 hours balanced by 
risk  (Symptomatic  Intra cerebral  Haemorrhage)”  and  allowed  investigators  to 
exclude the dose of 0.4mg/kg as inferior, but because the trial did not finish, an 
optimal  dose  between  the  other  doses  (0.1  and  0.25mg/kg)  could  not  be 
identified. 
116 Alteplase Tenecteplase Trial Evaluation for Stroke Thrombolysis  
(ATTEST)  trial  is  a  pilot  phase  study  that  would  compare  outcomes  between 
patients who would receive tenecteplase (dose: 0.25mg/kg; maximal dose 25mg) 
or alteplase (dose: 0.9 mg/kg administered as 10% bolus and then 90% of the 
dose  as  IV  infusion  over  1  hour;  maximum  dose  90  mg)  in  a  prospective, 
randomised, blinded outcome evaluation clinical trial design.
117  
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1.6 Clinical trials to evaluate therapy for acute ischaemic 
stroke 
The  invention  of  CT  technology  led  to  better  stroke  trials:  physicians  could 
select those patients for thrombolytic therapy who did not have intracerebral 
haemorrhage on CT brain. 
In  1992,  del  Zoppo  and  colleagues,  examined  outcomes  in  ischaemic  stroke 
patients who received alteplase in an 8 hours’ time window for cerebral artery 
occlusion.  The  study  reported  40%  rate  of  recanalisation,  9.6%  symptomatic 
intracerebral  haemorrhages  and  12.5%  mortality  (N=139).
118  Later,  Brott  and 
Haley showed that dose < 0.95 mg/kg was safe for use in these patients.
42,80   
Mori et al showed that use of thrombolytic therapy was associated with excess 
recanalisation rates.
119 Finally a “bridging trial”, in a randomised double blind 
controlled design (n=27, 20 treated in 90 minutes and 7 in 91 180 minutes; dose 
used 0.85 mg/kg) indicated the efficacy of alteplase in improving outcomes at 24 
hours. The study highlighted the need of a larger RCT.
120 
1.7 Randomised controlled trials for alteplase use in 
acute ischaemic stroke 
1.7.1 European  Australasian  Collaborative  Acute  Stroke  Study 
(ECASS) I 
In ECASS I trial, patients were treated with a dose of 1.1 mg/kg in a 0 6 hours’ 
time window. The target Population (TP) excluded protocol violators (17.4% of 
patients). This study failed to show a significant difference in primary endpoints 
(Barthel  Index  and  m RS  on  day  90)  in  Intention to Treat  (ITT)  analysis,  but 
showed significant improvement in outcomes in per protocol analysis (P=0.035), 
analyses of secondary end points (a combination of  Barthel index and Rankin 
scale) (P<0.001, in both ITT and TP analyses), and also analyses of neurological 
outcomes (P=0.03, TP analyses only). The rate of recovery was significant until 7 Nishant Kumar Mishra, 2011    Chapter 1, 38 
 
days for all patients and until a month for the target population. Hospital stays 
were  shortened  in  the  alteplase  arm  and  the  mortality  and  ICH  rates  were 
similar  in  both  arms.
121
  Investigators  concluded:  “intravenous  thrombolysis  in 
acute ischemic stroke is effective in improving some functional measures and 
neurologic outcome in a defined subgroup of stroke patients with moderate to 
severe neurologic deficit and without extended infarct signs on the initial CT 
scan.” 
121 
1.7.2 National Institutes of Neurological Diseases (NINDS) study 
The NINDS study (291 patients in part 1, 333 in part 2) was the first randomised 
controlled trial that showed safety and efficacy from use of alteplase in acute 
ischaemic stroke patients (dose:0.9 mg/kg, maximal dose of 90, time window: 
within3 hours of symptoms onset)  
Part I of the study defined early treatment response as improvement in NIHSS 
scores by > /= 4 or a complete recovery at 24 hours. 
24 Whereas analysis of early 
treatment  response  failed  to  show  a  statistically  significant  improvement,  a 
subsequent post hoc analysis noted improvement on median NIHSS scores at 24 
hours  (8  vs.  12,  p<0.02).    Global  outcome  scores  improved  in  patients  that 
received active treatment in part 2 (OR 1.795% CI: 1.2 2.6).   The study reported 
an  11 13%  absolute  increase  in  excellent  outcomes  and  a  non significant 
reduction  in  mortality  (17%  vs.  21%,  p=0.30).  The  rates  of  symptomatic 
haemorrhage  were  significantly  greater  in  the  treatment  arm  compared  to 
placebo  (6.4%  vs.  0.6%,  p<0.001).
122    It  was  the  first  study  to  demonstrate 
efficacy and safety of alteplase in a 3 hour window that led to its FDA approval 
for use in acute ischaemic stroke.
123 
1.7.3 European  Australasian  Collaborative  Acute  Stroke  Study 
(ECASS) II 
ECASS II examined outcomes in ischaemic stroke patients and used a dose of 0.9 
mg/kg  within  6  hours  of  symptoms  onset.  Though  it  failed  to  confirm  a 
statistically  significant  benefit  (p=0.2,  n=800)  when  data  were  examined  for 
patients  that  achieved  a  Rankin  score  of  0 1,  in  a  post hoc  analysis  better 
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functional outcomes defined by m RS = 0 2 (54.3% vs. 46%, p=0.02). Rates of 
symptomatic haemorrhages were 8.8% in thrombolysed patients and 3.4% in the 
non thrombolysed group.
124  
1.7.4 Streptokinase Trials  
Three streptokinase trials, the Multicentre Acute Stroke Trial in Europe (MAST E, 
1996),  the  Multicentre  Acute  Stroke  Trial  in  Italy  (MAST I,  1995)  and  the 
Australian  Streptokinase  Study  (ASK,1996)  were  all  terminated  prematurely 
because of complications.
48 50  
The  MAST E  study  showed  greater  mortality  (p=0.06)  and  a  trend  towards 
reduced  disability  (and  also  a  shorter  stay  in  a  rehabilitation  centre/nursing 
home) if the patient received streptokinase.
49  
The MAST I study failed to show benefit in any of its treatment compared to 
placebo  arms.  Symptomatic  haemorrhages  were  more  common  in  the 
streptokinase arm.
48  
The ASK study was characterised by higher mortality, worse clinical outcome and 
increased  ICH  rates.  Analyses  of  patients  who  received  streptokinase therapy 
within 3 hours of symptoms onset (N=70) with patients who were treated beyond 
3 hours (N= 270) showed that the former group had better outcomes.
50,125 
1.7.5 Alteplase  Thrombolysis  for  Acute  Noninterventional 
Therapy In Ischaemic Stroke Study (ATLANTIS)  
The ATLANTIS study started recruiting patients in August 1991 and had originally 
aimed to enroll patients within 6 hours of the onset of symptoms’.  In December 
1993, the time window was modified to 0 to 5 hours of symptom onset. After the 
publication of NINDS trial, the time window was narrowed down to treatment 
within 3 hours. Owing to these changes, the ATLANTIS trial was reported in two 
parts: part A (patients enrolled until December 1993, N=142) and part B.
126 128 
 
 
85% of patients in part A of the ATLANTIS trial received alteplase beyond three 
hours of symptoms’ onset.
128 There was a significant increase in proportion of 
patients that achieved 4 points improvement in NIHSS scale at 24 hours (40% vs. Nishant Kumar Mishra, 2011    Chapter 1, 40 
 
21% patients, P=0.02). There was a significant increase in proportion of SICH by 
tenth day of stroke (11% vs. 0%, P<0.01) and mortality by three months (23% vs. 
7%,  P<0.01).
127,128  The  outcomes  in  61  patients  treated  within  3  hours  of 
symptom onset were similar to the NINDS trial showing a 35% absolute increase 
in favorable outcomes.
126 
 
The  part  B  of  the  study  found  no  significant  difference  in  the  excellent 
neurologic  outcome  (defined  by  NIHSS  of  0  or  1  at  day  90),  between  the 
treatment and control arm (34% vs. 32%, P=0.65, N= 613).
127 
1.7.6 European  Australasian  Collaborative  Acute  Stroke  Study 
(ECASS) III  
ECASS III was the second positive t PA trial that showed efficacy of t PA in the 3 
4.5  hour  time  window  (52.4%  vs.  45.2%;  OR  1.34,  95%  CI  1.02 1.76,  P=0.04, 
N=821).
129 The trial was mandated by EMEA in order for the drug to receive the 
license within the European Union.
23 Though there occurred excess ICH (27% vs. 
17.6%, p=0.001) in the alteplase arm, the proportion of patients that suffered 
symptomatic  ICH  was  smaller  (2.4%  vs.  0.2%,  P=0.008).  Mortality  rates  were 
similar between the alteplase and the placebo group (7.7% vs. 8.4%, P=0.68).
129 
1.8  Findings from pooled data analyses and meta-
analyses of t-PA trials  
1.8.1  First pooled analyses of t-PA stroke trials   
Pooled  analyses  of  data  from  ECASS,  NINDS,  ATLANTIS  (N=2775)  showed  an 
inverse  relationship  between  the  time  since  symptom  onset  and  improved 
outcomes: OR=28 (95% CI 18—45) for 0—90 minutes, 16 (11—22) for 91—180 
minutes,  14  (11—19)  for  181—270  minutes,  and  12  (09—15)  for  271—360 
minutes(P=0.005)).  The  hazard  ratios  for  time  windows  0 90,  91 180,181 270 
were 1.0, and for time window 271 360, 145 (95% Confidence Interval 102—
207).  The risk of cerebral haemorrhage had a significant association with the 
use of t PA (5.9% vs. 1.1 %, p<00001). Whereas the time since symptom onset Nishant Kumar Mishra, 2011    Chapter 1, 41 
 
was  not  associated  with  occurrence of  cerebral  haematoma,  use  of  alteplase 
(p<0.0001) and age (p<0.0001) were. 
130  
1.8.2 Second pooled analyses of alteplase trials  
A  recent  pooled  analysis  of  t PA  trials  (2010)  by  Lees  et  al  reconfirms  the 
efficacy of t PA in 4.5 hours of symptoms onset.
131 
1.8.3 Cochrane review meta-analyses   
The Cochrane group reports a meta analysis of clinical trial data by examining 
the  safety  and  efficacy  of  thrombolytic  therapy  in  acute  ischaemic  stroke 
patients.  These  meta analyses  are  just  not  limited  to  alteplase  trials  (that 
constitute  55%  of  its  data),  but  also  include  trials  that  investigated 
streptokinase,  urokinase,  desmoteplase  and  pro urokinase  (N=  26  trials,  7152 
patients). About 0.5% of these patients are older than 80 years of age. Odds for 
death  or  dependency  (m RS  3 6)  in  patients  thrombolysed  in  3 6  hours  after 
stroke  onset  are  0.8,  95%  CI  0.73 0.90.  In  a  6  hour  window,  t pa  therapy  is 
associated  with  significant  odds  of  3.5  for  symptomatic  haemorrhage;  for 
mortality, these are OR 1.31, P<0.05. In a 3 hour time window, there occurred a 
significant reduction in the rates of death or dependency with odds of 0.7; for 
death, OR=1.13, 95%CI 0.86 1.48. Odds for all cause mortality  within  10 days 
were  1.8  for  all  patients  (95%CI  1.4 2.2,  N=4423);  for  those  who  got  t PA, 
OR=1.2, 95% CI 0.9 1.7, N=2500.
92  
1.9 Observational data on use of alteplase 
After the NINDS trials were reported, many physicians were still not convinced. 
They  argued  that  the  study  was  conducted  in  specialised  stroke  centres  and 
therefore data were not generalisable to other settings.
132 134 Hence, there was 
felt a need to examine outcomes in community hospitals. I report a summary of 
various observational studies that examined t PA for acute ischaemic stroke. Nishant Kumar Mishra, 2011    Chapter 1, 42 
 
1.9.1 Houston community experience 
Chiu  et  al  reported  outcomes  in  30  patients  treated  with  alteplase  between 
December 1995 and December 1996 (dose of 0.9mg/kg):  rate of symptomatic 
intracerebral haemorrhage: 7%; rate of fatal ICH: 3%; 37% patients recovered to 
full independence (Barthel Index 95 100) and 30% with m RS 0 1. The rate of 
mortality on day 90 was 20%.
135 
1.9.2 Cologne community experience 
Grond et al described their experience from Cologne (n=100): door to needle 
time: 48 minutes;  stroke onset to arrival time: 78 minutes;  day 90 Barthel 
Index of 95 100 achieved by 53% patients;  40%  achieved a m RS  of 0 1,  NIHSS 
score of 0 1: 42%; symptomatic ICH rate of  5%; and  mortality rate of 12%.
136 
1.9.3 Oregon community experience 
 33 patients received alteplase. The result indicated that t PA use was “feasible 
and efficacious”: mortality rates=18.2%; 36.4% patients achieved m RS of 0 1 at 
3 months. 
137 
1.9.4 Cleveland community experience 
By employing a chart review of 3948 patients enrolled in 29 different hospitals in 
Cleveland, Ohio, between1997 1998,  Katzen  et al aimed  to estimate rates  at 
which t PA was used in the community. 
138  This study highlighted that many 
patients were not getting t PA because the time window of t  3 hours was too 
short: only 17% of the patients could be hospitalised within the 3 hour time limit 
and only 1.8% finally received alteplase. NIHSS was recorded in 405 of patients, 
median  12.  This  study  highlighted  that  t PA  was  associated  with  excess  poor 
outcomes: symptomatic haemorrhages in 15.7% of the patients (a rate that was 
2.5  times  that  of  the NINDS study). A large  proportion  of  patients (50%) had 
deviated from the t PA guidelines. The deviations included use of antithrombotic 
agents  within  24  hours  of  alteplase  use  (in  37.1%  of  patients;  heparin  in  16 
patients, aspirin in 7 patients, their combination in 2 patients and ticlopidine in 
1 patient), thrombolysis beyond 3 hours (even those treated within 3 hours 5 
minutes were considered eligible, N=4 in these extra 5 minutes; 12.9% treated Nishant Kumar Mishra, 2011    Chapter 1, 43 
 
between 3 hours 10 minutes and 6 hours 13 minutes) and raised blood pressure.  
Excess deaths occurred if they received alteplase compared to those who did not 
receive  alteplase  (15.7%  vs.  5.1%,  p<0.01).  These  findings  differ  from 
experiences of other groups: STARS (discussed in subsequent section) reported   
rates of symptomatic haemorrhage = 3%, which were 5 times lower than what 
Cleveland experienced. Excess adverse events in Cleveland were attributed to 
practices that deviated from t PA guidelines. The Cleveland study differed from 
others: these were retrospective chart reviews; patients were identified based 
on the ICD system; data were collected on a 6 monthly basis; nurses would look 
for  cases  after  these  had  already  occurred  (case  ascertainment  bias);  a 
population that was different in characteristics compared to other centres that 
reported earlier (19.4% valvular heart disease in Cleveland cohort compared to 
only 8.3% in NINDS) and importantly deviations from guidelines. 
138 
A  subsequent  paper  from  the  Cleveland  group  described  patients  that  were 
admitted  to  their  Clinical  Health  System  between  2000  and  2001.  This  time 
investigators  practiced  performance  monitoring,  frequently  reviewed  data, 
provided  round the clock  access  to  the  stroke  team  by  introducing  a  stroke 
pager and raising the education level regarding stroke management. Now, 18.8% 
of the patients reached hospitals within 3 hours; the rate of symptomatic ICH 
was 6.4%; and protocol violations occurred in 19% of the patients. 
139 
These two studies from Cleveland highlighted that there was a need to educate 
participants in “chain of delivery” and strictly follow the t PA guidelines. 
138,139 
1.9.5 Standard  Treatment  with  Alteplase  to  Reverse  Stroke 
(STARS)  
STARS  was  an  American  study  that  aimed  to  examine  outcomes  in  ischaemic 
stroke patients that received alteplase between February 1997 and December 
1998  (N:  389  patients,  centre  participation:  24  academic  and  33  community 
centres). Median onset to treatment time was 2 hours 44 minutes; and, baseline 
NIHSS  score  13.  On  day  30,  mortality  rates  were  13%;  Rankin  score  0 1  35%, 
Rankin  score  0 2  43%;  rate  of  symptomatic  haemorrhage  3.3%  (N=13)  and 
mortality attributed to symptomatic haemorrhage N= 7. STARS showed that t PA 
could be safely administered in university and community settings. 
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1.9.6 Vancouver Experience 
Chapman et al report outcomes in 46 patients who were given t PA in a 3 hour 
time window and based on NINDS protocol. Here, SICH rates were 2.2 % (at 36 
hours); outcomes at 13 months were mortality 22%, 43% reaching a m RS of 0 1 
and 48% a Barthel Index of 95 100. 
141 
1.9.7 Calgary Experience 
Over half of the patients in Calgary data suffered ischaemic stroke (1168/2165; 
duration:  1996  to  1999).  Delay  in  patients’  arrival  accounted  for  73%  of  the 
patients’  exclusion.  Only  84  of  the  314  patients  received  alteplase  despite 
presenting  within  t PA  time  window;  overall,  only  4.7%  patients  received 
alteplase. Outcomes  of thrombolysed patients  on day 90 were comparable to 
randomised  data:  54%  of  reached  m RS  of  0 2  and  7.1%  patients  developed 
Symptomatic ICH. Reasons why some patients were excluded despite presenting 
within  3  hours  include:  presence  of  mild  stroke  (13.1%)  or  rapidly  improving 
stroke (18.2%) at baseline; delay in referral (8.9%); and, patient suffered other 
illnesses  that  would  have  adversely  affected  outcomes  (8.3%).    It  should  be 
noted that, about 32% of those patients who suffered a mild or rapidly improving 
stroke were still dependent upon discharge or had died while they were still in 
the hospital. The Calgary experience highlights that mild or rapidly improving 
stroke  patients  do  not  always  have  a  spontaneous  resolution  of  symptoms  or 
better outcomes. 
142 In chapter 7, I examine this question. 
1.9.8 Berlin Experience 
Koennecke  reported  data  collected  over  two  years  during  which  75  patients 
(9.4%) received alteplase. 2.7% suffered cerebral haemorrhages. 40% achieved 
m RS of 0 1, 32% a m RS of 2 3 and 13% a m RS of 4 5; 15% of the patients died. 
The  investigators  highlighted  that  performance  improved  with  time,  and 
gradually more and more patients could be enrolled). 
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1.9.9 Houston Experience 
Grotta et al reported improvement in neurological outcomes of 269 patients that 
received alteplase (baseline NIHSS 14.4+/  6.1 to 7+/ 7 at discharge) between 
January 1996  June 2000. SICH rates were 4.5 %.
144 
1.9.10  Canadian Activase for Stroke Effectiveness Study 
The Canadian group examined 1099 patients who received t PA during February 
1999 to June 2001.  Stroke severity was NIHSS=15.   46% patients achieved m RS 
of 0 2 on day 90 and the rate of ICH was 4.6%. Baseline Stroke severity, baseline 
ASPECT scores, age, atrial fibrillation and baseline blood sugar levels predicted 
outcomes  in  this  population.  Raised  blood  pressure  and  hyperglycaemia  at 
baseline were predictors of ICH occurrence. This study suggested that IV rt PA 
could safely be used in Canada.
145 
1.9.11  The  Safe  Implementation  of  Thrombolysis  in  Stroke 
studies 
Following  the  NINDS  trial,  alteplase  was  approved  in  the  USA  (in  1996)  and 
Canada  (in  1999)  for  use  in  acute  ischaemic  stroke.
123  But,  European  drug 
authorities were hesitant to permit its use in the European Union.
23 Alteplase 
was finally approved for use in ischaemic stroke patients in 2002 subject to the 
fulfilment of two conditions by the study sponsor (i.e. Boehringer Ingelheim): (a) 
to  conduct  a  pan European  observational  study  with  strict  monitoring  of 
outcomes in patients receiving t PA and (b) to conduct a randomised controlled 
trial evaluating outcomes beyond 3 hours of symptoms onset.
23 In order to fulfil 
the  first  requirement,  the  Safe  Implementation  of  Thrombolysis  in  Stroke 
Monitoring  Study  (SITS MOST)  a  study  was  conducted,  and  for  the  second 
requirement, the ECASS III.
129,146  
The  primary  aim  of  the  Safe  Implementation  of  Thrombolysis  in  Stroke 
Monitoring Study (SITS MOST) was to assess the safety and efficacy of alteplase 
in patients treated within the European Union, Iceland and Norway in a 3 hour 
time window. The study enrolled 6483 patients between 25 December, 2002 and 
30  April,  2006  from  285  centres  spread  across  14  member  states.  The  study 
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co ordinators and professional monitors in collaboration with the study sponsor, 
Boehringer Ingelheim, source verified sample source data. 
146 The study reported 
that “a minimum of 10% of patients recruited in SITS MOST were monitored and 
in UK  source data verification was done by independent clinical staff under the 
direction of the UK national coordinators who also checked for the completeness 
of registrations at all sites.” 
146 About half of the centres that participated had 
little  prior  experience  with  thrombolysis.  The  baseline  characteristics  were 
similar between the SITS MOST patients and the randomised trials. At 24 hours, 
the  SICH  rate  was  1.7%  per  SITS MOST  definition.  On  day  7,  7.3%  patients 
suffered SICH per Cochran definition (8.6% in randomised trials). Mortality by 90 
days was 11.3% compared to 17.3% as observed in the randomised trials. Thus, 
the  SITS MOST  study  showed  that  the  alteplase  could  be  safely  administered 
within three hours of symptom onset.
146 
The  Safe  Implementation  of  Treatments  in  Stroke  (SITS)  group  compared  the 
outcomes  in  patients  treated  in  the  3 4.5  hour  time  window  (n=664)  with 
patients  treated  in  the  <3  hours’  time  window  (n=11  865)  (enrolled  between 
December 25, 2002 and November 15, 2007) employing data that were recorded 
in  the  prospective  International  Stroke  Thrombolysis  Registry  (ISTR). 
147   
Outcomes  did  not  differ  significantly  between  the  two  groups:  the  rates  of 
symptomatic  intracerebral  haemorrhage  within  24  h  (haemorrhage  type  2 
associated  with  National  Institutes  of  Health  Stroke  Scale  [NIHSS]  ≥4  points 
deterioration)  were  22%  versus  16%,  p=024;  mortality  at  3  months:  127% 
versus 122%, p=072 and adjusted p=0053); and independence (modified Rankin 
Score 0 2) at 3 months 580% versus 563%, p=042 and adjusted p=018. 
147 The 
findings offered some data to show that alteplase could safely be given in a 3 
4.5 hour time window after ischaemic stroke. 
147 Later the ECASS III trial showed 
that  use  of  alteplase  was  indeed  associated  with  improved  outcomes  when 
patients were treated in a 3 4.5 hour time window. 
129 
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1.10 Brain Imaging 
1.10.1  Introduction 
 
The  invention  of  Computed  Tomography  (CT)  technology  was  a  major 
technological advance in the field of clinical medicine. It led to the award of a 
Nobel prize to Dr Hounsfield.
148 With a CT scan, a physician could now exclude 
an  intracranial  haemorrhage  and  the  stroke  mimics.  It  is  a  widely  available 
imaging modality that is used by stroke physicians to image stroke patients.  
 
Brain  MRI  is  considered  better  because  it  provides  the  physicians  with  some 
additional information. For example, s/he can see the hyper acute ischaemic 
changes on the Diffusion Weighted Imaging (DWI) sequences, haemorrhages on 
Gradient Echo (GRE) sequences and predict the timing of stroke onset based on 
Fluid  Attenuated  Inversion  Recovery  (FLAIR)  sequences  (DWI FLAIR 
mismatch).
149,150   
 
Perfusion  brain  imaging  gives  information  about  the  haemo dynamic  changes 
that occur after cerebral ischaemia (e.g. cerebral blood flow, volume and other 
perfusion parameters). CT Angiography (CTA) or MR Angiography (MRA) give the 
visual details of brain vessels (e.g. the occlusions). Physicians aim to achieve 
recanalisation/reperfusion, and therefore on being able to see a vessel occlusion 
on CTA or MRA, physicians can implement an appropriate recanalisation strategy 
for  treatment  of  these  patients.
151  For  example, patients  having  occlusion  of 
“Carotid T” occlusion of middle cerebral arteries are known to respond poorly to 
iv t PA and these patients may be considered as candidates for intra arterial or 
mechanical thrombolysis by some physicians.
152 
 
  
1.10.2  Ischaemic Penumbra  
 
That  an  ischaemic  penumbra  develops  after  a  cerebral  vessel  occlusion  was 
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treatment of acute ischaemic stroke.
29,30,153,154 When a cerebral artery occludes 
the core of ischaemic lesion suffers irreversible injury and surrounding tissue is 
functionally silent because of hypo perfusion. If the hypo perfusion persists, the 
central  core  enlarges  and  gradually  the  whole  of  hypo  perfused  brain 
parenchyma  undergoes  infarction.  However,  if  the  perfusion  is  restored  early 
enough, a large portion of surrounding hypo perfused tissue can be prevented 
from undergoing infarction.
29  
 
The  rate  at  which  penumbra  recruits  into  the  infarct  core  differs  between 
individuals, for it is a dynamic process, and depends upon vasomotor response to 
ischaemia and collateral circulation that are specific to an individual and differ 
between individuals.
29  From the statistical analyses of randomised t PA trials 
data, we know that the odds for improved outcomes are significantly >1 only 
until 4.5 hours after onset of the symptoms.
131 The patients that were treated in 
the 4.5 6 hour time window had odds of (for better outcomes) 1.22 but here the 
confidence  intervals  were  wide,  i.e.,  0.92  to  1.61.
131    Current  interest  is, 
therefore, in the identification of those patients who may still have salvageable 
parenchyma despite delayed presentation. In the confidence interval for OR in 
the time interval 4.5 6 hours suggests that while some patients might benefit 
from t PA, others would suffer excess  harm.
131 There is a potential to select 
patients despite delay in their arrival based on presence of penumbra.
46 
 
 
1.10.3  Multimodal Stroke Imaging  
 
Multimodal  stroke  imaging  aims  to  provide  information  about  the  extent  of 
salvageable brain tissue, site of vessel occlusion, state of the collaterals. It also 
helps exclude cerebral haemorrhage or a stroke mimic.
155 162 
 
Multimodal  MRI  protocol  takes  <  ½  hour  and  includes  sequences  like  T2 
Weighted,  Fluid  Attenuated  Inversion  Recovery  (FLAIR),  T2*   and  diffusion 
weighted imaging (DWI) along with the perfusion weighted imaging (PWI) and MR 
angiography.  
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Standard  T1 ,  T2 weighted,  and  FLAIR  sequences  are  sensitive  to  vasogenic 
oedema.  After  the  stroke  onset,  these  take  hours  to  develop.  T2 weighted 
images  or  FLAIR  images  provide  information  about  tissue  characteristics  that 
help  the  physician  to  exclude  stroke  mimics.  Diffusion  weighted  imaging  is 
sensitive  to  regions  of  ischaemia  and  develops  within  minutes  of  symptoms 
onset. Hence, it allows detection of ischaemic areas soon after the stroke onset. 
This is because DWI reflects signal changes that occur due to relative restriction 
of  intracellular  protons  resulting  from  the  failure  of  ATP  dependent  Na
+/K
+ 
pumps. These pumps pump the intracellular water out of the cells. While ADC 
values return to normal within days of ischaemia, hyper intensity on DWI may 
persist for weeks.
163,164  
 
Immediate visualisation  of an ischaemic stroke lesion is  an  advantage  of DWI 
imaging over CT imaging. However, a study based on analyses of DEFUSE trial 
data  indicated  that  the  DWI  lesions  might  be  reversible  (referred  to  as 
“Reversible  Acute  Diffusion  Lesion  Already  Reperfused  (RADAR)”)
165  Recently, 
however,  an  analysis  of  DEFUSE  and  EPITHET  data  (n=119)  indicated  that  a 
clinically relevant diffusion lesion reversal (DLR) is uncommon.
166,167 The findings 
from  the  former  study  describing  RADAR  were  attributed  to  errors  in  co 
registration of images and/or infarct atrophy.
 166,167  
 
DWI is a useful tool and shows up hyper acute ischaemic lesions as hyper intense 
signals on MR scans. Clinically, there are scenarios when a patient with a prior 
stroke presents with a recurrent stroke with symptoms suggesting a new infarct 
in the same territory. It is also likely that these patients may not have a new 
stroke but seizure activity from the scar of a previous lesion or symptoms due to 
deranged  metabolic  parameters  or  underlying  infections.  In  order  to  decide 
whether new symptoms are due to a previous event or from a fresh infarct, the 
physician may want to use DWI sequence of MRI that can help confirm a fresh 
ischaemic lesion by the presence of bright hyper intense signals. Also, DWI shows 
up smaller lesions that are very subtle on CT scans (e.g. lesions in  posterior 
fossa). 
 
Gradient Recalled Echo (GRE) sequences and other T2*W images are equal in 
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also pick up signals from deposits of hemosiderin, thus allowing identification of 
patients that suffer vasculopathies and are prone to spontaneous bleeding.
168 
 
Further, there appears to be a potential for FLAIR images in wake up stroke: 
FLAIR negative DWI positive MRI may indicate a time window of less than 3 (or 
4.5  hours)  from  symptoms  onset  (specificity  0.93,  positive  predictive  value: 
0.94; but, sensitivity 0.48 and negative predictive value 0.43).
149,169  
 
Also, Fluid attenuated inversion recovery (FLAIR) is the most sensitive MRI pulse 
sequence for detecting subarachnoid haemorrhage and shows the lesion as high 
signal intensity.
170,171 MRI can also identify a cerebral venous sinus thrombosis. 
Acute thrombus contain deoxyhemoglobin which is visible on T2*W imaging as 
linear or dot shaped low signal areas of magnetic susceptibility in a blood vessel 
lumen.
172 174   
 
In addition, 3 D Time of Flight (TOF) MRA imaging informs the state of vascular 
flow: when  a saturation  pulse is applied repeatedly, stationary protons in an 
excited plane get saturated while the flowing blood protons do not. Vascular 
contrasts  are  preferred  because  they  have  a  relative  independence  from  the 
flow dynamics and substantially reduce artefacts.
175 MRA also allows visualisation 
of vascular occlusion or a stenosis. 
 
MR  perfusion  imaging  refers  to  various  techniques  that  allow  non invasive 
measurement of tissue perfusion and give haemodynamic data like tissue blood 
volume,  blood  flow  and  mean  transit  time.  This  technique  involves  serial 
measurement of signal changes that occur in surrounding tissue when a contrast 
bolus passes through its capillaries.
29,176 Data so obtained are then transformed 
into  relative  tissue concentration  time  course  data.  The  haemodynamic 
parameters are measured based on a model that expresses the manner in which 
tracer  passes  through  (or  gets  distributed  within)  the  tissue.  Variables  that 
influence these parameters are the method of infusion (bolus vs. constant) and 
the pharmacokinetics of the contrast agent used for imaging (diffusibility of the 
agent, volume of distribution and half life to reach equilibrium). The exogenous 
tracer method works on an assumption that the tracer stays restricted within the 
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endogenous  tracer  method  works  on  an  assumption  that  the  tracer  diffuses 
freely between the intravascular and extravascular compartment.
177,178  
 
In the case of ischaemic stroke patients, the exogenous tracer method based 
Dynamic state MR perfusion technique is used. When a bolus of paramagnetic 
tracer passes through a capillary network, there occur rapid alterations of the 
local  magnetic  field  of  surrounding  brain  tissue.  These  signal  changes  are 
measured  by  ultrafast  imaging  techniques  like  Echo  Planar  Imaging  MRI.
178,179 
Signal time course data so obtained are then transformed into  relative tissue 
concentration  time  course  data  which  then  lead  to  the  calculation  of 
haemodynamic parameters like Mean Transit Time (MTT, average time taken by 
the  contrast  to  pass  through  capillaries),  cerebral  blood  volume  (CBV;  blood 
volume per unit of brain), relative cerebral blood flow (CBF; blood flow per unit 
brain mass per minute), time to peak (TTP; time to peak of the contrast agent 
in the vessel) and T max (Time to peak of residue function). Because  of the 
rapid passage of the bolus through the capillaries, a good temporal resolution 
can be achieved. 
177,178 Because CBF, CBV and MTT depend on variables like bolus 
injection (dose, rate of injection, paramagnetic property of contrast) or patient 
characteristics (total body vascular volume and cardiac output)) that have intra  
and inter individual variability, semi quantitative (relative) values obtained by 
using  an  internal  reference  point  (like  normal  grey  or  white  matter)  are 
preferred.
177,178 The Cerebral Blood Volume is calculated by measuring the area 
under  curve  of  the  tracer  concentration  time  graph. 
144,145  Calculation  of 
cerebral blood flow requires extensive processing of imaging data and includes 
steps like deconvolution  of arterial input function. 
144,145 Cerebral Blood Flow 
then equals cerebral blood volume divided by mean transit time. The arterial 
input function varies between the voxels. Because most methods assume them 
to  be  a  constant,  there  are  chances  of  committing  an  error  (e.g.  when  the 
middle cerebral artery is diseased on one side).
177,180   
 
The concept of Diffusion Perfusion mismatch was recently tested in a few studies 
but  failed  to  show  success  in  achieving  the  primary  end  points.
111,181 
Investigators attributed the failure to trial design, e.g., in DIAS II mild strokes 
were  recorded.  Whereas  these  studies  defined  mismatch  as  a  ratio  of  1.2 
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trials data later suggested that an optimal ratio should have been 2.6.
182 There is 
a potential to select patients in a 3 6 hour  time window based on MR diffusion 
perfusion  mismatch  criteria:  in  DEFUSE  there  was  a  significant  association 
between a successful recanalisation and reduction in infarct growth in patients 
with mismatch (OR 5.4, P=0.04).
183  
 
Contraindications  to  the  use  of  MR  based  imaging  include  patients  having 
pacemakers, metallic implants, electronic devices or obesity. Some patients may 
also need sedation for agitation or claustrophobia.   
 
Further, thanks to the efforts of regulatory authorities that led to better clinical 
practices (e.g. screening patients and not using gadolinium when GFR is below 
30ml/minute per 1.73 metre square) and likely new treatment(s), the incidence 
of nephrogenic systemic fibrosis have substantially reduced (≈0).
184 186   
 
Multimodal  CT  imaging  includes  non contrast  CT,  a  perfusion  CT  and  a  CT 
angiography. These take about ten minutes.  
 
Non contrast CT is used to exclude haemorrhages and other stroke mimics. It is 
widely  available  and  can  be  done  rapidly. Non  contrast  CT  scan  can  identify 
some early ischaemic changes like hyper dense vessels, insular ribbon sign, loss 
of clarity of the lentiform nucleus or loss of grey white matter differentiation; 
but these are subtle in the first 3 hours of stroke onset (sensitivity is only 25% 
compared  to  DWI).
187  Non contrast  CT  provides  structural  information  and  no 
physiologic information; and hypo attenuation is highly specific to infarction.  
 
CT angiography provides detailed information on vessel characteristics like the 
site of occlusion and may confirm recanalisation after the drug use. In addition, 
it can be used to assess flow in collateral blood vessels.
188  
 
In the CT perfusion studies, it is the entry and washout of iodinated contrast 
agent  that  is  studied;  and  the  signal  density  of  contrast,  while  in  its  transit 
through the capillaries, is analysed for image interpretation. CT contrast agent 
and CT tissue density have a linear relationship and therefore it is simpler to 
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unable  to  image  the  whole  brain  as  they  scan  a  2 4  cm  section  of  brain 
parenchyma in each contrast bolus administered; but better newer CT scanners 
allow greater brain coverage.
188 
 
Dynamic  perfusion  CT  involves  measurement  of  brain  haemo dynamics  by 
employing first pass tracer methodology.
189 The method involves a continuous 
cine  scanning  lasting  about  45  seconds (scan  rate:  1  image  per  second).  The 
patient  is  injected  with  ≈  50  cc  of  350  mg/dL  iodinated  contrast  material 
intravenously.
 190 Because low kilovolts (about 90 kilovolt peaks) or milli amperes 
(about  150mA)  protocols  are  used,  patients  are  not  exposed  to  excessive 
radiation.
190 Whereas an unenhanced CT brain results in radiation exposure of 
2.5  mSv,  perfusion  CT  leads  to  an  exposure  of  1.6 2.0  mSv.
149  Unless  the 
contrasts are used in patients suffering renal failure or diabetes mellitus, the 
use of contrast is considered safe.
191  
 
In 2009, it was discovered that more than 200 patients had received a radiation 
overdose in Cedars Sinai Medical Centre, Los Angeles California over a period of 
1.5  years.
  186 
192  Subsequent  investigation  by  the  United  States  Federal  Drug 
Agency led to the identification of a total of 385 patients from six hospitals that 
had  been  exposed  to  radiation  overdose.
192 
193  The  investigations  failed  to 
identify violations of the laws or regulations; and noticed that when the scanners 
were  used  according  to  the  specifications  given  by  the  manufacturer, 
overexposure to radiation did not occur.
193 This incidence had occurred because 
of  an  error  in  the  computer  tomography  console,  and  the  overexposure  was 
discovered  when  a  patient  reported  suffering  hair  loss  after  receiving  a  CT 
scan.
186 
192  The  levels  of  radiation  were  8  times  higher  than  the  permissible 
limits.
186 
192 40% of the patients suffered alopecia because of these exposures. 
192 
To prevent recurrence of similar incidents , CT quality assurance programs are 
needed.
186 US FDA had recommended that “(a) imaging facilities assess whether 
patients  who  underwent  CT  perfusion  scans  received  excess  radiation;  (b) 
imaging  facilities  review  their  radiation  dosing  protocols  for  all  CT  perfusion 
studies to ensure that the correct dosing is planned for each study; (c) imaging 
facilities implement quality control procedures to ensure that dosing protocols 
are followed every time and the planned amount of radiation is administered; 
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performing a study to make sure the amount of radiation to be delivered is at 
the  appropriate  level  for  the  individual  patient;(e)if  more  than  one  study  is 
performed on a patient during one imaging session, practitioners should adjust 
the dose of radiation so it is appropriate for each study.”
192 Wintermark and Lev, 
in an editorial, highlight that “while unnecessary radiation exposure should be 
avoided,  a  medically  needed  CT  scan  obtained  with  appropriate  acquisition 
parameter has benefits that outweigh the radiation risks.”
186 
 
Helical CT scanners, operating in cine mode are employed to obtain perfusion CT 
data. Multi slice CT scanners are better because these allow for greater tissue 
coverage in each of the acquisitions.
189 Automatic injectors are used; rate of 
contrast injection: 3 4 cc/second; Catheter size employed >/=22 gauge.
189,194,195  
 
Post processing software used to process CT perfusion data (time taken: about 5 
minutes) employ methods like rate of upslope estimation of cerebral blood flow 
(when  the  infusion  rates  are  above  about  6  cc  per  second)  or  deconvolution 
analysis  (when  the  infusion rates  are  4 5  cc  per second);  the  latter  provides 
quantitatively accurate rates.
196   
 
CBF, CBV, MTT are read on the computer console allowing a physician appreciate 
visually  the  image  at  the  same  time  as  quantitatively  analyse  the  region  of 
interest. MTT are prolonged in areas where brain perfusion is reduced; and are 
sensitive to haemodynamic changes in the brain. Under perfusion they can be 
examined by comparing the CBV, CBF and MTT between the brain regions that 
are abnormal to their mirror images in the control area. Areas with prolonged 
MTT and increased CBV are considered to be the “tissue at risk”. Areas with 
reduced CBV with prolonged MTT correspond to an infarct core.
197  
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Table   1-2  Acquisition and Post processing Parameters recommended for CT and MR perfusion 
 
Acquisition Parameter       Suggested by Roadmap for CT       Suggested by Roadmap for MR 
Type of sequence           Not applicable           Single shot gradient echo EPI 
Duration             2 phase acquisition         90–120 s 
Temporal resolution         1000 ms            </=1500–2000 ms 
Other technical details         Peak kilo voltage 80kvp, current 100mAs   Echo time 1.5T (35–45 ms);  
3T (25–30 ms), flip angle   
  1.5T (60–90°); 3T (60°) 
 
Magnet strength           N/A               1.5 or 3.0T 
Anatomic Coverage          20 mm (minimum) coverage per bolus    >/=12 slices 
Slice thickness           5–10 mm             5 mm 
Field of view             about 24cm            about 24cm 
Avoidance of lenses         above orbits            Not Applicable 
Basal ganglia coverage         Yes              Not Applicable 
Slice orientation stated         Yes               Yes 
Contrast type           N/A               Gadolinium use stated 
Contrast volume           35–50 mL            Not Applicable 
Contrast concentration         350–370 mg/ml          Not Applicable Nishant Kumar Mishra, 2011                     Chapter 1, 56 
 
Injection delay           N/A               10s 
Injection rate           4–6 mL/s             4–6 mL/s 
Saline chaser described         Yes               Yes 
Power injector used         Yes               Yes 
Cannula gauge           18–20G             18–20G 
Side of injection           Right               Right 
Antecubital vein used         Yes               Yes 
Post processing parameter       CT perfusion         MR perfusion 
Use of deconvolution         Yes              Yes 
Arterial input function selection lateralisation   Yes              Yes       
Arterial input function selection artery    Yes              Yes 
Venous output function site       Yes              N/A 
 
[Source: Dani KA, Thomas RG, Chappell FM, Shuler K, Muir KW, Wardlaw JM. Systematic Review of Perfusion Imaging With Computed 
Tomography  and  Magnetic  Resonance  in  Acute  Ischaemic  Stroke:  Heterogeneity  of  Acquisition  and  Post  processing  Parameters:  A 
Translational  Medicine  Research  Collaboration  Multicentre  Acute  Stroke  Imaging  Study.  Stroke,  2011,  e pub 
doi:10.1161/STROKEAHA.111.629923. Permissions obtained from Wolters Kluwer Health, License Number 2783781063122.]
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Multimodal  brain  imaging  has  potential  for  use  in  selecting  patients  for 
thrombolytic  therapies.  At  the  moment,  however,  there  is  a  need  for 
standardising the image processing methods.
198,199 
 
 
1.11 Adverse events after use of thrombolytic therapy 
Thrombolytic  therapy  is  associated  with  adverse  events  like  intracerebral 
haemorrhage, systemic bleeding or allergic reactions (like orolingual oedema, 
laryngeal oedema, anaphylaxis, or rash). 
Intracerebral  Haemorrhage  is  the  most  feared  complication  of  thrombolytic 
therapy. Its rate of occurrence is examined as an outcome measure (for safety) 
in  clinical  trials  of  thrombolytic  therapy.  Symptomatic  intracerebral 
haemorrhage (SICH) has various definitions. The NINDS definition of SICH 
 is any 
haemorrhage  that  is  associated  with  any  neurological  deterioration.
122  The 
ECASS II definition of SICH is any haemorrhage with neurological deterioration, 
as indicated
 by an NIHSS score of 4 or more than the value at baseline or the 
lowest
 value within 7 days, or any haemorrhage leading to death.
124 In the ECASS 
III  protocol,  symptomatic  intracranial  haemorrhage  was  defined  as  “any 
apparently  extravascular  blood  in  the  brain  or  within  the  cranium  that  was 
associated with clinical deterioration, as defined by an increase of 4 points or 
more in the score on the NIHSS, or that led to death and that was identified as 
the predominant cause of the neurologic deterioration”.
129 Hence, this definition 
is a modification of ECASS definitions in which it is further specified that the 
haemorrhage has to be identified as the predominant cause of the neurologic 
deterioration.
129  As  per  SITS-MOST  criteria,  the  symptomatic  intracerebral 
haemorrhage (SICH) is defined as a local or remote parenchymal haemorrhage
 
type 2 on the 22 to 36 hour post imaging scan, combined
 with a neurological 
deterioration of 4 or more points compared with
 baseline NIHSS or the lowest 
NIHSS value between baseline and
 24 hours.
146 Haemorrhagic infarction type 1 
refers  to  small  petechiae  along  the  margins  of  the  infarct.  Haemorrhagic 
infarction type 2 refers to confluent petechiae within the infracted area, but Nishant Kumar Mishra, 2011    Chapter 1 , 58 
 
without  space occupying  effect.  Parenchymal  haematoma  types  1  are  the 
haematoma  that  occupy  ≤30%  of  the  infarcted  area  with  some  slight  space 
occupying effect. Parenchymal haematoma type 2 refers to dense haematoma 
occupying  larger  than  30%  of  the  infarcted  territory  and  occupies  substantial 
space, or as any haemorrhagic lesion outside the infarcted area.  
Orolingual oedema or the oedema of throat and mouth may occur from the use 
of intravenous t PA.
200 202 Hill et al report 9 cases of orolingual angioedema in a 
series  of  consecutively  enrolled  176  patients.  The  severity  was  reported  as 
“mild, transient and contra lateral to the ischaemic hemisphere”.
200 The authors 
reported  a  significantly  increased  risk  of  orolingual  oedema  with  the  use  of 
angiotensin converting enzyme inhibitors (Relative Risk 13.6, 95% CI 3.0 62.7).
200  
1.12 Exclusion of patients from receiving alteplase 
Investigators  that  design  randomised  controlled  trials  want  to  pick  up  the 
positive  “signals”  of  treatment  effect  and  not  let  the  “noise”  (effect  of  a 
heterogeneous study population that trials enrol) dilute it. In order to achieve 
this,  the  trialists  a  priori  decide  to exclude  certain  subgroups  of  the  patient 
population that according to them would add to the “noise”. Hence, when t PA 
trials were designed, certain subgroups of patients were excluded from getting 
t PA. Investigators assumed that these patients were more likely to suffer poor 
outcomes (e.g. baseline severity >25 on NIHSS scale) or would get better any 
way  (e.g.  mild  strokes).  As  a  result,  when  the  trials  turned  positive,  those 
patients that were recommended for exclusion were not given approval in the 
drug license. This is because of lack of randomised data and not because the 
trial had shown poor outcomes in those patients.( See Table 1 3) Nishant Kumar Mishra, 2011              Chapter 1 , 59 
 
Table   1-3 Table showing various exclusion criteria that were incorporated in the t-PA trials  
 
Exclusion criteria  NINDS
122  ATLANTIS A* 
126 128  ECASS III
129  EPITHET
181 
Intracranial haemorrhage   Yes  Yes  Yes  Yes 
Unknown time since 
symptoms onset 
Yes  Yes  Yes  Yes 
Rapidly improving symptoms 
or only minor before start of 
infusion 
Yes  Yes; minor stroke< 4 
points on NIHSS 
Yes  Minor stroke 
defined as m RS 
<5; rapidly 
improving stroke 
Seizure at stroke onset  Yes  Yes, if known active 
seizure disorder; or first 
seizure within the 6 
hours immediately 
before administration 
of study drug 
Yes  Yes 
Stroke or serious head 
trauma within previous 3 
months  
Yes  Head trauma in last 90 
days; stroke in past 6 
weeks 
Yes  Yes 
Combination of diabetes and  No  No  Yes  No Nishant Kumar Mishra, 2011              Chapter 1 , 60 
 
previous stroke 
Platelet < 100000/ml  Yes    Yes  Yes 
Systolic BP>185 and Diastolic 
BP>110. 
Yes, if aggressive 
blood pressure 
treatment was 
needed. 
Yes; or if requiring 
aggressive treatment to 
bring down the BP to 
normal. 
Yes, and if 
aggressive 
treatment was 
needed. 
Yes, if aggressive 
treatment was 
needed. 
Blood glucose level   Yes, if <50  and > 400 
mg/dl 
Yes, if <50 or >400 
mg/dl 
Yes if <40 or > 400 
mg/dl 
Yes if <40 or > 400 
mg/dl 
Symptoms suggestive of SAH 
even if CT is normal 
Yes  Yes  Yes  Yes 
Anticoagulant treatment  Yes, if received 
heparin in previous 
48 hours and had an 
elevated PTT;PT>15 
seconds 
  Yes  Yes, if received 
heparin in 
previous 48 hours 
and had an 
elevated 
PTT;PT>15 
seconds 
Major surgery or severe 
trauma in previous 3 months 
Surgery within 14 
days. 
Surgery in last 30 days; 
or a biopsy of a 
parenchymal organ; or 
Yes  Surgery in last 14 
days Nishant Kumar Mishra, 2011              Chapter 1 , 61 
 
trauma with internal 
injuries or ulcerative 
wounds; 
Gastrointestinal or Urinary 
Tract Haemorrhage 
Yes, if within 
previous 21 days 
    Yes, if within last 
21 days. 
Arterial puncture on non 
compressible site 
Yes, if within 
previous 7 days 
    Yes, within 
previous 7 days 
Other medical disorders 
associated with increased 
risk of bleeding 
  Hereditary or acquired 
haemorrhagic diathesis 
(raised 
APTT,PT;Coagulation 
factor deficiency; oral 
anticoagulant therapy 
with raised PT) 
Yes   
Others    Coma, severe 
obtundation, fixed eye 
deviation or complete 
hemiplegia; previous 
intracranial 
haemorrhage, 
Age <18 or > 80 
years 
If patient presents 
before 3 hours or 
after 6 hours; age 
below 18; non  
contrast CT scan 
showing Nishant Kumar Mishra, 2011              Chapter 1 , 62 
 
neoplasm, 
arteriovenous 
malformation or 
aneurysm; presumed 
septic embolus, 
pericarditis, presence 
of vascular thrombus or 
aneurysm related to 
AMI; other serious 
advanced  terminal 
illness; any other 
condition that 
investigator felt would 
cause  significant harm 
to patients if the drug 
was given; if patient 
was participating in any 
other trial; CT Brain 
showing high density 
lesions suggesting 
haemorrhage and 
major early 
ischaemic 
changes; inability 
to undergo MRI; 
history of ICH; if 
confounding 
neurological 
illnesses present 
like dementia or if 
patient suffered a 
life threatening 
illness. Nishant Kumar Mishra, 2011              Chapter 1 , 63 
 
haemorrhage, 
significant mass effect  
showing midline shift or 
SAH; pregnancy, 
lactation or parturition 
within last month. 
 
*ATLANTIS B had similar exclusion criteria. In addition it considered the presence of parenchymal hypo density, loss of grey/white matter distinction, 
and/or effacement of cerebral sulci in 33% of the middle cerebral artery territory as exclusion criteria; these were based on data from ECASS trial.
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It is more than 15 years since the first positive t PA trial, NINDS trial (two parts, 
published  together),  was  reported.
24      So  far  only  the  time  criteria  of  drug 
licensing has been examined in a randomised trial design in which the findings 
suggested that the time window could be extended until 4.5 hours of symptoms 
onset.
129  Many of the original exclusions continue to persist in routine clinical 
practice  and  prevent  a  significant  proportion  of  patients  from  getting 
thrombolysis therapy.  
Large  proportions  were  excluded  from  the  NINDS  trial.  17367  patients  were 
originally  screened.  Then,  investigators  had  excluded  8708  (51.6%)  patients 
because  of  delayed  presentation,  10%  (N=1749)  due  to  rapidly  improving 
symptoms,  7.8%  (N=1306)  due  to  intracranial  haemorrhage,  6.6%  patients 
(N=1106)  due  to  minor  symptoms,  6.1%  (N=1021)  because  of  age  <18  or  >80 
years,  2.9%  (N=490)  due  to  serious  illnesses,  2.3%  (N=391)  due  to  seizure  at 
stroke onset, 2.2% (N=373) because they were not stroke, 1.3% (N=219) because 
of a recent stroke, 1.2% (N=210) due to prior use of oral anticoagulant and 1% 
(N=169) due to previous subarachnoid haemorrhage.  Only 3.5 % of the screened 
patients were finally enrolled to the NINDS trial.
122,123   
David  Tong  and  colleagues  reported  Simplified  Management  of  Acute  Stroke 
Using  Revised  Treatment  criteria  (SMART)  for  thrombolytic  therapy.  In  the 
absence of these criteria, a large proportion of patients would be excluded from 
getting t PA (as shown in figure 1 2). According to SMART recommendations all 
ischaemic stroke patients are considered for use of thrombolytic therapy despite 
presence of common exclusions (see figure 1 2).
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Figure   1-3 Figure shows frequency of common 
relative  contraindications  to  the  use  of 
alteplase in acute ischaemic stroke.  
 
 
 
 
 
 
 
 
 
Source: http://www.westernstroke.org/files/4_ExtendingTimeWindow_Tong.pdf (permissions obtained from Dr D Tong)
203,204  
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Because  the  various  non evidence based  (i.e.  randomised  data  are  lacking) 
exclusions  are  suggested  by  drug  licensing  agencies,  many  physicians  strictly 
follow  them.  As  a  result,  large  proportions  of  patients  who  have  ischaemic 
stroke  and  present  within  the  therapeutic  time  window  fail  to  receive 
thrombolytic  therapy.  In  this  thesis,  I  revisit  the  rationale  behind  these 
exclusions  and  then  examine  outcomes  in  those  who  are  recommended  for 
exclusion from getting t PA.  For this, I asked various t PA trialists about the 
deliberations that took place during the period that preceded these trials (at the 
design phase), and got some information from NINDS investigator, Prof James 
Grotta.  I mention them here. 
t-PA was selected for use in the NINDS trial at a dose of 0.9mg/kg based on two 
underpowered  studies.
42,80  These  studies  had  suggested  that  there  were 
increased risks with the use of higher doses. Regarding exclusion criteria, there 
were no numerical cut-offs prescribed for baseline severity in the NINDS trial. 
Regarding a query about exclusions based on blood sugar levels, I was informed 
that these were based on consensus in the group: it was decided to exclude 
patients  whose  blood  sugar  levels  were  low  enough  to  cause  stroke-like 
symptoms  or  high  enough  to  lead  to  neurological  problems.  Regarding 
appropriate  cut-offs  for  platelet  count  or  prothrombin  time  at  baseline,  a 
consensus  was  built  based  on  the  practices  by  cardiologists  for  myocardial 
infarctions.  The  purpose  of  exclusions  was  that  the  investigators  wished  to 
reduce risks, i.e., chance of bleeding, in most cases. Exceptions to this were the 
situations  like  seizures,  rapid  improvement  of  symptoms  and  high  or  low 
glucose  level  which  were  included  to  eliminate  the  stroke  mimics.  Rapidly 
improving or minor symptoms were excluded because investigators wished to 
exclude the TIAs. The source of many of the exclusions in the NINDS trial was 
from the exclusions prescribed for patients having myocardial infarctions e.g., 
patients having prior stroke or serious head trauma within preceding 3 months 
and major surgery in previous 14 days, gastrointestinal haemorrhage or urinary 
tract  haemorrhage  within  the  previous  21  days,  arterial  puncture  at  a  non-
compressible site within prior 7 days or platelet counts below 100,000 per cubic 
millimetre.The upper limit of systolic blood pressure was set at 185 mm of Hg Nishant Kumar Mishra, 2011    Chapter 1, 67 
 
and diastolic blood pressure at 110 mm of Hg based on prior experience of Dr T 
Brott.  Patients  having  symptoms  which  suggested  that  they  suffered  a 
subarachnoid  haemorrhage  were  also  recommended  for  exclusions.  This  was 
because  at  that  time  the  CT  imaging  did  not  have  great  resolution  and  the 
investigators  were  afraid  that  they  would  miss  a  subtle  SAH.  Patients  with 
seizures at symptoms onset were recommended for exclusions because if the 
patients had some of their symptoms because of Todd’s paralysis, its resolution 
might  be  due  to  natural  history  and  not  related  to  improvement  of  stroke. 
There  was  no  vascular  imaging  at  that  time  that  would  have  allowed 
visualisation  of  occluded vessels patients  suffering ischaemic stroke and  also 
have seizures at stroke onset. It was not, therefore, possible to include patients 
with  seizure  at  stroke  onset  in  the  trial.  Patients  who  were  taking 
anticoagulants or who had received heparin within 48 hours preceding the onset 
of  stroke  and  had  an  elevated  partial-thromboplastin  time  were  also 
recommended  for  exclusion. At  that  time,  investigators  did  not  know  if  re-
occlusion was going to be a big problem. As is known, it is a problem in coronary 
recanalisation.  If it occurred, then the investigators were going to be more 
inclined to allow the use of anticoagulants since that was being done after t-PA 
use for patients with myocardial infarction.  It was an assignment meant for Dr 
J Grotta to examine evidence that re-occlusion occurred after stroke.  He was 
unable  to  find  any  reports  documenting  re-occlusion.  He  acknowledges  that 
there were no good angiographic studies of acute stroke to rely on.  In addition, 
at that time there were no reports of improvement followed by deterioration 
which  would  have  suggested  recanalisation  followed  by  re-
occlusion.   Therefore, the  investigators  didn’t  think  that  the  evidence  for 
reocclusion  was  worth  the  risk  of  causing  bleeding  by  allowing  the  use  of 
anticoagulants, so they were very strict about the levels of PT and PTT that 
they  would  allow.   Investigators  also  prospectively  built  into  the  trial  the 
objective  of  looking  for  deterioration  following  improvement  (DFI)  as  a 
surrogate for reocclusion.  The reason they wrote the 48 hour heparin use was 
that because of the half-life of heparin, they were very sure it all would be 
gone within 48 hours if the PTT was normal. Regarding exclusion criteria  of 
prothrombin times, cut-off at 15 seconds was a guess and the reasoning was 
based on Myocardial Infarction (MI) data.     Investigators had agreed to exclude 
patients  from  receiving  alteplase  if  aggressive  treatment  was  required  to Nishant Kumar Mishra, 2011    Chapter 1, 68 
 
reduce  their  blood  pressure  to  the  specified  limits.  This  was  based  on  the 
viewpoint  of  Dr  Brott.  Further  by  aggressive  they  meant  IV  infusions,  in 
particular, nitroprusside.  At that point, nicardipine was not in use, but within 
a short time Dr Grotta’s department at Houston had begun using it and clarified 
with  the  steering  committee  that  its  use  was  allowed.  (Source:  personal 
communication with Prof James Grotta, UT Houston, USA) 
Exclusion criteria in other trials were similar to NINDS trial (See table 1 3), and 
probably had a similar logic. ATLANTIS B considered little additional exclusion 
like  the  presence  of  parenchymal  hypodensity,  loss  of  grey/white  matter 
distinction, and/or effacement of cerebral sulci in 33% of the middle cerebral 
artery  territory  based  on  data  from  the  ECASS  trial.
127  Exclusions  resulted  in 
serious reduction of sample size in each of these studies.   
The EMEA’S document “summary information on a referral opinion following an 
arbitration pursuant to article 29 of directive 2001/83/EC for actilyse” prepared 
by  European Agency  for the Evaluation  of Medicinal  Products (EMEA), London 
informs  about  the  status  of  alteplase  use  within  the  European  Union.
23  The 
document  states  that  within  EU,  alteplase  is  indicated  for  acute  ischaemic 
stroke patients presenting within 3 hours of symptoms. The drug should be used 
at a dose of 0.9 mg/kg (maximum dose 90 mg/kg, 10% given as bolus) and cannot 
be given concomitantly with the aspirin or heparin.
23 
 
Interestingly,  the  exclusions  differ  between  the  jurisdictions  reflecting 
regulatory acceptance of either NINDS criteria (US and Canada) or ECASS criteria 
(EMEA). US guidelines include different restrictions for <3h and 3 4.5h use. (See 
table 1 1)
25 
 
  
1.13 Utilisation of thrombolytic therapy in acute 
ischaemic stroke 
In  cardiology,  a  large  volume  of  data  is  available  to  show  that  thrombolytic 
therapy  reduces  mortality:  Gruppo  Italiano  per  lo  Studio  della  Streptochinasi Nishant Kumar Mishra, 2011    Chapter 1, 69 
 
nell’Infarto miocardico (GISSI 1; N=11806)
205, Intravenous Streptokinase in Acute 
Myocardial  Infarction  (ISAM;  N=1741)
206,  APSAC  Intervention  Mortality  Study 
(AIMS;  N=1004)
207  ,  Second  International  Study  of  Infarct  Survival  (ISIS 2; 
N=17187)
208,209,  Anglo Scandinavian  Study  of  Early  Thrombolysis  (ASSETS; 
N=13318)
210,  Urochinasi  per  via  Sistemica  nell’Infarto  Miocardico  (USIM; 
N=2531)
211,  Third  International  Study  of  Infarct  Survival)  Collaborative  Group 
(ISIS 3,  N=41299)
212,  Estudio  Multicentrico  Estreptoquinasa  Republicas  de 
America  del  Sur  (EMERAS;N=4534)
213  and    Late  Assessment  of  Thrombolytic 
Efficacy (LATE; N=5711)
214. These trials showed strong and significant treatment 
effect  and  were  published  around  a  similar  time  period.  The  findings  caught 
wide media attention and created enthusiasm and the thrombolytic agents were 
rapidly accepted by the cardiologists for the treatment of myocardial infarction. 
Large  volume  of  these  data  on  their  own  showed  efficacy  of  thrombolytic 
therapy in AMI; and, when examined in meta analysis reconfirmed the benefit 
(Mortality rate 9.6% vs. 11.5%, p<0.0001, N=58600).
215 
In the case of ischaemic stroke, the story has been different. Though, efficacy of 
alteplase  in  acute  ischaemic  stroke  had  been  endorsed  by    several  medical 
bodies  (like  American  Academy  of  Neurology,  American  Heart  Association  or 
European Stroke Organisation), the claims for better outcomes were based on 
fewer data from only three randomised trials (the NINDS trial (two parts, N=291 
and 333, data published together, in 1995) and ECASS III study (N=821, published 
in 2008))
122,129. Amongst the NINDS, ECASS, ECASS II and ATLANTIS, only NINDS 
trial was positive and reported efficacy of t PA in acute ischaemic stroke in a 3 
hours’ time  window.
122 But, the NINDS trial was underpowered to detect  any 
influence  on  mortality  (t pa  vs.  placebo  17%  vs.  21%,  p=0.3).
122    The 
Streptokinase  trials  showed  excess  complications  and  therefore  had  to  be 
abandoned.
48 50  So  far,  only  7152  patients  have  been  thrombolysed  in  26 
thrombolysis trials; and, only 3670 patients received t PA.
92,131  Fewer patients 
have been enrolled in thrombolysis trials compared to cardiology trials for acute 
myocardial  infarction.
215  Despite  FDA  approval  and  upgrading  of  the  level  of 
evidence  by  American  Heart  Association  (AHA,  from  Class  IIb  to  Class  I 
intervention i.e., from “optional” to “definitely recommended”), the drug was 
not  widely  accepted  by  physicians.
122,123 
216,217  Many  physicians  remained 
unconvinced by the data arguing that the data were few and were based on a Nishant Kumar Mishra, 2011    Chapter 1, 70 
 
highly selected population; and, the treatment could only be given effectively  
by the experts.
132 134,218  
Then there was a range of controversies about trial and AHA recommendations. 
In  an  article  published  in  BMJ,  in  March  2002,  Jeanne  Lenzer, a  medical 
investigative journalist, questioned the process leading to AHA recommendations 
for  t PA  use  in  acute  ischaemic  stroke  as  it  was  based  on  just  one  single 
randomised trial.
134 In that BMJ paper, the following issues were raised
134: It was  
argued that the NINDS trial could have been positive merely by chance.
218,219,134 
Questions  were  raised  around  imbalances  in  baseline  severity  data  of  those  
patients  that  were  treated  in  the  91 180  minutes  time  window  of  the  NINDS 
trial.
134 So far, NINDS was the only positive study that had shown benefit while 
various others had failed to show benefit; and, had instead demonstrated excess 
mortality from use of thrombolytic agent. 
134,218 222 Based on chart reviews of 
consecutive  patients  examined  in  emergency departments (between  1990  and 
1992), it was found that 19% of the patients were stroke mimics. Hence there 
was  a  logical  worry  that  a  physician  might  offer  a  t PA  therapy,  which  is 
associated with excess risk of haemorrhagic complications, to a patient who may 
not have a stroke. 
223  Further, the public health impact from the use of t PA was 
predicted to be minimal. 
134,224 Emergency physicians favoured a more restrictive 
licensing  than  the  one  endorsed  by  the  American  Heart  Association.
132,221  
Standard  Treatment  with  Alteplase  to  Reverse  Study  (STARS)  had  indicated 
effectiveness  of t PA. But, there is a  question  as  to whether a study can  be 
considered  to  be  an  “effectiveness”  study  if  the  participating  centres  had 
already had experience of working as the sites for the ATLANTIS trial. 
134 The 
ATLANTIS  trial  had  received  sponsorship  of  Genentech,  a  pharmaceutical 
company that manufactures alteplase.
134 Further, it was worrisome to see the 
reports from Cleveland study that had shown poor outcomes in patients treated 
with t PA.
134 The American Heart Association had claimed that t PA saved lives, 
but the data did not show reduction in mortality.
134 Lenzer highlighted that AHA 
had  received  massive  funding  from  Genentech  implying  a  strong  conflict  of 
interest.
134  In  summary,  there  were  some  controversies  about  the  manner  in 
which the t PA guidelines were framed or NINDS trial findings were promoted.
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The  European  Medicines  Agency  did  not  license  t PA  in  European  Union  for 
several years, and when it did, it required the sponsors to show efficacy and 
safety  by  conducting  what  were  later  to  be  known  as  the  SITS MOST 
observational  study  and  the  ECASS  III  trial.
23    It  was  only  after  several 
observational  studies  (see  section  1.9)  and  importantly  the  SITS MOST  and  a 
positive phase III ECASS III trial (see section 1.7), (confirming effectiveness of 
alteplase until 4.5 hours of symptoms onset) that the scepticism around the use 
of alteplase got considerably reduced. But the body of randomised clinical data 
continues to remain small.
92,131  
It  is  expected  that  a  larger  body  of  trials  data  would  influence  clinical 
practice.
225 In the case of cardiology, Ketley and Woods undertook to examine 
the temporal profile of the manner in which the thrombolytic therapy for acute 
myocardial infarction was adopted in the Trent Regional Health Authority Area 
after the thrombolysis trials got published.
225 They based their analyses on the 
supply of thrombolytic drugs from all sources (district pharmacy services or trial 
organisations) for the period of 1987 1992.
225 The results of the study are shown 
in figure 1 3. The study showed that the supply was negligible for the first two 
years after the GISSI study but gradually increased after ISIS 2 and reached an 
approximate plateau at around 1991 1992.
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Figure   1-4 Figure shows the trend in the thrombolytic use over time (1987-1992) for patients 
suffering acute myocardial infarction in the Trent Regional Health Authority area of Central 
England.  The  central  thick  line  shows  the  mean  values,  the  other  two  lines  show  the 
standard deviation.   
 
 
[Source:  Ketley  D,  Woods  KL.  Impact  of  clinical  trials  on  clinical  practice:  example  of 
thrombolysis for acute myocardial infarction. Lancet 1993; 342:891-4. Permissions obtained 
from Elsevier Limited, The Boulevard, Langford Lane Kidlington,Oxford,OX5 1GB,UK; License 
number 2783780816358]
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Ketley  and  Wood’s  study  shows  that  there  was  a  lag  phase  after  which  
thrombolytic therapy began to pick up its pace of usage in the community and 
then reached a plateau between 1991 1992.
225   
But, it has not always happened that the trial findings influence clinical practice 
(for  example,  despite  a  showing  that  diethylstilboestrol  did  not  benefit, 
pregnant women continued to use it during the 1950s).
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Figure   1-5 t PA usage in the United States of America 
 
(Source: Adeoye O, Hornung R, Khatri P, Kleindorfer D. Recombinant tissue type 
plasminogen activator use for ischaemic stroke in the United States: a doubling of 
treatment rates over the course of 5 years. Stroke 2011; 42:1952 5. Permissions 
obtained from Wolters Kluwer Health 2783780982628) 
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In  case  of  thrombolysis  trials  for  stroke,  the  manner  in  which  their  data 
influenced  stroke  practices  in  the  past  (prior  to  ECASS  III)  may  only  be 
speculated upon. Unlike cardiology, there were fewer data of stroke patients 
having  better  outcomes  after  receiving  thrombolytic  therapy.  There  was  an 
original  scepticism  about  the  efficacy  of  t PA.  These  factors  may  have 
contributed to initial poor usage of thrombolytic therapy. Another reason would 
have been that the stroke care is resource intensive and requires the setting up 
of a stroke unit, imaging facilities and access to an experienced clinical staff. 
These things take a while to get organised in hospitals. Adeoye et al report that, 
in  USA,  there  has  been  a  significant  increase  in  the  t PA  usage  between  the 
years 2005 and 2009 (1.1% to 3.4%, p<0.001 for trend). The rates were stagnant 
between 2001 and 2005 (figure 1 4).
228 The following reasons were cited for the 
increased rates of usage after 2005: financial incentive given to the hospital, 
Joint  Commission  certification  of  primary  stroke  centres,  initiatives  to 
standardise  acute  stroke  care,  and  the  aggressive  Get  With  The  Guidelines 
(GWTG) campaign.
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Figure   1-6 Figure shows number of patients recorded in SITS registry in each quarter  
 
Source:    Ahmed  N,  Wahlgren  N,  Grond  M,  et  al.  Implementation  and  outcome  of 
thrombolysis with alteplase  3 4.5 h after an  acute  stroke: an updated analysis from 
SITSISTR. Lancet Neurol 2010; 9:866 74; Permissions obtained from Elsevier Limited The 
Boulevard,  Langford  Lane,  Kidlington,  Oxford,  and  OX5  1GB,  UK,  License  number: 
2783781166304.
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After the NINDS trial, it was only the ECASS III trial that was positive and has 
shown  better  outcomes  amongst  stroke  patients  (in  3 4.5  hours’  time 
window).
129 So, did it influence the clinical stroke practice? SITS ISTR registry 
recorded  an  “immediate  and  lasting”  effect  of  ECASS  III  publication  with  no 
change  in  the  presentation to hospital  to  initiation of treatment  time.
229 
Similarly, a Swedish  Stroke Registry has reported that after the publication of 
ECASS III trial,  rates of t PA utilisation increased from 0.5% to 2.1% (between 
2008 2010 in patients treated within 3 4.5 hours’ time window).
230 The rates in 
0 3 hours had increased from 0.9% in 2003 to 6.6% in late 2008 and then levelled 
at  a  thrombolysis  rate  of  about  6%
230.  There  was  no  difference  between  the 
median time of arrival to hospital and the start of treatment (p=0.06).
230  Here, 
the 0 3 hour time window thrombolysis program had developed over the years, 
but, the 3 4.5 hours t PA use could be initiated soon after the ECASS III results 
went public. This was only possible because these centres had already developed 
the necessary infrastructure and the experienced physicians. Increased usage of 
t PA after ECASS III trials suggests that the ECASS III trial had an impact on the 
clinical practice.
230 
Further,  the  Swedish  noted  a  plateau  effect  for  the  use  of  alteplase.  It  was 
attributed to the fact that the these hospitals had reached a saturation level for 
the rate of thrombolysis they could achieve within their jurisdiction.
230  It may 
be speculated that the t PA use in 3 4.5 hour time window might also level off in 
a similar fashion when the hospitals would reach saturation levels for the use of 
t PA.    So,  for  the  next  rise  in  t PA  usage  to  commence,  one  would  need 
additional  high  quality  clinical  evidence  for  the  treatment  of  some  more 
additional patients that at present do not get treated with t PA. This is possible 
because, some of the Swedish centres that practice off label use of t PA report a 
higher rates of thrombolysis (≈10 15%).
230  
So it can be thought that in order for change in current clinical practice to occur 
and to treat more patients, we should have more randomised controlled clinical 
data. Only randomised controlled trials can provide the best quality of clinical 
evidence and assuage the fears of poor outcomes in stroke patients. Data on 
subgroups that are currently excluded would allow physicians to better select 
patients.  But,  conducting  such  a  trial  would  be  a  difficult  task  because Nishant Kumar Mishra, 2011    Chapter 1, 78 
 
physicians  do  not  have  uniform  opinion  regarding  the  effectiveness  of  t PA 
therapy in the several patients’ subgroups (e.g. physicians differ in their opinion 
regarding treatment of mild ischaemic strokes or the elderly patients that suffer 
an  ischaemic  stroke)  or  for  treatment  approach,  (like,  intravenous  vs.  intra 
arterial); and, therefore  there is  a lack  of equipoise. Alteplase is already an 
approved treatment for acute ischaemic stroke in most countries. Some centres 
employ  practices  in  which  they  are  extremely  good  (e.g.  intra arterial 
thrombolysis).  Hence,  participation  in  randomised  controlled  trials  may  be 
difficult for these physicians.
231 Also, the enrolment of patients in t PA trials is a 
slow process that takes a while to reach the target sample size. About a decade 
ago, IST 3 trialists set out with a target of 6000 patients to be randomised within 
6 hours of symptoms onset.
232 So far, they have only been able to enrol about 
3000  patients.
233,234  Recruitment  would  also  be  challenging  because  patients 
meant for exclusion constitute only a small fraction of those that get treated 
(e.g. in SITS ISTR, 2.6% patients have concomitant diabetes and previous stroke, 
n/N=602/23062).   
1.14 Why aren’t many eligible patients treated with t-PA in 
the routine clinical practice? 
In routine clinical practice, there are other variables that influence patients’ 
selection: delay in arrival at a stroke treatment facility within the time window,  
lack of awareness (including amongst some physicians
235)
18, delay in admission to 
a  stroke  treatment  facility  and  lack  of  local  stroke  care  facility/expertise.
236  
Many physicians fear excessively about the bleeding complications and therefore 
they  do  not  thrombolyse  those  patients  that  belong  to  any  of  the  exclusion 
mentioned in the list of the t PA exclusion criteria.
236,237  Some expert centres 
practise off label use of t PA based on a physician’s clinical judgement; but fear 
of litigations or causing harm (due to valid reasons that had originally influenced 
the drug authorities to considering patients for exclusion) prevent many others 
from  using  t PA  in  scenarios  that  do  not  find  clear  mention  in  treatment 
protocol.
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In those countries where the costs of health care are borne by the patients and 
relatives, t PA may not be used, because it is an expensive therapy.
238 The loss 
of disability adjusted life years incurred by underuse of thrombolytic therapy 
carries a large economic and societal cost. Hence, national governments need to 
initiate programs to treat acute stroke patients.
18,20  
There  is  wide  variation  in  the  usage  of  t PA  for  ischaemic  stroke  between 
centres.  For  example,  an  analysis  of  Healthcare  Benchmarking  Systems 
International  (HBSI)  EXPLORE  database  showed  that  35%  of  the  community 
hospitals (profit and non profit hospitals throughout USA) did not use t PA at all; 
and the variables that significantly influenced the use of t PA in these hospitals 
were race, age and disease severity(N=137 centres, 23058 patients).
239  
There is an intra and inter country variability in the use of t PA as well (figure 1 
6,  for  UK  contribution  to  SITS Centres).
240,241  The  variation  between  centres 
could reflect the limited evidence that is available for the use of t PA in various 
subgroups.  Physicians  are  also  concerned  about  the  patients’  safety  and 
therefore  might  not  treat  those  patients  for  whom,  based  on  their  clinical 
judgement, the potential for harm outweighs the possible benefit. Nishant Kumar Mishra, 2011    Chapter 1, 80 
 
 
 
Figure    1-7    Figure  shows  UK  SITS  centres  with  size  of  circle  denoting  the  number  of 
patients recruited within the SITS registry from each of these centres 
 
 
 
Source: Lees KR, Ford GA, Muir KW, et al. Thrombolytic therapy for acute stroke in the 
United Kingdom: experience from the safe implementation of thrombolysis in stroke 
(SITS) register. QJM 2008;101:863-9; Permissions obtained from Oxford University Press, 
License Number: 2783781419775 
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Thrombolysis  is  a  standard  practice  for  the  treatment  of  patients  suffering 
myocardial  infarction,  but  the  acceptance  rate  is  lower  amongst  physicians 
caring  for  acute  stroke:  only  about  5%  of  the  patients  receive  thrombolytic 
therapy.
228 
 Alteplase is associated with absolute benefit of 10 15%, but because 
it  is  infrequently  used,  it  hasn’t  had  the  kind  of  public  health  impact  it  is 
expected to have. There is a need to enhance community awareness about the 
need  for  emergent  stroke  care  and  encourage  participation  of  community 
hospitals in providing stroke care. 
Racial  differences  are  known  to  influence  stroke  outcomes,  and  inter ethnic 
differences in risk factor profiles are well described.
242 244 The Japanese drug 
agency  approved  a  lower  dose  of  0.6mg/kg  in  lieu  of  0.9  mg/kg  for  the 
treatment of acute ischaemic stroke. 
245 249251 The Chinese examined outcomes in 
patients treated with a lower dose of 0.6mg/kg (n=116) and standard 0.9mg/kg 
(n=125) and observed that there occurred excess symptomatic haemorrhages in 
the standard group (rates were, per NINDS, 10.4% vs. 5.2%; per ECASS definition, 
8.0%  vs.  2.6%;  SITS MOST  definition,  5.6%  versus  1.7%,  respectively)  and 
mortality  at  90  days  (12.8%  versus  6.9%)  in  the  patients  that  received  the 
standard 0.9mg/kg dose.
250 These differences may be attributed to the ethnic 
variability in the rate of fibrinolysis.
251 253 It is likely that certain ethnic groups 
respond differently to the use of t PA; and, therefore these physicians might be 
cautious when extrapolating thrombolysis data on their population. 
 
1.15 Present Thesis 
When  the  NINDS  trial  proved  the  efficacy  of  alteplase,  the  US  FDA  promptly 
approved its use within its jurisdiction.
123 However, EMEA was not immediately 
convinced  and  argued  whether  findings  based  on  an  non European  trial  that 
studied only over a thousand patients could be extrapolated onto the European 
population.
23 Proponents of alteplase argued that though European trials (ECASS 
I, II) had not shown favourable outcomes similar to the NINDS trial, failure could 
be attributed to differences in trial design.
23 An ad hoc expert group had also 
failed to show a definitive and a big treatment effect from the use of alteplase 
in elderly stroke patients, patients having diabetes or patients having a severe Nishant Kumar Mishra, 2011    Chapter 1, 82 
 
stroke.
23 The expert group suggested that a randomised controlled trial in this 
subgroup of the patient population would be required to confirm the efficacy of 
use of the alteplase.
23  The Committee for Proprietary Medicinal Product (CPMP) 
felt the need to undertake a randomised dose comparator study for time window 
0 3 hours, but conducting such a  study was  not considered feasible owing  to 
ethical concerns.
23 Several centres had already incorporated alteplase in their 
local clinical practice.
23  Hence, it was proposed to study efficacy of alteplase in 
a  3 4  hour  time  window  in  a  randomised  controlled  trial  design  and  by 
undertaking a safety study of observational data for patients treated within the 
3 hour time window.
23 While the ECASS III trial showed efficacy and safety of 
alteplase  in  acute  ischaemic  stroke  patients  when  administered  between  3 
and 4.5 hours after the symptoms onset, the SITS MOST study confirmed that i.v. 
alteplase is safe and effective in routine clinical use when used within 3 h of 
stroke onset.
129,146  
When  formulating  CPMP  approval,  the  EMEA    recommended  few  exclusion 
criteria that were incorporated in ECASS III study.
23  After outcomes were shown 
to be better for the patients treated in 3 4.5 hour time window in the ECASS III 
trials,  uncertainties  continue  to  persist  for  those  that  were  excluded  from 
trials.
23 Now that alteplase is proven to be effective in ischaemic stroke, it is 
desirable to investigate if other exclusions are justified and if treatment could 
be  extended  to  other  patients  that  are  included  in  current  EMEA  list  of 
exclusions.
23 
In the present thesis I have tackled following questions:  
 
1.  Should  elderly  patients  receive  alteplase  for  their  acute  ischaemic 
stroke? [Chapter 3 and Chapter 4] 
2.  Should patients having a concomitant diabetes and history of previous 
stroke receive alteplase therapy? [Chapter 5 and Chapter 6] 
3.  Should patients having mild or severe stroke receive alteplase for acute 
ischaemic stroke?[Chapter 7] 
4.  Should thrombolytic therapy be administered to stroke patients based 
on mismatch criteria and beyond 3 hours of symptoms onset? [Chapter 
8]        
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2   Methodology 
Here I describe the methodology that I have used with its merits and limitations. 
2.1 Introduction 
Clinical  Investigation  refers  to  the  examination  of  clinical  data  for  the 
association of intervention(s) with the outcomes in a study population. Expert 
opinions  based  on  anecdotal  evidence  are  likely  to  result  in  flawed 
conclusions.
254  Clinical  trials  are  the  best  means  of  investigating  treatment 
interventions.
254  
I  selected  data  from  the  Safe  Implementation  of  Thrombolysis  in  Stroke 
International Stroke Thrombolysis Register (SITS ISTR) and Virtual International 
Stroke Trials Archive (VISTA) for this thesis for reasons of time and practicality 
and  undertook  to  examine  outcomes  in  patients’  subgroups  that  were 
recommended for exclusion by the European drug authorities.
147,255 I hoped that 
if my findings were consistent between the two datasets, I would have given a 
useful piece of evidence to support (or reject) thrombolytic therapy for those 
patients that are currently recommended for exclusions. These findings could be 
an  important  source  of  information  for  physicians  until  further  confirmatory 
randomised data are available. 
For SITS  and VISTA  analyses, blinding and randomisation techniques could not 
be employed. These data were already collected per the protocol of SITS group 
or VISTA trialists. I undertook a controlled comparison using controls from VISTA 
dataset. VISTA controls were compared with patients that received alteplase in 
VISTA trials or in SITS ISTR registry.
147,255 
  
2.2 Data Source 
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VISTA  is  a  collaborative,  not for profit,  register  of  stroke  trials.
255  The 
treatments studied in these trials range from putative neuro protectants through 
anticoagulants  and  thrombolytic  agents  to  simple  rehabilitation  measures.  All 
trials  in  VISTA  hold  necessary  review  board  and  regulatory  approvals,  and 
patients consented to participation; only anonymised data are held by VISTA and 
the trial source is not disclosed as per VISTA guidelines. All stroke patients were 
treated  as  per  institutional  practice  and  stroke  guidelines  acceptable  at  the 
point of trial conduct. Monitoring for protocol compliance was undertaken on 
behalf  of  sponsors  for  these  trials.  This  implies  that  where  thrombolysis  was 
administered,  this  was  in  accordance  with  marketing  authorisation  for  the 
relevant country, i.e. that treatment commenced within 3 hours of stroke onset; 
however, the onset to treatment delay is not recorded for thrombolysis in these 
trials. Further, note that the reason for withholding thrombolysis in each patient 
was not recorded in VISTA, but will include absence of marketing approval in the 
region at that time, clinical uncertainty over the use of thrombolysis for stroke 
generally, absence of treatment facilities for thrombolysis in the hospital at that 
time,  and  contraindications  to  thrombolysis  for  the  individual  patient.  These 
data were derived mainly from Northern American (60%), European (16%) and 
Australasian (13%) centres.
255 
 
For  my  research,  VISTA  data  were  obtained  from  neuroprotection  trials  that 
were  conducted  between  1998  and  2007.  These  trials  hold  necessary  review 
board  and regulatory approvals. The  patients had consented  to participation. 
VISTA holds only anonymised data. These data were rigorously collected by the 
trialists.  Some  of  the  patients  in  the  studies  received  an  investigational 
neuroprotective agent. One or more of these neuroprotective agents could have 
interacted with thrombolysis; however each contributing trial has already tested 
for  and  excluded  significant  interaction.  VISTA  data  handling  procedures 
preclude  further  testing  for  effects  of  the  original  neuroprotection  agent  or 
identification  of  source  trials.  Hence,  I  cannot  identify  the  trials  that 
contributed to VISTA dataset, nor did I ever have access to these: I was given 
access to an anonymised dataset of 9665 patients from VISTA.  
SITS ISTR  is  an  ongoing  internet based,  academic driven,  interactive 
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University Hospital, Stockholm. The methodology of the SITS ISTR including the 
procedure  for  data  collection  and  management,  patient  identification  and 
verification of source data has been described in their early publications. It is a 
prospective, open, multinational, observational monitoring registry for clinical 
centres using thrombolysis and other interventions for the treatment of acute 
ischaemic  stroke.  The  registry  is  open  to  all  countries,  and  collects  data  on 
patients who receive thrombolytic therapy for acute ischaemic stroke.
147,256 
 
I was given SITS ISTR data after their extraction from the SITS ISTR and on my 
arrival at the Department of Neurology, Karolinska University Hospital. For the 
present thesis, data were extracted for a period December 2002 to November 
2009.  These  data  were  then  combined  with  a  control  group  derived  from 
untreated  stroke  patients  (untreated  for  t PA)  within  VISTA  neuroprotection 
trials conducted between 1998 to 2007 and held within the Virtual International 
Stroke Trials Archive, VISTA (www.vista.gla.ac.uk). Referred to as “SITS VISTA”, 
this combined dataset is employed for analyses in chapter 4 and 6.   
I show the details of data extraction in the figure 2.1.to indicate completeness 
of data that were available for present analyses. Further, information on missing 
data for various co variates can be inferred from the  baseline characteristics 
that I report in each chapter. Nishant Kumar Mishra, 2011                                                                                          Chapter 2, 87 
 
 
 
 
 
 
 
 
 
Figure    2-1  Flow  chart  showing  the  details  of  data  extraction  for  VISTA 
(above) and SITS-ISTR (below) which are employed for analyses in the present 
thesis 
2 
                                                 
2   I published these figures in two papers: Mishra NK, Diener HC, Lyden PD, Bluhmki E, Lees KR; VISTA Collaborators. 
Influence of age on outcome from thrombolysis in acute stroke: a controlled comparison in patients from the Virtual 
International Stroke Trials Archive (VISTA). Stroke. 2010 Dec;41(12):2840-8. and Mishra NK, Ahmed N, Andersen G, 
Egido JA, Lindsberg PJ, Ringleb PA, Wahlgren NG, Lees KR; VISTA collaborators; SITS collaborators. Thrombolysis in 
very elderly people: controlled comparison of SITS International Stroke Thrombolysis Registry and Virtual International 
Stroke Trials Archive. BMJ. 2010 Nov 23;341:c6046. doi: 10.1136/bmj.c6046 respectively; Permissions were obtained 
from Wolters Kluwer Health (License Number- 2790451375765) and BMJ Publishing Group Limited (License 
Number- 2783790122184) respectively. Nishant Kumar Mishra, 2011                                                                                          Chapter 2, 88 
 
 
When  reporting  findings  from  the  analyses,  I  describe  the  baseline 
characteristics  of  the  data  and  also  examine  them  for  completeness  of 
covariates (Figure 2.1).  
Data  on  9665  patients  were  collated  from  VISTA.  Of  these,  5342  (59%)  were 
enrolled from non European sites. To avoid dual publication with SITS MOST, I 
excluded 2789 patients (28%) enrolled from European sites between 2002 and 
2006, and 177 patients for whom the data lacked information on nationality.
146 
 
2.3 Ethics Approval 
Because  clinical  studies  ought  to  be  based  on  current  ethical  standards,  and 
because there is a range of procedures that ought to be followed in order to 
obtain consent, it was necessary to clarify these requirements from VISTA and 
similarly  later  from  SITS ISTR.    Ethical  considerations  are  an  important 
component of clinical investigations. In VISTA, participating patients had already 
consented to their participation in VISTA trials, and therefore it was deemed 
unnecessary to seek additional consents from the patients for the projects that 
had been proposed for the present thesis; it would also have been impractical 
since most by now would have died, even if they could somehow be identified.  
In order to obtain an unbiased and blinded feedback from other experts, a study 
proposal was circulated  between the VISTA steering  committee members and 
similarly to the SITS ISTR steering committee members. SITS Steering Committee 
members comprise members from all across Europe and the VISTA from all over 
the world. (See appendix)  
 
2.4 Outcome Measures 
Outcomes measured in randomised trials should be valid, reliable, robust and 
responsive. Common outcome measures that were employed in stroke research 
include the modified Rankin Scale, National Institute of Health Stroke Scales, 
Barthel Index and Scandinavian Stroke Scale.
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The Modified Rankin Scale (m RS) was originally not meant for use in trials, but 
now, it is a commonly used measure of outcome assessment employed in Stroke 
Trials.
257 It is an ordinal scale that scores patients for their functional status on a 
scale of  0 to 6 in which zero refers to the absence of any disability while  a 
score of six means that the patient is dead. Rankin scores are associated with 
substantial inter observer variability that is most apparent for the Rankin scores 
1 to 4.
258 Whereas one may find it easier to score a patient 0, 1, 5 or 6, it is 
often  difficult  to  distinguish  a  2  from  3  or  3  from  4  on  this  scale.    An 
examination of a hundred paired assessment suggested that kappa statistics for 
inter observer  variability  were  lower  than  those  for  intra observer  variability 
(0.57  vs.  0.72).
258  There  was  no  significant  difference  observed  between  a 
structured interview method and a standard m RS method.
258  But, two previous 
studies have also shown that weighted kappa statistics for agreement between 
raters of m RS scores were greater when a structured interview was used instead 
of the conventional method (k 0.91 vs 0.71 and 0.93 vs 0.78)
259,260In order to 
reduce  bias  arising  from  inter observer  variability,  measures  like  structured 
interviews or video training are employed.  
Scores on a modified Rankin scale
261 
·  0=no symptoms from stroke 
·  1=no severe disability, despite symptoms 
·  2=slight disability in which patients are unable to do all previous activities 
but able to look after themselves without help 
·  3=moderate disability that requires some help, but patients can walk by 
themselves 
·  4=moderately severe disability in which patients are unable to walk 
without assistance and need help for bodily needs 
·  5=bedbound patients who are incontinent or require personal attention 
·  6=death 
 
The National Institute of Health Stroke Scale (NIHSS) is a scale used to measure 
the neurological outcomes in stroke trials.
262 Its use is associated with increased 
power.
263 Baseline stroke severity measured on NIHSS is an excellent predictor of 
outcomes.
264 Age and baseline stroke severity account for maximal variance in 
stroke outcomes; which is why these are employed as covariates for adjusted 
analyses when comparing outcomes from use of t PA in present analyses.
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patient having a left sided brain lesion scores higher on NIHSS compared to a 
similar  right  sided  brain  lesion.
266  By  combining  the  NIHSS  scale  with 
neuropsychological tests like line bisection tests and visual perception tasks, one 
can augment its sensitivity for right brain lesions as well.
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Table   2-1 Modified National Institutes of Health Stroke Scale 
 
Source: Lyden P, Brott T, Tilley B, Welch KM, Mascha EJ, Levine S, Haley EC, Grotta J, Marler J. 
Improved reliability of the NIH Stroke Scale using video training.NINDS TPA Stroke Study Group. 
Stroke.  1994  Nov;25(11):2220 6.  Permissions  obtained  from  Wolter  Kluwer  Health,  License 
Number: 2813100962854 Nishant Kumar Mishra, 2011                                                                                          Chapter 2, 92 
 
 
For  analyses  presented  here,  from  VISTA,  I  had  access  to  two  measures  of 
outcome: modified Rankin scale and NIH stroke scale both measured on day 90 
of  the  stroke  occurrence.  From  SITS ISTR,  I  had  access  to  the  baseline 
demographics  and  only  m RS  score  on  day  90  of  stroke  as  a  measure  of 
outcomes. 
 
2.5 Errors and Bias 
Before beginning to collect data, it is desirable to consider the measures that 
can reduce errors or bias in a study.  
 
Errors are of two types:  random errors and systematic errors.  Random sampling 
error refers to chance variation that is observed between one study population 
and another. Bias refers to the deviation from truth of inferred results. It is a 
form of systematic error that is ubiquitous, results in erroneous estimates of 
association, and cannot be completely removed. Methods to prevent it should be 
thought  out  early  during the  design  and execution  phase  of  the study. When 
attempting  to  reduce  bias,  an  investigator  may  introduce  another  bias 
compromising  generalisability  of  the  results.  A  good  understanding  of  bias 
permits  better  interpretation  of  the  results  in  a  more  meaningful  way.  Bias 
occurs because of various reasons. For example, selection bias (sampling bias) 
occurs  when  a  sample  does  not  represent  the  population  under  study.  For 
instance,  predicting  the  rates  of  cardiac  disease  in  athletes  would  introduce 
selection bias because athletes are less likely to suffer cardiac illness. Berkson’s 
bias refers to a bias that is introduced from the hospital stay. Measurement bias 
occurs  when  information  gets  distorted  due  to  the  unique  characteristics  of 
methodology by which the data were collected. These include instrument bias or 
insensitive  measure  bias.  The  Hawthorne  effect  refers  to  situations  when 
attention is paid to the subjects under study that alters their behaviour and thus 
the  outcomes.  Intervention  Bias    results  from  abnormal  or  distorted 
interventions and leads to bias like contamination bias where the control group 
mistakenly receives treatment, co intervention bias  when some subjects receive 
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provided for a longer duration, compliance bias when there are differences in 
the  compliances  of  the  patients  enrolled  in  the  study  arms,  withdrawal  bias 
because some subjects withdrew from the study, proficiency bias that occurred 
when the interventions are not equally applied to the various subjects owing to 
differences in the proficiencies of the investigator and/or the differences in the 
resources or procedures employed at different centres.  
 
Hypothetically, by increasing the size of data, it is possible to reduce random 
sampling  error  and  bring  it  close  to  zero.  On  the  other  hand,  bias  has  no 
relationship to population size of study. In order to reduce bias, one can take 
the following measures: incorporate a placebo arm; undertake a blinded study; 
consider a cross over study design; apply good randomisation techniques; train 
the investigators about various stages of the study (e.g. ECASS II study, in which 
the investigators were trained in reading CT scans).   Despite measures to reduce 
bias, some bias may persist in a study; and, an exact degree of bias is never 
precisely known. An investigator may want to consider a trade off between bias 
and  variance,  and  logically,  accept  the  measurement  with  the  lowest  mean 
square of standard error.
268 
 
For my thesis, I undertook analysis of data that were already lodged in VISTA and 
SITS ISTR.  I  could  only  undertake  a  controlled  comparison  employing  robust 
statistical  techniques.  It  was  not  possible  to  employ  principles  of  blinding  or 
randomisation procedures in these datasets.  
 
2.6 Data Analyses 
The  Global  statistics  method,  responder  analysis  method  and  shift  analysis 
method  are  often  used  to  analyse  data  in  stroke  trials.
261,269 274    In  addition, 
simple analyses of dichotomised outcomes measures are also often used. In the 
global statistics method, one examines  outcomes employing a combination of 
multiple outcomes scales.
261,270 Responder analysis permits one to consider the 
prior disability  when examining the outcomes.
261  Shift analysis has the merit in 
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(or  poor)  outcomes.
261  In  the  case  of  stroke,  this  is  a  meaningful  method  of 
analysing data because the therapy does not always cure the patients, but shifts 
them in one or the other direction of the outcome spectrum. 
261,271  Analysis of 
artificially dichotomised outcomes scales is a simple method but is associated 
with  loss  of  information,  confusing  interpretation  of  results,  an  artificial 
creation of patients’ groups that are considered good or poor and loss of study 
power.
261,272,273    For  example,  Jeffrey  Saver  discusses  that  “When  the  7-level 
mRS is dichotomised as 0 to 2 vs. 3 to 6, a traditional breakpoint in binary trial 
analysis, the resulting analysis examines only one important transition in health 
state, from vocationally impaired, but able to live independently, to requiring 
assistance in daily living. However, this analysis places absolutely no value on 
other  health  state  transitions  that  are  pertinent  to  patients.  For  example, 
going from vocationally impaired (mRS=2) to no symptoms at all (mRS=0) is not 
counted as a clinically meaningful improvement, nor is going from dead (mRS=6) 
to moderately disabled and able to walk on one’s own (mRS=3). Binary outcome 
analyses prioritise only a single health state transition as clinically worthwhile, 
whereas  patients  naturally  place  great  value  on  several  health  state 
transitions.”
261  Nevertheless,  dichotomisation  has  its  advantages:  analyses  of 
ordinal  data  by  dichotomisation  of  outcomes  are  simple  and  proportions  so 
obtained can be easily converted to clinically intuitive values such as “number 
needed to treat”. Hence, the results so obtained are easy to interpret.
261 
However, unlike dichotomisation where one examines a few arbitrarily selected 
health  states,  shift  analyses  examine  all  health  states.
261,269  For  the  present 
thesis, I  decided to  undertake  “shift analyses” by  employing ordinal  analyses 
using  proportional  odds  logistic  regression  analyses  and  a  non parametric 
Cochran Mantel Haenszel  (CMH)  test.  In  addition  to  this,  I  also  analysed 
outcomes by dichotomising them. 
 
CMH  is  a  non parametric  approach  that  avoids  invoking  an  assumption  of 
proportional odds in which the odds ratios are common across all cut points of an 
ordinal outcome scale. Koch and Edwards described the relationship between 
the van Elteren test
275 and the extended Mantel Haenszel
276 procedure.
277 In SAS, 
the CMH test is done by employing proc freq procedure (see appendix). It is a 
powerful procedure available to SAS users. “cmh” in the code tells SAS software 
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Modified ridits (used to calculate within stratum standardised midrank scores) 
are employed to undertake transformations that are necessary to run the right 
calculations. 
 
Mantel Haenszel methods can be employed in situations of IxJ tables, where I>2 
and/or J>2, that is, when in a case control study, the exposure levels and/or the 
outcome levels are more than 2.   
 
In the present analyses, there were two possible exposures with respect to use 
of the use  of alteplase: thrombolysis  or  no thrombolysis (controls). Outcomes 
had 6 levels in case of m RS outcomes and 9 levels in case of NIHSS categorised 
outcomes.  The  CMH  test  tested  for  an  association  of  “use  of  t PA”  (C)  and 
“outcomes” (D) by controlling by stratification for covariates (A and B, see an 
example code in the appendix) that were introduced in the model. 
275 277 
 
The  CMH  test  gives  3  different  sets  of  correlation  statistics:    Non-zero 
correlation, Row Means Scores Differ and general association. If the p value for 
Non-zero correlation is significant, results are interpreted as linear correlation 
between two ordinal variables for at least one stratum. If the p value for Row 
Means Scores Differ (RMSD) is significant, the interpretation is, for an ordinal 
column variable the mean CMH scores differ across the columns for at least one 
stratum.  If  the  p value  for  general  association  is  significant,  there  is  an 
association  between  the  two  variables  for  at  least  one  stratum.  The  RMSD 
statistic when significant suggests that an effect across the m RS spectrum is 
significant. RMSD is used for interpretation when the data are arranged such that 
only the columns have an order (in case of analyses presented in this thesis, the 
Rankin Scores or the NIHSS scores, that have an order).  
 
In order to undertake adjusted  analyses, covariates were introduced into  the 
CMH test. As mentioned earlier, adjusted analysis involving the CMH test occurs 
by  means  of  stratification  of  outcome  data  of  thrombolysed  and  non 
thrombolysed patients for various covariates. Therefore, this is limited by the 
sample  size  and  can  preclude  simultaneous  adjustment  for  several  variables. 
Hence,  I  prospectively  planned  to  adjust  for  age  and  baseline  NIHSS  and  to 
consider  other  variables  only  in  exploratory  analyses.  The  choice  of  baseline Nishant Kumar Mishra, 2011                                                                                          Chapter 2, 96 
 
 
factors for adjustment was based on two influences.
278 First, age and baseline 
severity are the two most powerful prognostic factors for stroke and are usually 
included in outcome distribution analyses. Baseline NIHSS accounts for about 80% 
of  the  variance  in  outcome  data  of  stroke  patients.
265,279,280  Second,  age  and 
NIHSS data were available for  our  entire sample, whereas some of the  other 
factors  of  potential  interest  were  incomplete.  However,  I  also  undertook  a 
sensitivity  analysis  by  considering  the  combined  effect  of  the  variables  that 
differed significantly at baseline.  
 
Because  the  CMH  test  does  not  measure  the  extent  of  association,  I  also 
undertook a proportional odds logistic regression analysis.  
 
Ordinal  Regression  Analysis  (Proportional  Odds  Logistic  Regression  Analysis)  is 
employed  when  the  distribution  of  scores  is  not  normal  and  the  majority  of 
respondents scores are at extremes of the scale.
281,282 SAS software allows an 
analysis  that  fits  a  proportional  odds  model  based  on  ranked  scores  and 
computes common odds at each cut off level of ordinal scores. The proportional 
odds assumption is tested based on a score test which if significant, indicates 
that  the  proportionality  assumption  does  not  hold.  The  score  test  for 
proportionality assumption tends to be extremely sensitive for larger data.
 281,282  
 
Analyses involved shift in outcomes (Rankin scores and NIHSS scores in case of 
VISTA only analysis and Rankin scores in case of SITS VISTA (NIHSS data were 
unavailable in SITS ISTR)) when patients received alteplase compared to those 
who  did  not  receive  alteplase.  Choice  of  NIHSS  as  an  additional  measure  of 
outcomes  is  supported  by  the  European  Medicines  Evaluation  Agency  (EMEA) 
Points  to  Consider  for  reporting  trials.
283,284  As  per  this  document,  the  EMEA  
allows the use of the full range of the Rankin scores and then further suggests 
that this can be supported by a secondary analysis of another outcome measure 
such  as  NIHSS.
284  I  analysed  supporting  endpoint,  neurological  outcomes 
measured by NIHSS scores, by grouping the NIHSS scores into categories: 0 (no 
measurable  deficit),  1 4,  5 8,  9 12,  13 16,  17 20,  21 24,  ≥25  (most  severe 
neurological deficit) or dead. I then the compared distribution of patients across 
the NIHSS categories in a manner similar to one done for the mRS. Here again, to 
test for a significant association of outcome distribution with intervention/drug Nishant Kumar Mishra, 2011                                                                                          Chapter 2, 97 
 
 
exposure, I employed the Cochran Mantel Haenszel [CMH] test and calculated 
the  odds  ratio  based  on  proportional  odds  logistic  regression  analyses.  The 
ordinal outcomes can be compared, adjusting for covariates.
 
 
Chapter 8 of this thesis examines data by means of meta analyses. For detailed 
methodology refer to chapter 8. 
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3  Influence of age on outcome from thrombolysis 
in acute stroke 
3.1 Introduction 
Thrombolysis  for  acute  ischaemic  stroke  has  proven  benefits  but  randomised 
trial data in patients >80 years are limited.
92,122 To date, the European Medicines 
Evaluation Agency (EMEA) has not approved thrombolysis with alteplase amongst 
the very elderly.
23 Patients older than 80 years represent about 30% of acute 
stroke incidence.
285 287 Many  experienced centres  treat the  elderly but others 
observe the terms of product approval.
240 
237,288 292 
 
 
 
 
Figure   3-1 Figure showing rapid increase in the proportions of elderly in European Union 
 
The coloured boxes represent age group with grey showing people older than 80 years, black 
showing age group 65 to 79 years and different shades of orange showing age group 0 14,15 24 
and 25 to 49. [Source: Features and Challenges of Population Ageing: The European 
Perspective by Asghar Zaidi; Permissions obtained by e mail from  Dr Asghar ZAIDI, Director 
Research European Centre for Social Welfare Policy and Research (Affiliated to the United 
Nations) Berggasse 17, A 1090 Vienna, Austria ]
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Figure    3-2 Projections for world population for  age group 0-14, 15-59,  60-79  and 80 and 
above. 
 
(Source:  Implications of Population Ageing for Economic Growth  by David E. 
Bloom, David Canning, and Günther Fink; Permissions obtained from Oxford 
University Press for the publication “David E. Bloom, David Canning, Günther 
Fink, Oxford Review of Economic Policy content title Implications of population 
ageing for economic growth”, License Number 2784230886123).
294  
 
The NINDS trial initially restricted enrolment to patients aged up to 80 years. 
The age criterion was lifted after enrolling 188 patients in part A of the trial but 
only 42 very elderly patients were enrolled.
122 All ECASS trials applied an upper 
                                                 
3  I published Chapter 3 in Stroke(Mishra NK, Diener HC, Lyden PD, Bluhmki E, Lees KR; VISTA 
Collaborators.  Influence  of  age  on  outcome  from  thrombolysis  in  acute  stroke:  a  controlled 
comparison in patients from the Virtual International Stroke Trials Archive (VISTA). Stroke. 2010 
Dec;41(12):2840-8.) Permissions were obtained  from Wolters Kluwer Health (License Number: 
2790451375765) Nishant Kumar Mishra, 2011                                                                                        Chapter 3, 101 
 
 
age limit of 80 years, and recent studies with desmoteplase
 also excluded the 
elderly.
109 111,121,124,129  
 
The main reasons advanced for withholding treatment from the elderly patients 
in  clinical  practice  are  fears  that  advancing  age  is  associated  with  poorer 
prognosis  with  greater  risk  for  haemorrhage  and  in hospital  mortality.
23,295,296 
Conversely, a meta analysis of pooled thrombolysis data concluded that the risks 
of symptomatic intra cerebral haemorrhage ICH did not increase amongst the 
elderly  despite  less  favourable  outcomes.
297    Less  favourable  outcomes  are 
expected to occur in the elderly, mostly due to comorbidity.
237,298 
 
The proportion of elderly is rising in our society.
285 287,293,294 In the UK alone, the 
population aged >80 years has doubled since 1982.
299 Effective treatments should 
not be withheld from the elderly in the absence of compelling data suggesting 
unacceptable risk or proven lack of benefit. It was therefore hypothesised that 
clinical practice over the last decade would have been sufficiently diverse to 
allow  analysis  of  existing  rigorously  collected  clinical  data  to  construct  a 
comparison  of  thrombolysis  against  matched  controls,  with  the  possibility  of 
adjusting for any imbalance in severity. I anticipated that the use in the elderly 
would be sufficiently frequent to assess the influence of age on any association 
of stroke outcome with thrombolysis treatment.  
 
 
3.2 Methods  
3.2.1 Data Source and Patients  
Details  of  data  source  are  provided  in  Chapter  2.  Briefly,  I  collated  data  on 
demographics,  clinical  data  and  measures  of  functional  outcome  from 
neuroprotection trials conducted in  the period 1998  to  2007, held within the 
Virtual International Stroke Trials Archive, VISTA [www.vista.gla.ac.uk] 
255 
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3.2.2 Statistical Analyses  
I  undertook  a  non randomised,  adjusted  comparison  of  outcomes  between 
patients who received rt PA and patients who did not receive rt PA (henceforth 
referred to as treated and control group respectively) amongst patients who met 
the age criterion for the European alteplase marketing authorisation. I repeated 
the  comparison  amongst  patients  aged  ≥81  years.  I  then  examined  the 
association of thrombolysis treatment with outcome within each age decile to 
illustrate the strength of evidence across the full age range. For each contrast, I 
compared the overall distribution of all seven categories of day 90 mRS scores of 
the two groups, i.e. from 0 (asymptomatic) through 5 (bedbound and completely 
dependent),  to  6  (dead).  For  analysis  of  the  supporting  endpoint,  NIHSS,  I 
grouped adjacent scores into categories: 0 (no measurable deficit), 1 4, 5 8, 9 
12,  13 16,  17 20,  21 24,  ≥25  (most  severe  neurological  deficit)  or  dead.  The 
distribution of patients across these categories was then compared between the 
groups as for mRS. To test for a significant association of outcome distribution 
with thrombolysis exposure I employed Cochran Mantel Haenszel [CMH] statistic, 
adjusting for both age and baseline NIHSS.  Because CMH does not express the 
extent of the association, I also applied logistic regression analysis, also adjusted 
for age and baseline NIHSS, to estimate the odds ratio under the assumption of 
proportional  odds  and  its  associated  95%  confidence  interval.
.  In  addition  to 
undertaking an age and baseline adjusted analyses, I also undertook a sensitivity 
analysis  by  considering  the  combined  effect  of  the  variables  that  differed 
significantly at baseline (as shown in table 3.1). 
 
For comparison with prior randomised trial and registry reports, I also present 
dichotomised  analyses  of  mRS,  based  on  favourable  outcome  (mRS  0 1), 
independence (mRS 0 2) and survival; these analyses  were  expressed  as odds 
ratios adjusted for age and bNIHSS, as for the primary and secondary endpoints. 
Proportional  Odds  ratios  in  these  analyses  express  the  common  odds  of  an 
improved  distribution  of  outcome  in  association  with  alteplase  treatment. 
Reliable information on symptomatic haemorrhage was not available since post 
treatment imaging was not routinely applied in neuroprotection trials to patients 
who had not been treated with alteplase. 
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3.3 Results  
3.3.1 Patient Sample  
Complete data were available for analysis of mRS in 5817 patients and on NIHSS 
in 5715. (See figure 2.1 for information on completeness of VISTA data) Baseline 
characteristics are shown in table 3.1.  
 
Of  the  5817  patients  with  mRS  outcome  data,  1585  (27.2%)  received 
thrombolysis.  Baseline  severity  was  higher  by  one  NIHSS  point  amongst  the 
younger  patients  who  received  thrombolysis  therapy  compared  to  our  control 
group;  amongst  patients  aged  ≥80,  severity  was  equal  between  treated  and 
control groups. The delay between stroke onset and initiation of alteplase was 
not  recorded,  but  the  delay  to  research  enrolment  and  initiation  of 
investigational  product  was  shorter  in  the  thrombolysis  group  than  control 
patients  irrespective  of  age  (3.7  versus  5.1  hours,  p=0.0001).  Independently, 
baseline NIHSS accounted for 28% and age for 9.7% of the variation in 90 day 
outcome  by  mRS  (both  p<0.0001)  and  were  included  in  all  models,  together 
explaining 33.5% of the variation. 
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3.3.2 Overall Outcome  
Across  the  whole  sample,  the  distribution  of mRS  scores  was  better  amongst 
thrombolysed patients, CMH p<0.0001; OR: 1.39 (95% CI: 1.26 1.54). 
 
3.3.3 Outcomes amongst patients aged ≤80 years   
Amongst the 4623 patients with 90 day mRS data, treatment with thrombolysis 
was associated with a significantly more favourable distribution of mRS scores: 
CMH p<0.0001, adjusted odds ratio (a OR) 1.4 (95%CI: 1.3 1.6). The unadjusted 
odds  ratio  was  1.2  (95%  CI:  1.1 1.4).  Dichotomised  comparisons  were  also 
significant for independence (mRS 0 2 versus 3 6), OR=1.54 (95% CI 1.33 1.79, 
p<0.0001); for favourable outcome (mRS 0 1 versus 2 6), OR= 1.31 (95%CI 1.12 
1.53, p=0.0008); and for survival OR=1.44 (95% CI 1.18 1.76, p=0.0004). 
 
The  functional  outcomes  were  supported  by  the  secondary  endpoint.  The 
spectrum  of  NIHSS  scores  at  90  days  was  significantly  better  amongst  the 
thrombolysed patients than controls: CMH p<0.0001, a OR = 1.6 (95% CI: 1.4 
1.8), n=4537. The unadjusted comparison yielded OR=1.3 (95%CI: 1.2 1.5). 
 
The sensitivity analysis, in which I adjusted for age, baseline NIHSS, previous 
stroke, hypertension  and  atrial fibrillation, as  these differed at baseline (see 
table 3 1) also yielded OR 1.4 (95% CI 1.2 1.6), N=4387, CMH p<0.0001. 
 
3.3.4 Outcomes amongst patients aged ≥ 81 years   
Amongst the 1194 very elderly patients with 90 day mRS data, treatment with 
thrombolysis was associated with a significantly more favourable distribution of 
mRS scores : CMH p=0.002, a OR= 1.34 (95%CI: 1.05 1.70). The unadjusted odds 
ratio was 1.26 (95% CI: 1.00 1.59), CMH p<0.05. The dichotomised comparison 
was  significant  for  independence  (mRS  0 2):  OR=1.  52  (95%  CI  1.06 2.17, 
p=0.022). For favourable outcome (mRS 0 1), the OR was 1.46 (95%CI: 0.97 2.20, 
p=0.07); and for survival the OR was 1.20 (95%CI: 0.90 1.65, p=0.20). Nishant Kumar Mishra, 2011                                                                                        Chapter 3, 106 
 
 
The  functional  outcomes  were  supported  by  the  secondary  endpoint.  The 
spectrum  of  NIHSS  scores  at  90  days  was  significantly  better  amongst  the 
thrombolysed patients than controls: CMH p=0.0004, a OR= 1.4 (95%CI: 1.1 1.8), 
n=1178. The unadjusted comparison yielded a similar estimate: OR=1.4 (95%CI: 
1.1 1.7). 
The  sensitivity  analysis,  in  which  I  adjusted  for  age,  baseline  NIHSS, 
hypertension, previous stroke and atrial fibrillation, also yielded OR= 1.2 (0.96 
1.57), N=1152, CMH p=0.02. 
A figure showing proportions of patients within different Rankin categories of 
SITS MOST and the pooled RCT data are pasted below (source: from SITS MOST 
study 
117). Proportion of patients in randomised data shown here are similar to 
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Figure   3-3 Figure shows proportions for patients belonging to various Rankin categories in the SITS-MOST data and also the pooled randomised data 
 
   
Source: Wahlgren N, Ahmed N, Dávalos A, Ford GA, Grond M, Hacke W, Hennerici MG, Kaste M, Kuelkens S, Larrue V, Lees KR, Roine RO, Soinne L, Toni D, 
Vanhooren G; SITS-MOST investigators. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring 
Study (SITS-MOST): an observational study. Lancet. 2007 Jan 27; 369(9558):275-82; Permissions obtained from Elsevier Limited The Boulevard, Langford Lane, 
Kidlington, Oxford, OX5 1GB, UK; License Number- 2783791420125
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Figure   3-4 Functional outcomes after use of thrombolytic therapy in patients suffering ischaemic stroke 
Diagram showing association of functional outcomes with use of rtPA in the younger patients (age <=80 years) and elderly patients (age >80 years) having acute ischaemic stroke. 
Each box of the horizontal bar corresponds to the mRS category specified by the colour code. Upper horizontal bar belongs to control group of young and elderly patients and 
lower to the rtPA-treated patients in each age group. Numbers in each box denote the percent of total patients belonging to a specific treatment category (tPA or control) and 
representing the mRS score corresponding to the box. Nishant Kumar Mishra, 2011                                    Chapter 3, 109 
 
 
 
 
Figure   3-5 Neurological outcomes after use of alteplase in patients suffering acute ischaemic stroke 
Diagram showing association of neurological outcomes with use of tPA in the younger patients (age <=80 years) and elderly patients (age >80 years) having acute ischaemic 
stroke. Each box of the horizontal box corresponds to the mRS category specified by the colour code. Upper horizontal bar belongs to control group of young and elderly patients 
and lower to the tPA-treated patients in each age group. Numbers in each box denote the percent of total patients belonging to a specific treatment category (tPA or control) and 
representing the mRS score corresponding to the box. Nishant Kumar Mishra, 2011              Chapter 3, 110 
 
 
3.3.5 Association of thrombolysis with outcome by age decile 
Both  functional  outcome  and  neurological  outcome  were  significantly  better 
amongst thrombolysed patients than controls within each decile of age from 51 
years  to  90  years;  and  except  amongst  the  small  sample  of  21 30  year  old 
patients, point estimates for the adjusted odds ratios were consistent across all 
age groups (Fig 3 7 and 3 8) 
 
 
 
Figure   3-6 Functional outcomes after thrombolytic therapy  
The Forest plot shows a significant association of use of alteplase with improved functional outcomes in 
age group from 41 to 50 until 81 to 90. Point estimates are indicative of improved outcomes even for 
age group 31 to 40 and 91 to 100.  The odds ratio (OR) are shown for age groups stratified by age 
ranges of 10. CMH P refers to the test statistic for Cochran-Mantel-Haenszel Test and N refers to total 
sample size. 
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Figure   3-7 Neurological outcomes after thrombolytic therapy  
 
The figure shows an association of neurological outcomes with improved outcomes in patients who 
received thrombolytic therapy. Patients are shown stratified by age groups and corresponding forest 
plot, OR, CI, CMH P, and sample size are marked. 
 
 
3.4 Discussion  
Analyses reported in this chapter demonstrate that the use of thrombolysis for 
acute stroke is associated with better functional and neurological outcomes, and 
probably lower mortality, in all adult patients who are treated irrespective of 
their age. It supports the limited randomised trial data and places data on safety 
from stroke registries in context.  
 
These  data  draw validity from four  origins. First,  the source clinical trials of 
investigational  medicinal  products  were  undertaken  under  strict  controls  on 
reporting of concomitant treatments and outcomes, and on site data verification 
procedures were in place for each trial. Second, attitudes to treatment of the 
very elderly vary amongst clinicians, some European clinicians strictly following 
the EMEA marketing authorisation, others in Europe and North America treating 
without regard to age.
240,300 Third, the estimates of control outcomes correspond 
closely to those from the published RCTs of thrombolysis,
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outcomes amongst the treated group aged ≤ 80 years are similar to those of the 
RCTs* 
4,
146 and the estimate of treatment odds ratios in the patients aged <=80 
years closely corresponds to treatment effects demonstrated in the RCTs.
129 131 It 
should be acknowledged that dose finding studies have not been undertaken in 
the very elderly, however. Fourth, I chose as the primary endpoint the modified 
Rankin  scale, which is the most  prevalent outcome measure in recent  stroke 
trials
257 and I followed an approach to analysis that is described in the EMEA 
Points to Consider for interpretation of clinical trials in acute stroke.
284 There, 
comparison of the distribution of the full range of the Rankin is proposed as 
acceptable, with supporting evidence from a secondary endpoint such as NIHSS: 
both  are  positive  and  give  similar  estimates  of  benefit  in  our  comparison. 
Further, although the less powerful dichotomised analyses are not all significant 
amongst  the  very  elderly,  they  each  give  point  estimates  for  magnitude  of 
association that correspond to the estimates derived in the young and from the 
full mRS or NIHSS distributions. 
                                                
4  ** I obtained the SITS-MOST data from the figure 3.3. I undertook an unadjusted comparison of 
the Rankin scores in the non-elderly patients SITS-MOST data with the VISTA data (age below 
80  years)  by  employing  proportional  odds  logistic  regression  analysis.  The  point  estimates 
suggested  a shift towards better outcomes when the pooled data of the thrombolysed patients 
recruited  in  the  randomised  controlled  trials  (RCT)  were  compared  with  the  VISTA  non-
thrombolysed patients (OR 1.1, 95%CI 0.9-1.3).  When the VISTA controls were compared with 
the RCT placebo group, OR=0.9, 95% CI 0.8-1.1. When SITS-MOST patients were compared 
with the VISTA thrombolysed patients, OR=1.3, 95% CI 1.2-1.5. It should be noted that these 
are  unadjusted  analyses:  influence  of  age  and  baseline  severity  on  outcomes  in  these 
comparisons  could  not  be  incorporated  in  the  proportional  odds  logistic  regression  analysis 
model as I donot have access to the SITS-MOST raw data. 
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Figure   3-8 Figure shows the relationship of onset to treatment time with adjusted odds for mortality in a pooled analysis of patients from randomisation 
controlled trials that investigated t-PA (N=3670) 
 
(Source: Lees KR, Bluhmki E, von Kummer R, Brott TG, Toni D, Grotta JC, Albers GW, Kaste M, Marler JR, Hamilton SA, Tilley BC, Davis SM, Donnan GA, 
Hacke W; ECASS, ATLANTIS, NINDS and EPITHET rt PA Study Group, Allen K, Mau J, Meier D, del Zoppo G, De Silva DA, Butcher KS, Parsons MW, Barber PA, 
Levi C, Bladin C, Byrnes G. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, 
and EPITHET trials. Lancet. 2010 May 15; 375(9727):1695 703.Permissions obtained from Elsevier Limited, The Boulevard, Langford Lane, Kidlington,Oxford, 
OX5 1GB, UK; License Number: 2783800078653)
131 
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Present data indicate a reduction in mortality of non elderly (12.3% vs. 14.8%) 
and elderly (32.2% vs. 36.1%) patients (figure 3 4) and confirm improved survival 
(1.4 (95%CI 1.2 1.8) amongst non elderly. Pooled analyses of all trials have seen 
the  trends  for  favourable  outcomes  in  t PA  arm  (see  figure  3 8)  through 
modelling.
131  Also,  these  findings  are  consistent  with  the  meta analysis  data:  
while odds for death or dependency  were OR 0.71 and 95% CI 0.52 to 0.96,  the 
odds for death were 1.1 with a confidence interval that was wide, 95%CI 0.9 to 
1.5.
92 In the present analysis for the elderly, the odds for survival are 1.2 and 
confidence intervals wide, 95%CI 0.9 1.7 (N=301 patients in t PA group). These 
data indicate benefit by reduction in mortality including amongst the elderly. 
Mortality was shown to have reduced owing to larger sample size, and thereby 
giving greater power to the subgroup age </=80 years (N=1284).  
 
Elderly patients usually do poorly after a stroke because of pre existing illnesses 
and  on going  poly pharmacy.    For  example,  elderly  are  more  likely  to  suffer 
from  cardiac  diseases  like  atrial  fibrillation,  cardiac  failure,  coronary  heart 
disease and hypertension. Prevalence of cardiac disorders increases with age: in 
the Framingham Heart Study, incidence for atrial fibrillation was 0.2/1000 for 
age group 30 39 while 39/1000 for age group 80 89 years.
301  With increasing age 
there  is  also  a    steady  rise  in  the  proportion  of  patients  who  suffer  stroke 
because  of  arrhythmia  (in  age  group  80  to  89  years,  the  rates  are  36.2%).
301 
Patients suffering cardio embolic stroke are more likely to have larger infarcts or 
suffer  multiple  infarctions  involving  different  territories.  Further,  the  cardio 
embolic strokes are associated with greater risk of haemorrhagic transformation: 
it occurs in about a fifth of cardio embolic stroke patients.
302 Further, some data 
indicate  that  patients  suffering  cardio embolic  strokes  may  fail  to  recanalise 
despite the use of alteplase.
303,304 This could be due to a unique clot composition 
in  these  patients  that  renders  itself  unresponsive  to  alteplase  and  because 
cardio embolism  occurs  more  frequently  amongst  the  elderly,  these  patients 
could be the ones more at risk of not responding to the use of alteplase. But, the 
data presented in this chapter support the contrary: the elderly responded to 
the use of alteplase. Outcomes improved not only on Rankin scores but also on 
the NIHSS scores in the age group >80 years. 
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It is known that compared to younger population, elderly patients have larger 
deposits of cerebral amyloid material.
305 These deposits could have contributed 
to increased risk of post thrombolysis intracerebral haemorrhage. Further, these 
patients  have  poorer  cognitive  reserve  and  may  be  having  poorer  abilities  to 
employ neuroplasticity and regain functions.
306  Further, their abilities to recruit 
collaterals after an ischaemic insult might be poorer than the younger patients. 
These biological substrates are more likely to result in poorer outcomes in the 
elderly  age  group.  In  the  present  analysis,  I  failed  to  show  that  t PA  use  in 
elderly interacts differently compared to the non elderly population. Instead, I 
show  that  despite  excess  poorer  outcomes  in  the  elderly,  these  patients 
responded to the t PA use and showed improved outcomes. Further, there is no 
evidence from other disease areas, like myocardial infarction, to support this.
237  
 
There are also limitations to my study that must be considered. The data are 
based  on  a  non randomised  comparison,  and  there  is  a  high  potential  for 
selection  bias  for  thrombolytic  treatment.  Although  many  of  the  usual 
descriptors  of  baseline  prognosis  are  reasonably  matched  between  the  two 
groups, thrombolysis and controls, and although I have adjusted our analyses for 
the most important of these – age and baseline severity,
265,307 which together 
account for 33.5% of the variation in outcome I could not adjust for every factor. 
I planned to adjust for all variables that differed at baseline but did not include 
presence  of  use  of  antithrombotic  agents  (prior  use  of  antiplatelet  and 
anticoagulant  agents) in the sensitivity analyses.  This is because on trying to 
adjust  for  antithrombotic  agents,  along  with  other  variables  that  differed  at 
baseline, the sample size for the analysis reduced dramatically both for elderly 
population (from 1193 to 454) and non elderly (4624 to 1930) population. This 
occurred because observations got deleted (739 and 2694 respectively) by the 
program  due  to  missing  values  for  the  response  or  explanatory  variables. 
Further,  atrial  fibrillation,  use  of  warfarin  and  prior  diabetes  were  all  less 
prevalent  amongst  the  treated  group.  However,  the  magnitude  of  these 
differences was small, the absolute differences were equal for young versus very 
elderly, and the sensitivity analyses with adjustment for these additional factors 
also  yielded  significantly  positive  findings.  This  implies  that  although  the 
estimate of the association of treatment with outcome may be imprecise, the 
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patients in this study received an investigational neuroprotective agent and it 
must be considered that one or more of these could interact with thrombolysis; 
however,  each  contributing  trial  has  already  tested  for,  and  excluded,  a 
significant interaction. VISTA data handling procedures preclude further testing 
for effects of the original investigational agent or identification of source trials. 
 
The  delay  between  stroke  onset  and  treatment  initiation  in  the  thrombolysis 
group was not known, but the time of baseline NIHSS assessment is earlier in the 
thrombolysed than non thrombolysed patients. Presentation delay is associated 
with outcome, but this is mediated through earlier presentation of more severe 
stroke, a factor that favoured our control group in the young only. Last is the 
possibility  of  systematic  bias  in  other  aspects  of  care  and  thus  outcome, 
between centres that used thrombolysis routinely versus those that did not, or 
that restricted use in the elderly. It is difficult to counter criticism on this point, 
except to indicate that the contributing trials sought to minimise such effects 
through site selection, training of investigators and monitoring of care and of 
outcomes; and to point again to the correspondence of outcomes in each of the 
treatment groups with those from RCT and registry data. 
 
Trials and registries of thrombolysis generally report three outcomes: functional 
attainment,  mortality  and  symptomatic  or  serious  intracranial 
haemorrhage.
122,146 VISTA lacked data on the last of these, since patients who 
are not treated with thrombolysis generally do not undergo follow up cerebral 
imaging  for  routine  detection  of  haemorrhagic  transformation.  Fortunately, 
information  on  this  aspect  can  be  inferred  from  other  sources:  the  rate  of 
serious or symptomatic bleeding is very low amongst patients who do not receive 
thrombolysis –approximately 1%
131 and registry data such as SITS inform us on the 
rate amongst treated patients and have found no significant increase in the very 
elderly compared to the young.
292,308 
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Figure   3-9 Figure shows the functional outcomes in patients for various age bands in SITS registry 
 
Source: Ford GA, Ahmed N, Azevedo E, Grond M, Larrue V, Lindsberg PJ, Toni D, Wahlgren N. Intravenous alteplase for stroke in those older than 80 years old. 
Stroke. 2010 Nov;41(11):2568 74.Permissions obtained from Wolters Kluwer Health, License Number 2783791484358 
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Figure   3-10 Figure shows rates of symptomatic intracerebral haemorrhages per SITS-MOST definition, NINDS definition and parenchymal haemorrhage 
(including type II) in the SITS registry. 
 
Source: Ford GA, Ahmed N, Azevedo E, Grond M, Larrue V, Lindsberg PJ, Toni D, Wahlgren N. Intravenous alteplase for stroke in those older than 80 years old. 
Stroke. 2010 Nov;41(11):2568 74.Permissions Obtained from Wolters Kluwer Health, License Number 2783791484358 
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A more important response on the issue of serious bleeding comes from our use 
of the full mRS distribution as our outcome measure. Bleeding is relevant only if 
it affects eventual functional outcome. Dichotomisation of mRS outcomes into 0 
1 versus 2 6 or 0 2 versus 3 6 could conceal harmful results of serious bleeding 
reflected  by  higher  proportions  of  severely  disabled  patients  within  the 
unfavourable outcome group (for example more mRS 5 amongst patients with 
mRS  3 5).  The  data  and  analysis  approach  exclude  this  possibility:  even  if 
haemorrhage were more common in the very elderly than young, which has been 
discounted,
308,309 this does not translate into poorer functional outcomes after 
adjustment for age and stroke severity. 
 
Data on stroke outcomes associated with thrombolysis use in the elderly come 
from  3  other  sources.  A  meta analysis  of  cohort  studies  by  Ringleb  and 
colleagues  in  2007  found  that  the  elderly  experienced  similar  rates  of 
symptomatic haemorrhage to the young (6.1% versus 5.1%) but higher mortality 
(32% versus 14%), with fewer attaining favourable outcome by 90 days (mRS 0 1: 
26% versus 41%).
309However, within one of the largest studies in this analysis, the 
baseline severity of stroke was much higher in elderly than young patients (NIHSS 
16 versus 13.9 respectively).
292Outcomes of very elderly patients described by 
the Safe Implementation of Thrombolysis in Stroke (SITS) registry reinforce these 
findings:  stroke  severity  was  higher  in  the  643  elderly  versus  6749  younger 
patients,  NIHSS  15  v  13.  Symptomatic  ICH  was  no  more  common  in  the  very 
elderly (2.0 [95% CI 1.1 3.5] versus 1.5 [1.2  1.8] per cent), but 90 day mortality 
was higher (31 [27 36] versus 15 [14 16] per cent); and independence (mRS 0 2) 
was  achieved  less  frequently  (30  [26 34]  versus  52  [51 53]  per  cent).
310 
Interpretation  of  these  uncontrolled  registry  findings  is  compromised  by  the 
known  influence  of  age  and  stroke  severity  on  outcome  in  the  absence  of 
thrombolysis  treatment.  Only  164  patients  aged  >=80  years  were  included 
amongst the large randomised trials combined.
311 The elderly group was again 
more severely affected at baseline than the younger patients, but there was also 
a severity imbalance amongst the elderly that favoured the controls. A pooled 
analysis  of  these  data  in  the  elderly  (0 4.5  hours  subgroup:  N=137/2199) 
estimated odds ratios for independence (mRS 0 2 at day 90) and mortality under 
alteplase versus placebo of 1.09 and 1.28 respectively based on unadjusted data. Nishant Kumar Mishra,2011                                                                                      Chapter 3, 120 
 
 
However, after adjustment for the demonstrable imbalance in baseline NIHSS 
the odds ratios respectively were 1.77 and 0.96. 
311  The sample size was small 
and none of these outcomes reached statistical significance. Thus, the present 
findings are entirely consistent with the randomised trial data, not only in terms 
of the estimated extent of benefit from treatment but also with regard to the 
influence of baseline severity on the interpretation of outcomes. 
 
Treatment  allocation  in  this  study  was  not  randomised,  and  a  randomised 
controlled  trial  would  more  conclusively  inform  the  influence  of  rt PA  on 
outcomes  amongst  elderly.  Two  trials  currently  aim  to  examine  this 
topic.
232,234,312 There is an Italian trial that has so far enrolled around 10% of the 
planned 600 patients, over a 2 year period.  The International Stroke Trial 3 
[IST 3] aims to examine outcomes amongst all patients who receive thrombolytic 
therapy and has prescribed no upper age limit.
232,234  The trial has so far enrolled  
3035 patients from the originally planned 6000.
233  1756 of these patients are 
very  elderly  and  being  treated  within  the  time  window  of  interest.
233,313,314 
Though the present analysis is not a randomised controlled trial, it is the only 
source  of  evidence  to  support  the  registry  and  RCT  data  that  currently 
available.
290,292,297  
 
In summary, outcome amongst patients treated with thrombolysis as standard of 
care within clinical research trials is more favourable than amongst patients who 
are not offered thrombolysis, and this apparent advantage to patients who are 
treated extends to patients aged 81 years and older. From this analysis, I not 
only  fail  to  find  evidence  to  support  the  present  restriction  of  the  European 
marketing authorisation for alteplase use in the elderly; I  find positive evidence 
that alteplase is beneficial amongst patients aged 81 90 years and that this is 
likely to extend even to patients aged 91 100 years. These data support and 
extend the extensive uncontrolled data on outcomes from registries, and the 
limited  randomised  controlled  trial  data.  Age  is  not  a  relevant  factor  when 
considering whether to use alteplase for acute stroke. 
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4  Outcomes from thrombolytic therapy amongst 
elderly patients recruited in SITS Registry: 
validation of VISTA findings on SITS-VISTA data 
 
4.1 Introduction 
In chapter 3, I described findings from analysis of VISTA dataset and showed that 
outcomes  improve  amongst  elderly  patients  who  receive  alteplase  for  acute 
ischaemic  stroke.  The  results  were  based  on  a  robust  statistical  analysis. 
Findings were consistent on two different measures of outcomes, namely, the 
NIHSS scale and the modified Rankin Scale. Point estimates for the approved 
population were similar to the ones observed in randomised trials, thus allowing 
us to anchor our results on the elderly onto the randomised data. Because it was 
not a randomised study, which I acknowledge as a weakness, I also looked at the 
prospects of the two on going randomised trials, the IST III
232,233,313 and TEPSI
312, 
but from the rate at which these studies are recruiting patients, it appears that 
clinicians will have to wait for a while before the randomised data are available. 
IST 3 originally targeted to recruit 6000 patients.
234 Per September 2011 issue of 
IST 3  times,  the  total  recruitment  figures  were  3035.  Of  these,  1756  were 
elderly.
233 
In order to confirm the findings from VISTA only analyses in previous chapter, I 
planned to validate results in another dataset. For this, I decided to examine 
outcomes  in  elderly  patients  whose  data  were  held  within  the  SITS ISTR  at 
Karolinska University Hospital. Below, I report methods and results from the data 
derived from SITS ISTR registry.  Nishant Kumar Mishra,2011                           Chapter 4,123 
 
 
5 
4.2 Method 
4.2.1 Data Source and patients 
I describe the SITS ISTR data in chapter 2. Briefly, I collated the data of stroke 
patients  who  received  thrombolytic  therapy  through  the  SITS ISTR  between 
December  2002  and  November  2009.  The  control  group  comprised  untreated 
stroke patients from neuroprotection trials conducted between1998 to 2007 held 
within  the  VISTA.  From  both  of  these  sources,  I  collated  the  demographics, 
clinical  data  and  information  of  functional  outcome  as  measured  with  the 
modified Rankin scale (mRS) score after 90days. 
4.2.2 Patient Sample 
Details of data extraction are shown in figure 2.1. The sample for this analysis 
comprised 29500. Data on baseline NIHSS for 272 of these patients were missing, 
reducing the sample for the baseline severity adjusted analysis  
4.2.3 Statistical analysis 
I  compared  90  days  outcome  between  patients  who  received  intravenous 
thrombolysis and non thrombolysed controls for the whole cohort. I repeated the 
comparison  amongst  patients  aged  ≤80  and  >80  years.  I  then  examined  the 
association of thrombolysis treatment with outcome within each age decile to 
illustrate the strength of evidence across the full age range. 
For each contrast, I compared the overall distribution of all seven categories of 
day  90  mRS  scores  of  the  two  groups,  i.e.  from  0  (asymptomatic)  through  5 
(bedbound and completely dependent), to 6 (dead).    
                                                
5  I published this chapter in BMJ (Mishra NK, Ahmed N, Andersen G, Egido JA, Lindsberg PJ, 
Ringleb PA, Wahlgren NG, Lees KR; VISTA collaborators; SITS collaborators. Thrombolysis in 
very elderly people: controlled comparison of SITS International Stroke Thrombolysis Registry 
and  Virtual  International  Stroke  Trials  Archive.  BMJ.  2010  Nov  23;341:c6046.  doi: 
10.1136/bmj.c6046.).  Permissions  were  obtained  from  BMJ  Publishing  Group  Limited 
2783790122184 
 Nishant Kumar Mishra,2011                           Chapter 4,124 
 
 
To test for a significant association of outcome distribution with thrombolysis 
exposure I used the Cochran Mantel Haenszel [CMH] statistic, adjusting for both 
age  and  baseline  NIHSS as  continuous  variables.  However,  I  also  undertook  a 
sensitivity  analysis  by  considering  the  combined  effect  of  the  variables  that 
differed significantly at baseline.  
Reliable information on symptomatic intracerebral haemorrhage (sICH) was not 
available from VISTA controls since post treatment imaging was not routinely 
applied  in  neuroprotection  trials  to  patients  who  had  not  been  treated  with 
alteplase. However, the rates of sICH for the definitions used within SITS (local 
or remote parenchymal haemorrhage type 2 on the imaging scan at 22–36 h after 
treatment, combined with a neurological deterioration of 4 or more points on 
the NIHSS from baseline, or from the lowest NIHSS score between baseline and 
24 h, or leading to death) and the NINDS study (any intracranial haemorrhage in 
the post thrombolysis imaging scans if it was not seen on a previous imaging scan 
and any decline in neurological status) for younger and older patients of the 
SITS ISTR registry was compared. 
 
4.3 Results 
4.3.1 Baseline Characteristics of the Patients 
Baseline  characteristics  are  shown  in  table  4.1.  Baseline  stroke  severity  was 
similar between thrombolysed versus non thrombolysed patients amongst both 
the >80 elderly (p=0.6) and ≤80 years age groups (p=0.3).Independently, baseline 
NIHSS accounted for 25.5% and age for 7.4% of the variation in 90 day outcome 
by  mRS  (both  p<0.001)  and  were  included  in  all  models,  together  explaining 
29.6% of the variation.   
It is to be noted that the number of patients in control arm differs between the 
SITS VISTA  analyses  reported  in  this  chapter  and  those  shown  in  previous 
chapter. This is because, in the previous chapter, I had excluded 2789 patients Nishant Kumar Mishra,2011                           Chapter 4,125 
 
 
that were likely to have been in SITS MOST. I did not employ a similar exclusion 
criterion for the analyses presented in this chapter. Nishant Kumar Mishra, 2011    Chapter 4, 126 
 
 
Table   4-1 Baseline characteristics of patients enrolled in SITS-VISTA data 
  Thrombolysis  Control  P value 
Mean (SD) and median (range) age (years) 
All    67.1 (12.4), 69 (10-98);    n=23 334     70.1 (12.2), 72 (21-101);  n=6166  <0.001 
≤80    65.3 (11.63), 68 (10-80);  n= 21 099     66.5 (10.7), 69 (21-80);    n=4929  <0.001 
>80    84.4 (3.25), 84 (81-98);    n=   2235     84.84 (3.36), 84 (81-101); n=1237  <0.001 
No (%) of men 
All  13 594/23 334 (58.3)  3271/6166 (53.0)  <0.001 
≤80  12 744/21 099 (60.4)  2783/4929 (56.5)  <0.001 
>80  850/2235 (38.0  488/1237 (39.5)  0.41 
Median (range) baseline score on National Institutes of Health stroke scale 
All  12 (0-42), n=23 062  12 (2-37), n=6166  0.14 
≤80  12 (0-42), n=20 860  11 (2-32), n=4929  0.32 
>80  14 (0-39), n=2202  14 (2-37), n=1237  0.61 
No (%) who had previously taken antithrombotic agents 
All  8776/22 792 (38.5)  1267/2968 (42.7)  <0.001 
≤80  7537/20 623 (36.5)  977/2414 (40.5)  <0.001 
>80  1239/2169 (57.1%  290/554 (52.3)  0.04 
No (%) with known diabetes mellitus 
All  3962/22 968 (17.2)  1449/5896 (24.6)  <0.001 
≤80  3570/20 784 (17.2)  1203/4704 (25.6)  <0.001 
>80  392/2184 (17.9)  246/1192 (20.6)  0.06 
No (%) with previous stroke 
All  3005/23 013 (13.1)  2014/5993 (33.6)  <0.001 
≤80  2629/20 840 (12.6)  1521/4776 (31.8)  <0.001 
>80  376/2173 (17.3)  493/1217 (40.5)  <0.001 
No (%) with congestive heart failure 
All  1932/22 840 (8.5)  277/3167 (8.7)  0.59 
≤80  1581/20 697 (7.6)  185/2579 (7.2)  0.39 
>80  351/2143 (16.4)  92/588 (15.6)  0.67 
No (%) with hypertension 
All  14331/22 875 (62.6)  4170/5896 (70.7)  <0.001 
≤80  12687/20 683 (61.3)  3273/4704 (69.6)  <0.001 
>80  1644/2192 (75)  897/1192 (75.3)  0.87 
No (%) with atrial fibrillation 
All  5835/22 753 (25.6)  1712/5896 (29.0)  <0.001 
≤80  4837/20 613 (23.5)  1147/4704 (24.4)  0.19 
>80  998/2140 (46.6)  565/1192 (47.4)  0.67 
*Of patients with baseline National Institutes of Health stroke scale score in SITS datasheet, two 
(0.32%) in age group 31-40, five (0.30%) in age group 41-50, nine (0.25%) in age group 51-60, six 
patients (0.1%) in age group 61-70, eight (0.09%) in age group 71-80, and two (0.1%) in age group 
81-90 were coded as having baseline score of 0 and treated with alteplase. They were assumed to 
have neurological deficit considered potentially disabling but not measured by restricted rules of the 
scale (such as distal limb weakness). These few cases will have no material impact on findings. Nishant Kumar Mishra, 2011    Chapter 4, 127 
 
 
4.3.2 Overall outcome 
Across the whole sample, the distribution of mRS scores at 3 months was better 
amongst thrombolysed patients, p<0.0001; OR: 1.59 (CI: 1.51 1.67). (Figure 4 2) 
4.3.3 Outcomes amongst patients aged ≤80 years 
Treatment with thrombolysis was associated with a significantly more favourable 
distribution of mRS scores at 3 months:  CMH p<0.0001, adjusted odds ratio (a 
OR) 1.6 (95%CI: 1.5 1.7); N= 25789. (Figure 4 3) The unadjusted odds ratio was 
1.5 (95% CI: 1.4 1.6) [N=26028]. Dichotomised outcomes were also significantly 
favourable for thrombolysed patients compared to control (mRS 0 2 versus 3 6), 
OR=1.87(95% CI 1.74 2.01); for excellent outcome (mRS 0 1 versus 2 6), OR= 1.55 
(95%CI 1.44 1.67); and for mortality OR= 0.87 (95% CI 0.79 0.95).  
The  sensitivity analysis, in which in addition to age and baseline stroke severity, 
I also adjusted for  sex, history of either diabetes or previous stroke, use of prior 
antithrombotic agents, and hypertension, for they differed at baseline, yielded  
CMH p<0.0001 and proportional odds of 1.6 (95% CI 1.4 1.7), N= 22148 in favour 
of thrombolysis. 
4.3.4 Outcomes amongst patients aged >=81years 
Amongst  the  3439  elderly  patients  above  80  years  old  with  90  day  mRS  and 
baseline stroke severity data, treatment with thrombolysis was associated with a 
significantly more favourable distribution of mRS scores at 3 months compared 
to control CMH p<0.0001, a OR= 1.43 (95%CI: 1.26 1.63), [N=3439] (Figure 4 4).  
The unadjusted odds ratio was 1.4 (95% CI: 1.23 1.58), CMH p<0.0001 [N=3472]. 
The dichotomised outcome analysis was significantly in favour for thrombolysed 
patients compared to control, for favourable outcome (mRS 0 2): OR= 2.06 (95% 
CI 1.72 2.48). For excellent outcome (mRS 0 1), the OR was 1.87 (95%CI: 1.53 
2.29); and for mortality the OR was 0.89 (95%CI:  0.76 1.04).  
The sensitivity analysis, in which, in addition to baseline NIHSS and age, I also 
adjusted  for    sex,  history  of  either  diabetes  or  previous  stroke,  use  of  prior 
antithrombotic and hypertension, for they differed  at baseline, yielded  CMH Nishant Kumar Mishra, 2011    Chapter 4, 128 
 
 
p=0.003 and proportional odds OR: 1.5,95% CI: (1.3 1.8), N=2593 favourable for 
thrombolysis. Nishant Kumar Mishra, 2011    Chapter 4, 129 
 
 
 
 
Figure   4-1Figure shows proportions for patients belonging to various Rankin categories in the SITS-MOST data and also the pooled randomised data 
 
(Source: Wahlgren N, Ahmed N, Dávalos A, Ford GA, Grond M, Hacke W, Hennerici MG, Kaste M, Kuelkens S, Larrue V, Lees KR, Roine RO, Soinne L, Toni D, 
Vanhooren G; SITS-MOST investigators. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring 
Study (SITS-MOST): an observational study. Lancet. 2007 Jan 27;369(9558):275-82; Permissions obtained from  Elsevier Limited The Boulevard, Langford Lane, 
Kidlington, Oxford,OX5 1GB,UK; License Number- 2783791420125)
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Figure   4-2 Outcomes after thrombolytic therapy in the entire population 
Scores on modified Rankin scale (from 0=no symptoms from stroke to 6=death) at three months between patients who underwent thrombolysis with alteplase and 
controls, indicating shift towards improved outcomes with thrombolysis. Numbers within coloured cells are percentages. Total Patients in alteplase arm 23 3334 and 
control arm 6166. 
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Figure   4-3 Outcomes after thrombolysis amongst the patients </= 80 years 
 
Scores on modified Rankin scale (from 0=no symptoms from stroke to 6=death) at three months between patients who underwent thrombolysis with alteplase and 
controls, indicating shift towards improved outcomes with thrombolysis. Numbers within coloured cells are percentage. Total patients in alteplase arm 21 099 and 
control arm 4929.Nishant Kumar Mishra, 2011                   Chapter 4, 132 
 
 
 
 
Figure   4-4 Outcomes after thrombolytic therapy amongst patients older than 80 years 
 
Scores on modified Rankin scale (from 0=no symptoms from stroke to 6=death) at three months between patients who underwent thrombolysis with alteplase and 
controls, indicating shift towards improved outcomes with thrombolysis. Numbers within coloured cells are percentages. Total patients in alteplase arm 2235 and 
control 1237.Nishant Kumar Mishra, 2011    Chapter 4, 133 
 
 
 
mRS  distributions  at  90  days  were  significantly  better  amongst  thrombolysis 
patients than controls within each decile of age from 40 years to 90 years and, 
except amongst the small samples of patients younger than 30 years and older 
than  90  years,  point  estimates  for  the  adjusted  odds  ratios  were  consistent 
across all age groups. (Figure 4 5) 
Functional outcome measured by mRS 0 1, mRS 0 2 and survivor analysis showed 
similar results in favour of thrombolysis. (Figure 4 6, 4 7 and 4 8) 
 
Figure   4-5 Shift towards better outcomes on mRS at 90 days adjusted for age and baseline 
severity  
Number of patients shown for age groups do not add up to 29￿228 because numbers of patients ages <21 
(n=38) and >100 (n=2) were too low to allow any comparison. All patients aged <21 were from SITS and 
underwent thrombolysis; 15 patients reached a 90 day modified Rankin score of 0, 10 patients attained a 
score of 1, eight patients reached a score of 2, one patient achieved a score of 3, and two a score of 4; two 
died. Two patients aged 101 did not undergo thrombolysis in VISTA neuroprotection trials; they achieved 
modified Rankin score of 0 and 4 at 90 days Nishant Kumar Mishra, 2011    Chapter 4, 134 
 
 
 
Figure    4-6  Age  and  baseline  severity  adjusted  odds  for  the  mRS  score  0-1  at  90  days 
amongst patients treated with alteplase 
 
 
 
Figure    4-7  Age  and  baseline  severity  adjusted  odds  for  the  mRS  score  0-2  at  90  days 
amongst patients treated with alteplase 
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Figure   4-8 Age and baseline severity adjusted odds for mortality amongst patients treated 
with alteplase 
 
4.3.5 Post Thrombolysis Intracerebral Haemorrhage 
The symptomatic intracerebral haemorrhage (SICH) rate per SITS definition (4 or 
more point increase in NIHSS from baseline or death within 24 hours and PH2 or 
PHr2 haemorrhage at 22 36h imaging scans) was 2.5% (54/2163) among >80 years 
compared to 1.9% (398/ 20759) among ≤80 years, and thus insignificantly higher 
(OR 1.31, 95%CI 0.96 1.75, p= 0.07). The corresponding rates for SICH per NINDS 
definition  (any  increase  in  NIHSS  from  baseline  and  any  parenchymal 
intracerebral haemorrhage) were significantly higher, 11.0% (229/ 2087) vs. 8.3% 
(1670/ 20220), (OR1.37, 95%CI 1.18 1.58, p<0.0001).  
4.3.6 Onset to Treatment Time 
The stroke onset to treatment time (OTT) of the administration of thrombolytic 
therapy to patients in SITS ISTR was calculated. The median OTT was similar, 
145 minutes (p= 0.25), between younger (<=80 years) and older (>80 years). Data 
on OTT for thrombolytic therapy were not collected in VISTA. 
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4.4 Discussion 
Comparing  patients  from  SITS ISTR  who  were  treated  with  alteplase  at  an 
average  of  145  minutes  after  stroke  onset  against  controls  from  VISTA  who 
received  no  alteplase  a  more  favourable  outcome  across  the  entire  range  of 
modified  Rankin  Scores  with  alteplase  is  observed  (Cochran Mantel Haenszel 
p<0.0001; Odds Ratio: 1.59 CI: 1.51 to1.67). The nature and extent of this effect 
of  alteplase  is  comparable  to  results  from  pooled  analysis  of  randomised 
controlled  trials, confirming the validity of the controlled  but nonrandomised 
analysis.
28  I  could  therefore  examine  outcomes  separately  among  nonelderly 
patients (aged </=80 years) and elderly patients (age group> 80 years). In each 
subgroup  a  more  favourable  functional  outcome  was  noted:  Odds  Ratios  1.6 
(95%CI: 1.5 to 1.7), N=25789 and 1.4 (95%CI: 1.26 to1.63), [N=3439] respectively.  
 
Extending  the  analysis  to  smaller  subgroups  of  age,  I  found  independently 
significant  benefits  from  alteplase  in  each  10 year  age  range  from  40  to  90 
years. I found no interaction of age with alteplase efficacy and across the full 
age range from under 20 years to over 100 years. Only at under 30 years did the 
trend not favour outcomes after alteplase use.  
 
In  summary,  I  show  that  association  between  thrombolysis  treatment  and 
outcome is maintained in all patients, even in the elderly regardless of generally 
poorer outcomes in these age groups. 
 
The analysis of SITS VISTA data is based on almost 30,000 patients and confirms 
that improved outcomes occur after acute ischaemic stroke among patients who 
are offered thrombolytic therapy. The extent of the apparent benefit matches 
that from published randomised trials. These observations extend to the elderly 
age groups and it is only in a small group of patients in age group 91 to 100 (137 
patients in alteplase group and 77 in the non thrombolysed group) that it fails to 
achieve a statistical significance where the point estimates are consistent but 
confidence intervals are wide. The point estimates for improved outcomes in age 
group 91 to 100 are also consistent with the published data.
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I  undertook  the  primary  analyses  employing  “shift  analysis”,  an  analytical 
approach  accepted  by  the  European  Drug  Licensing  agency. 
284  The  Cochran 
Mantel Haenszel  test  is  a  non parametric  approach  that  avoids  invoking  an 
assumption of a common odds ratio (i.e. proportionality) across all cut points on 
the  ordinal  outcome  scale.  It  provides  a  conservative  estimate  of  statistical 
significance. Because it does not express the extent of the association, I also 
applied an ordinal logistic regression analysis to estimate a common odds ratio 
across  modified  Rankin  scale  categories.  Again,  I  found  significantly  better 
outcomes, though the proportionality assumption was not satisfied. Whereas a 
non significant test for proportionality would imply that common odds may be 
assumed,  the  converse  does  not  necessarily  apply.
282  The  proportionality 
assumption  test  may  be  over sensitive  when  applied  to  large  sample  sizes.
316 
Further, it is a global test that cannot differentiate the heterogeneity resulting 
from alteplase or other covariates
316 The sample sizes were large and so I may 
still  be  justified  in  using  the  odds  estimated  from  ordinal  logistic  regression. 
Even  so,  for  final  confirmation  we tested  using  a less  powerful dichotomised 
approach. 
272,273 With all three methods I reach similar conclusions.   
 
There were improved outcomes among thrombolysis patients belonging to age 
groups encompassing 31 to 90 years. Analysis did not show improved outcomes 
for patients aged below 30 and above 90 years, but the small number of patients 
in  these  groups  greatly  reduced  statistical  power  for  these  analyses  and  the 
trends mostly followed the same pattern as for intermediate ages. 
 
I chose age and  baseline NIHSS for adjusted analysis mainly because  of  their 
established roles of influence on stroke outcomes.
265 However, I also undertook 
sensitivity  analysis  adjusting  for  differences  in  age,  sex,  history  of  either 
diabetes  or  previous  stroke,  use  of  prior  antithrombotic,  baseline  National 
Institutes  of  Health  Stroke  Scale  score  and  hypertension  between  the 
thrombolysed and non thrombolysed groups.
278 The adjusted analyses for these 
variables  confirmed  significant  findings  for  improved  outcomes  from 
thrombolysis regardless of age.  
 
The  baseline  demographic  characteristics  for  the  complete  dataset  give  an 
advantage to the thrombolysis group. This influence does not extend to patients Nishant Kumar Mishra, 2011    Chapter 4, 138 
 
 
aged >80 years, however. As a result, though the estimates of overall effect of 
alteplase  may  be  biased,  the  relative  differences  between  subgroups  should 
remain  reliable.    I  did  not  match  patients  by  co morbidity  score  or  baseline 
functional status, which may be considered a limitation. However, premorbid 
functional  status  is  difficult  to  establish  reliably  in  stroke  and  the  strong 
influence of baseline severity on outcome, for which I did adjust, is known and is 
discussed  in  chapter  7.  A  corresponding  analysis  examining  the  influence  of 
baseline severity on outcomes in SITS and VISTA data is underway.
317 
 
The  conclusions  derive  merit  from  having  been  based  on  a  huge  patient 
population  who  were  treated  in  routine  clinical  practice  [N  =  28136]  and 
compared against controls from rigorously conducted neuroprotection trials: any 
bias in quality of care should favour the control group.  The limitation of SITS 
ISTR data has been discussed extensively in previous publications.
146,147,229,318 In 
short,  SITS ISTR  is  a  registry  and  therefore,  it  is  impossible  to  guarantee 
completeness of inclusions and to exclude selection bias.
146,147,229 The SITS MOST 
publication reports: “Sample source data verification was done by professional 
monitors  working  with  national  coordinators  in  collaboration  with  the  study 
sponsor (Boehringer Ingelheim). A minimum of 10% of patients recruited in SITS-
MOST  was  monitored.  In  the  UK,  source  data  verification  was  done  by 
independent clinical staff under the direction of the UK national coordinators. 
This monitoring also checked for completeness of registrations at all sites.” 
146 
The SITS MOST investigators also report that: “Incomplete data entries could be 
saved for later updating, but data were not deemed to be complete or included 
in  report  generation  unless  confirmed  by  the  investigators  by  electronic 
signature. To be included in the SITS-MOST cohort, all baseline data entry had 
first  to  be  confirmed  by  the  investigator.  SITS-MOST  report  generation  was 
updated every 24 h via an automatic statistical package, which displayed main 
outcome details, demographic and baseline statistics, logistic information, and 
a recruitment report with indication of complete and delayed data. Registered 
centres could review statistical details for their own centres, and compare with 
country statistics and with the total SITS-MOST dataset.” 
146 Finally, the SITS 
MOST publication reports that “in the UK, source data verification was done by 
independent clinical staff under the direction of K R Lees and G A Ford”. 
146 
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In  SITS MOST,  individual  investigators’  results  are  not  published,  limiting  the 
incentive for selection; in contrast, the sharing of total enrolment numbers may 
act as an incentive to be inclusive.
115 Almost identical main outcomes in SITS 
MOST
146 and RCTs
131 after adjustment for baseline differences suggests that the 
influence from such potential bias is limited. Subsequent studies based on SITS 
ISTR  data  also  show  the  similar  outcome  for  the  overall  study  population  as 
compared to the SITS MOST.
129,229 None of the neuroprotective agents used for 
the patients in the VISTA control group has an influence on outcome, and over 
half of the VISTA cohort received only placebo. 
 
Because  VISTA  lacks  data  on  repeat  brain  imaging  among  non thrombolysed 
patients, I had no data on SICH in the control group. Therefore, I compared the 
SICH rates between over 80 years and ≤ 80 years old patients only with SITS 
data. There was no difference in SICH rates between over 80 years and ≤ 80 
years as per SITS MOST definition but slightly higher as per NINDS definition. In a 
complementary per protocol analysis of SITS ISTR data (i.e. patients’ selection 
based  on  SITS MOST  criteria
115  except  for  its  age  criterion),  no  significant 
difference in SICH rate was noted amongst very elderly patients compared to the 
younger cohort [per SITS 1.8% VS. 1.7%, P=0.70, adjusted odds ratio (aOR)=0.90 
(95%CI  0.73  to  1.09) 
308  The  SITS  patients  in  the  SITS VISTA  dataset  are 
unselected  and  therefore  SICH  rates  are  slightly  higher  in  the  current  study. 
Regardless, I now show that even if there were any more haemorrhages amongst 
elderly patients who receive thrombolysis, based on a conservative definition, 
there appears to be no adverse influence on the distribution of outcomes. In 
fact,  one  observes  a  beneficial  effect  on  mortality  of  these  patients.  Others 
have concluded that factors such as comorbidity rather than alteplase use are 
responsible for the observed increase in late case fatality among the elderly.
319 
321 
 
The present analyses reach the same conclusions as analyses employing VISTA 
data, as shown in previous chapter, or the limited pooled randomised trial data 
in the elderly (supplemental data).
311 Elderly patients treated with thrombolysis 
in trials reported from VISTA in the previous chapter (N= 5817) had significantly 
better  adjusted  outcomes  than  nonthrombolysed  comparators  (p=0.002;  Odds 
Ratio=1.34,  95%CI  1.05  to  1.70).
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randomised trials showed a trend towards better adjusted outcomes (modified 
Rankin score 0 to 2 versus 3 to 6) than non thrombolysed comparators (Odds 
Ratio  1.77;  95%  CI  0.73–4.25,  N=137).  Previous  studies  have  shown  findings 
consistent  with  results  in  present  chapter,  but  on  very  small  data  sets. 
290,292,297,315,320,322,323  Despite these points, treatment allocation in this study was 
not  randomised.  More  extensive  randomised  controlled  trial  data  could  more 
conclusively  answer  this  question.  Two  trials  currently  aim  to  examine  this 
topic.
232,312 There is an Italian trial that has so far enrolled around 10% of the 
planned 600 patients, over a 2 year period.
312  A trial from UK, International 
Stroke  Trial 3  [IST 3],  aims  to  examine  outcomes  amongst  all  patients  who 
receive  thrombolytic  therapy  and  has  no  upper  age  limit  prescribed  in  its 
inclusion  criteria.
232,234,313    Over  more  than  a  decade,  the  trial  has  enrolled 
around 3035 patients from the originally planned 6000, 1756 patients are very 
elderly and being treated within the time window of interest.
233  
 
In this analysis, patients who were treated with intravenous alteplase had better 
outcomes than their untreated comparators, and this effect was not dependent 
on their age. In particular, patients aged over 80 years derived similar benefit 
from treatment as younger patients. The weight of evidence to date indicates a 
potential for benefit in the elderly and there is no a priori reason to suspect a 
diminished  effect  compared  to  the  non elderly.  Furthermore  there  are 
reassuring  safety  data  on  the  risk  of  intracerebral  haemorrhage.  It  may  be 
concluded that clinical treatment guidelines should be revised to remove the age 
restriction in use of intravenous alteplase for acute ischaemic stroke. Age alone 
should not be a barrier to treatment. 
   
 
 
 
 
Chapter 5 
Presence of Diabetes and Previous Stroke in 
Acute Ischaemic Stroke Patients: Is it a valid 
exclusion criterion? 
 
 Nishant Kumar Mishra, 2011                           Chapter 5, 142 
 
 
5  Presence of Diabetes and Previous Stroke in 
Acute Ischaemic Stroke Patients: Is it a valid 
exclusion criterion? 
 
5.1 Introduction 
The European Medicines Agency (EMEA) recommends that the ischaemic stroke 
patients suffering from hypo  or hyperglycaemia (blood glucose levels at baseline 
<50  and  >  400  mg/dl  respectively)  should  be  excluded  from  receiving  the 
thrombolytic therapy.
23 EMEA also recommends that if a patient suffering from 
the onset of new ischaemic stroke has diabetes and a prior  stroke, he should not 
be  thrombolysed  with  the  t PA.
23  These  recommendations  often  put  a  stroke 
physician into a difficult situation. This is because the hyperglycaemia occurs in 
about 70% of the ischaemic stroke patients and only 20% of these patients report 
suffering  from  diabetes  mellitus.
324,325  Hyperglycaemia  at  baseline  may  be 
associated  with  the  diabetes  (uncontrolled  or  unrecognised  diabetes  or  poor 
glucose  tolerance)  or  it  may  be  a  response  to  an  acute  stress  (stress 
hyperglycaemia).
325  It should be noted  that, though overlapping, true diabetes 
and  post stroke  hyperglycaemia  are  distinct  entities.
326  E  Melamed  describes 
transitory reactive hyperglycaemia in about a third of ischaemic stroke patients 
who had no history of diabetes mellitus and also in those who had history of 
diabetes prior to stroke.
327 The following reasons have been attributed to the 
hyperglycaemic reaction to the acute ischaemic stroke: “a non specific reaction 
to acute stress and tissue injury with the associated autonomic, hormonal and 
metabolic  alterations;  uncovering  of  underlying  latent  diabetes  by  the  acute 
stroke;  increased  secretion  of  growth  hormone  due  to  stroke induced 
hypothalamic dysfunction; and irritation of the glucose regulatory centres in the 
hypothalamus  and  brain  stem  by  blood laden  cerebrospinal  fluid  or  local 
ischaemia”.
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The  thrombolytic  therapy  is  the  only  proven  therapy  known  to  enhance 
outcomes  in  ischaemic  stroke  patients.
122,129  Its  mechanism  involves  a 
recanalisation and a rapid reperfusion of the critically hypoperfused brain tissue, 
which  in  turn  restores  the  function  of  ischaemic  brain  parenchyma.
122,328 
Reperfusion induced improvement in outcomes depend on local factors in the 
ischaemic brain tissue such as the extent of neuronal damage, cerebral perfusion 
pressure (systemic blood pressure), oxidative stress, intracellular acidosis and 
mitochondrial  dysfunction.
328,329  Animal  studies  indicate  that,  following  a 
cerebral ischaemia, hyperglycaemia enhances the super oxide anion production, 
the local acidosis and the production of the advanced glycation end products 
that are damaging to the blood vessels.
330,331,328,332 335 Superoxide production may 
predispose  the  brain  to  greater  risk  of  blood  brain  disruption  and  thereby 
intracerebral haemorrhage.
336 338 A systematic review of the animal studies that 
examined  association  of  the  infarct  volume  with  the  hyperglycaemia  in  the 
ischaemic stroke animal models (streptozotocin induced hyperglycaemia models, 
N=303 animals and  dextrose induced hyperglycaemia models, N=356 animals), 
hyperglycaemia was associated with a 94% larger infarct size. 
325 Infarct volume 
in streptozotocin model was greater than the infarct volume in dextrose model 
(140%  vs.  48%  increase). 
325  However,  in  seven  studies,  there  were  non 
significant  reduction  of  infarct  size  if  insulin  were  used.
325  The  authors 
concluded:  “Although  hyperglycaemia  exacerbates  infarct  volume  in  MCAO 
models,  studies  are  heterogeneous,  and  do  not  address  the  common  clinical 
problem  of  post  stroke  hyperglycaemia  because  they  have  used  either  the 
streptozotocin model of type I diabetes or extremely high glucose loads. Insulin 
had a nonsignificant and significantly heterogeneous effect. Further studies with 
relevant models may inform clinical trial design.”
325  
 
Because  post stroke  hyperglycaemia  results  in  poor  outcomes,  trialists 
investigated the outcomes after treatment with the insulin in the patients having 
post stroke hyperglycaemia. A meta analysis of randomised controlled trials (16 
studies, 2459 patients) showed that the use of insulin in these patients does not 
affect  the  mortality  (OR  1.1,  95%  CI  0.9  to  1.5,  p=0.29,  n=  1236)  or  the 
favourable functional outcome (OR 1.03, 95% CI 0.7 to 1.5, p=0.88, n=1217), and 
instead,  may put the patient to the risk of hypoglycaemia ( range: 8% to 80%).
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6 
Clinical studies have largely shown adverse influence of hyperglycaemia on the 
outcomes of non lacunar ischaemic stroke patients. 
328,329,340 Poorer response to 
thrombolysis  in  these  patients  is  considered  to  be  a  result  of  increased 
plasminogen activator inhibitor 1 activity, resistance to antithrombotic agents, 
excessive  up  regulation  of  metalloproteinase  and  higher  prevalence  of 
atherosclerosis. 
328,340 342  Stroke  recurrence  is  another  major  problem 
encountered  in  clinical  practice,  and  prior  stroke  in  patient  is  suspected  to 
reduce  the  benefits  attainable  from  thrombolytic  therapy. 
343  Because  these 
patients are already on antithrombotic therapy, several clinicians mostly worry 
about haemorrhagic complications when administering the thrombolytic therapy. 
An  analysis  of  patients  who  were  treated  during  0 6  hours  of  stroke  onset 
(N=2184) enrolled in 5 thrombolysis trials
122,124,127,128 has shown that a previous 
stroke and diabetes mellitus may predict poor outcome (p for t PA prior stroke 
interaction <0.05; p for diabetes <0.0001, p for prior stroke= 0.06).
343 
7 
Whereas the clinical trials have shown improved outcomes amongst patients who 
receive  alteplase  for  acute  ischaemic  stroke,  t PA  was  granted  marketing 
authorisation in Europe in 2002 and patients with prior stroke and concomitant 
diabetes  mellitus  were  excluded  from  the  approval.
23  The  basis  for  this 
restriction is  described in  the review  documents:  “The  therapeutic benefit is 
reduced in patients that had a prior stroke or in whom an uncontrolled diabetes 
is  known,  thus  the  benefit/risk  ratio  is  considered  less  favourable,  but  still 
positive in these patients.”
23  These were based on unpublished results of data 
analysed by regulatory authorities. Hence, ECASS III trialists excluded patients 
having diabetes mellitus or a history of stroke when designing ECASS III study.
23 
As  per  the  recent  press  release  of  Boehringer  Ingelheim  dated  4
th 
November,2011,  “Actilyse®  has  been  approved  through  a  mutual  recognition 
                                                
6  
7    I  published  Chapter  5  in  Diabetes  Care  (Mishra  NK,  Davis  SM,  Kaste  M,  Lees  KR;  VISTA 
Collaboration. Comparison of outcomes following thrombolytic therapy among patients with prior 
stroke and diabetes in the Virtual International Stroke Trials Archive (VISTA). Diabetes Care. 
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solely  to  indicate  this  fact.”  Further  see    http://creativecommons.org/licenses/by-nc-
nd/3.0/  
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procedure  for  15  European  countries*  for  thrombolytic  treatment  of  acute 
ischaemic stroke up to 4.5 hours of onset of stroke symptoms and after prior 
exclusion  of  intracranial  haemorrhage.”
344    Now,  the  European  drug  labelling 
continues to retain those exclusion criteria that have not been formally tested.
23  
For example, the use of rt PA in acute stroke is not recommended in Europe 
amongst patients who suffer from concomitant presence of diabetes mellitus and 
previous stroke.
23   Regardless, physicians still treat these patients in routine 
clinical  practice.
345  In  the  current  scenario,  an  ideal  approach  would  be  to 
conduct a randomised controlled trial and examine the influence of thrombolytic 
therapy  on  outcomes  of  these  patients.  But,  running  a  clinical  trial  for  this 
subgroup would not be feasible. Patient recruitment in stroke trials takes a long 
time. The IST 3 trialists started with an enrolment target of 6000 patients and 
have  so  far  been  able  to  enrol  only  3035  patients.
234  Further,  these  patients 
constitute a small proportion of all thrombolysed patients.  Within SITS ISTR, of 
all the patients that were recruited between December 2002 and November 2009 
(N=23062),  only  602  patients  had  suffered  from  both  diabetes  and  previous 
stroke. To the best of my knowledge, there is not any plan of any trial group to 
conduct such a trial. Therefore, I planned for an alternative approach. Similar to 
the method adopted in chapter 3, I decided to examine outcomes of patients 
who  received  rt PA  against  those  who  did  not,  from  the  data  of  the 
neuroprotection trials conducted between 1998 2007; and obtained these data 
from Virtual International Stroke Trials Archive [VISTA]. Employing an analytical 
approach recommended by EMEA, I compared outcomes amongst patients having 
diabetes, previous strokes and a combination thereof.
284  
 
 
5.2 Methods 
5.2.1 Data Source and patients 
I collated the demographics, clinical data and measures of functional outcome 
from neuroprotection trials conducted in the period 1998 to 2007, held within 
the Virtual International Stroke Trials Archive, VISTA. (See Chapter 2) 
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5.2.2 Statistical analysis 
I  compared  outcome  between  patients  who  received  thrombolysis  and  non 
thrombolysed controls amongst patients who had diabetes, prior stroke or their 
combination. For each contrast, I compared the overall distribution of all seven 
categories of day 90 mRS scores of the two groups, i.e. from 0 (asymptomatic) 
through 5 (bedbound and completely dependent), to 6 (dead), and also NIHSS 
categories  For analysis of the supporting endpoint, NIHSS, I grouped adjacent 
scores into categories: 0 (no measurable deficit), 1 4, 5 8, 9 12, 13 16, 17 20, 
21 24, ³25 (most severe neurological deficit) or dead. To test for a significant 
association  of  outcome  distribution  with  thrombolysis  exposure  I  used  the 
Cochran Mantel Haenszel  [CMH]  statistic,  adjusting  for  both  age  and  baseline 
NIHSS as continuous variables. Because CMH test does not express the extent of 
the association, I also applied logistic regression analysis, also adjusted for age 
and  baseline  NIHSS,  to  estimate  the  odds  ratio  under  the  assumption  of 
proportional odds and its associated 95% confidence interval. I also undertook a 
sensitivity  analysis  by  considering  the  combined  effect  of  the  variables  that 
differed significantly at baseline, but if this resulted in excessive diminution of 
study  sample,  I  did  not  quote  the  findings.  The  objective  was  mainly  to 
undertake ordinal distribution  or “shift”  analysis. I  also present  dichotomised 
analyses of mRS, based on excellent outcome (mRS 0 1), favourable outcome 
(mRS 0 2), and survival; these analyses were expressed as odds ratios adjusted 
for age and bNIHSS, as for the  primary and secondary endpoints. In order to 
remain consistent with the current age criteria of the EMEA, I examined if the 
interaction  of  age  with  t PA  had  influence  over  outcomes;  and  further, 
estimated CMH p and proportional odds by ordinal logistic regression analysis for 
patients belonging to age group</=80.  
 
Odds  ratios  in  the  ordinal  analysis  express  the  common  odds  of  an  improved 
distribution  of  outcome  in  association  with  alteplase  treatment.  Reliable 
information on symptomatic haemorrhage was not available since post treatment 
imaging was not routinely applied in neuroprotection trials to patients who had 
not been treated with alteplase.  
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5.3 Results 
5.3.1 Patient sample 
Complete data were available for analysis of mRS in 5817 patients and on NIHSS 
in 5711 (see figure 5.1).Baseline characteristics are shown in table 5.1.  
 
5.3.2 Analysis of outcomes  
I  have  shown  the  findings  on  the  analyses  of  outcomes  in  patients  having 
diabetes  or  no  diabetes,  outcomes  in  patients  having  previous  stroke  or  no 
previous stroke and the outcomes in patients having concomitant diabetes and 
previous stroke or their absence in figures 5 2 to 5 6. 
 
In  a  proportional  logistic  regression  analysis  adjusting  for  age  and  baseline 
NIHSS, we did not find any interaction of diabetes [p=0.49], prior stroke [p=0.72] 
and diabetes and prior stroke [p=0.8] with use of rt PA. For each of the analyses 
above,  I  also  considered  the  subgroup  of  patients  aged  <=80  years;  and  also 
sought  evidence  of  any  interaction  with  age.  I  failed  to  find  evidence  of  a 
differential effect or interaction with age. 
 
 
Figure   5-1Flow chart showing the description of the VISTA data employed for present analyses Nishant Kumar Mishra, 2011                           Chapter 5, 148 
 
 
 
 
Figure   5-2 Outcomes in approved population (i.e. patients having absence of diabetes or previous 
stroke or both) 
 
 
 
Figure   5-3Outcomes in patients population having diabetes prior stroke or both 
 Nishant Kumar Mishra, 2011                           Chapter 5, 149 
 
 
 
Figure   5 4 Figure shows outcomes in patients receiving alteplase or no alteplase in subgroups of 
patients  belonging to subgroups diabetes or no diabetes, previous stroke or no previous stroke 
and presence of diabetes and previous stroke together and absence thereof   
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Table   5-1 Baseline characteristics of patients enrolled in the VISTA trials 
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5.4 Discussion  
The present analysis reconfirms the occurrence of improved outcomes amongst 
patients who do not have diabetes and prior stroke, with significant odds of 1.4. 
These  odds  were  comparable  to  the  odds  obtained  from  large  thrombolysis 
trials,
131 suggesting outcomes following thrombolysis are similar in these patients 
to those seen in the trials. The present analysis shows a significant association of 
improved  outcomes  with  the  use  of  thrombolytic  therapy  in  patients  having 
diabetes or prior stroke. However, I failed to confirm statistical significance for 
a small group of patients that concomitantly had previous stroke and diabetes 
[OR  1.5,  95%  CI:  0.98 2.3].  I  attribute  this  to  a  type  2  error  in  this  smaller 
subgroup  of  sample  size,  N=491.  The  findings  from  shift  analyses  were  also 
supported  by  similar  results  from  the  analyses  of  dichotomised  outcomes.  It 
should be noted that the European license restrictions for the use of t PA in 
ischaemic  stroke  includes  the  subgroup  of  patients  that  have  concomitant 
presence of diabetes and previous stroke (and not “only diabetes” or “only prior 
stroke”).
23 The analysis failed to show significant odds ratios at p=0.05 for this 
particular subgroup of patients.  
 
These findings can be generalised not only because of the comparable odds to 
those obtained from the large trials data
131  but also because these results were 
replicated  on  another  analysis  involving  the  comparison  of    thrombolysed 
patients  [in  SITS  dataset]  with  the  non thrombolysed  controls  [from  VISTA] 
(reported in  chapter 6). In addition, I was informed of supportive findings that 
were available from the analyses of a collaborator, Prof Markku Kaste at Helsinki 
Thrombolysis Register. In their data, from 1200 consecutively treated patients, 
complete information was available for 1104 patients, 51% patients were treated 
despite licence contraindications. The analysis of 26 patients aged </=80 years 
who  had  both  DM  and  previous  stroke  suggested  poorer  favourable  outcomes 
(mRS 0 2) in univariate analysis when compared to those treated according to 
the  European  licence  of  alteplase;  but,  not  in  multivariate  analysis.  These 
patients had more symptomatic intracerebral haemorrhages than those treated 
on label  in  univariate  analysis  but  95%  CI  was  not  significant  and  in  a 
multivariate analysis there was no trend for symptomatic haemorrhage. I could Nishant Kumar Mishra, 2011                          Chapter 5, 152 
 
 
not  however  examine  the  symptomatic  brain  haemorrhages  in  the  VISTA 
patients, as these data were derived from neuroprotection trials, which had not 
routinely obtained imaging information of the untreated patients.  
 
I  based  the  conclusions  on  adjusted  analyses,  adjusting  for  age  and  baseline 
NIHSS, because prognostic variables differed at baseline; and, age and baseline 
severity have an established influence on stroke outcomes.
131 However, I could 
not adjust for all variables, as data were incomplete. Despite robust analyses 
and  adjustment  for  important  variables,  it  needs  to  be  acknowledged  that  a 
randomised study would have the best design. But, there are no such studies 
conducted yet, or are on going. The present study is the only analysis that is 
based on the largest dataset on thrombolysis patients available up to the present 
date.(except the data that are presented in the following chapter). It employs 
an  analytic  approach  recommended  by  EMEA,  and  replicates  findings  of 
functional outcomes on neurological outcomes.  
 
It is known that patients with premorbid m RS >1 were excluded from the VISTA 
trials,  but  the  pre stroke  functional  status  of  individual  patients  was  not 
recorded in VISTA. Hence, it is likely that any effect of pre stroke disability in 
the  patients  having  prior  stroke(s)  would  only  lead  to  an  underestimation 
treatment effect in the analyses. 
 
I  acknowledge  that  there  could  be  differences  on  outcomes  owing  to  centre 
specific  effects  on  treatment  of  patients.  This  would  however  occur  if  the 
patients  were  part  of  routine  clinical  care,  and  not  enrolled  in  a  rigorously 
controlled  clinical  trial.  Because  the  patients  in  VISTA  were  enrolled  in 
neuroprotection clinical trials during 1998 2007, I assume that they all received 
best standard of care at each participating centre.  60% of VISTA patients were 
from American centres where the thrombolytic therapy was approved soon after 
the NINDS trial results were published in 1995.
122 During the next years, even 
other centres [including European (16% patients)] practised thrombolytic therapy 
based on clinicians’ choice.
146 In 2002, the alteplase was approved in Europe as 
well.
23  This  would  imply  that  all  those  stroke  patients  who  were  eligible  for 
thrombolysis in the physician’s opinion received therapy. However, I could not 
adjust for centres, as centre specific information was missing in the dataset. Nishant Kumar Mishra, 2011                          Chapter 5, 153 
 
 
 
Table   5-2 Acute stroke treatment with respect to hyperglycaemia at base line in European 
Federation of Neurological Society member states 
(“a” refers to national estimates. The other numbers are from the stroke panel member centre.) 
(Source: Thomassen L, Brainin M, Demarin V, Grond M, Toni D, Venables GS; EFNS Task Force on 
Acute Neurological Stroke CareAcute stroke treatment in Europe: a questionnaire based survey 
on behalf of the EFNS Task Force on acute neurological stroke care.Eur J Neurol. 2003 
May;10(3):199 204.Permissions obtained from John Wiley and Sons, License number: 
2811330661886 ) 
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It should however be noted that the European centres/countries differ in their 
practices with regard to the treatment of hyperglycaemia at the stroke onset 
(table  5 2).
346  For  example,  some  centres  employ  insulin  infusion  to  control 
blood  sugars  when  the  patient  presents  with  stroke  with  hyperglycaemia. 
Physicians may differ in their choice of drugs for the secondary prevention of 
diabetes during the follow up period. These variables are likely to influence the 
outcomes  on  day 90.  It  can  be  guessed  that  the  participating  centres  in  the 
neuroprotection  trials  would  have  been  inconsistent  with  regard  to  the 
recommendations  for  the  control  of  hyperglycaemia  at  stroke  onset  and  the 
subsequent  secondary  prevention  treatments.  Treatments  are  likely  to  have 
been  different  between  the  individual  studies.  In  conclusion,  the  differences 
arising  from  the  varying  practices  across  the  participating  centres  in  the 
neuroprotection trials would have resulted in bias in my present study. Further 
because  the  data  lack  in  the  information  on  specific  centre  specific  clinical 
practices with regard to control of hyperglycaemia, I could not control for the 
resulting bias. 
 
In the present analysis, the 95% confidence interval for improved outcomes were 
0.98 to 2.3 and marginally missed the level of significance at p=0.05.One must 
consider that analyses like these are based on probabilistic models where level 
of significance is arbitrarily chosen (and conventionally set at 5%), and decision 
to thrombolysis is left to the clinicians who determine their own limits regarding 
taking  chances  whilst  offering  the  therapy.  The  group  of  patients  having 
concomitant  diabetes  and  previous strokes  missed  statistical  significance,  but 
had  a  favourable  point  estimate  of  1.5.  Had  I  considered  a  higher  level  of 
significance, the results would have been significant for outcomes amongst all 
subgroups of patients.   
 
In  summary,  the  analysis  shows  improved  outcomes  amongst  patients  with 
diabetes,  prior  stroke  and  those  with  diabetes  and/or  prior  stroke;  though 
marginally failed to show a statistically significant improvement in the patients 
who had both diabetes and prior stroke together. A potential benefit might exist 
for the combined group too, and withholding a proven therapy amongst these 
patients  would  not  be  justified.  Treatment  may  be  offered  to  a  carefully Nishant Kumar Mishra, 2011                          Chapter 5, 155 
 
 
selected patient, and trialists should now be encouraged to consider examining 
these patients by conducting a randomised controlled trial. Finally, it can be 
recommended  that  withholding  treatment  from  these  patients  would  be 
unjustified.  156 
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6  Presence of Diabetes and Previous Stroke in 
Acute Ischaemic Stroke Patients: A validation 
study to confirm findings from VISTA data  
 
6.1 Introduction 
Intravenous alteplase administration is a proven treatment for acute ischaemic 
stroke.
122,129  In  Europe,  it  was  granted  marketing  authorisation  in  2002  but 
patients with prior stroke and concomitant diabetes mellitus were excluded from 
approval.
23 The basis for this restriction is described in the review documents: 
“The therapeutic benefit is reduced in patients that had a prior stroke or in 
whom  an  uncontrolled  diabetes  is  known,  thus  the  benefit/risk  ratio  is 
considered less favourable, but still positive in these patients.”
23 Because of this 
restriction, the EMEA mandated third European Cooperative Acute Stroke Study, 
ECASS III, was required to exclude patients with prior stroke and concomitant 
diabetes from its protocol. In routine clinical practice many such patients are 
treated but others will be excluded due to confusion over the evidence.
129  In 
chapter 5, I reported the findings from data held within VISTA and suggested 
that  the  exclusion  of  patients  based  only  on  the  basis  of  the  presence  of 
diabetes and previous stroke would be unjustified.  
In  the  present  chapter,  I  describe  the  findings  from  another  controlled 
comparison, in which I examine thrombolysed patients from SITS ISTR compared 
against control patients within VISTA. Here, I examine the treatment effect of 
intravenous  alteplase  in  patients  with  diabetes,  prior  stroke  and  their 
combination, in order to clarify the validity of restriction on the latter group. 
For EMEA’s restriction to be valid, one ought to find that the benefit/risk would 
be diminished independently in each sub group, or at least diminished within the 
combined group due to an interaction of diabetes with prior stroke. Nishant Kumar Mishra, 2011.                                                                                    Chapter 6, 158 
 
 
8 
6.2 Methods 
6.2.1 Data source and patients 
I collated the data of stroke patients who received thrombolytic therapy through 
the SITS ISTR between December 2002 and November 2009,  and the controls 
were  derived  from  the  non thrombolysed  control  stroke  patients  from  the 
neuroprotection  trials  of  the  duration  1998  to  2007  held  within  the  Virtual 
International Stroke Trials Archive, VISTA (www.vistacollaboration.org) 
6.2.2 Patient Sample 
Patient sample employed for present analyses are shown in figure 2.1.  
 
6.2.3 Statistical analysis 
I compared the outcomes between patients who received thrombolysis and non 
thrombolysed controls amongst patients who had diabetes, prior stroke or both 
together.  For  each  contrast,  I  compared  the  overall  distribution  of  all  seven 
categories of day 90 mRS scores of the two groups, i.e. from 0 (asymptomatic) 
through  5  (bedbound  and  completely  dependent),  to  6  (dead).  To  test  for  a 
significant association of outcome distribution with thrombolysis exposure I used 
the Cochran Mantel Haenszel [CMH] statistic, adjusting for both age and baseline 
NIHSS.  Then  I  also  employed  proportional  odds  logistic  regression  analyses  in 
order  to  calculate  age  and  baseline  stroke  severity  adjusted  odds  for  better 
outcomes  in  each  subgroup  of  patients’  population.  Then,  I  undertook  a 
sensitivity  analysis  by  considering  the  combined  effect  of  the  variables  that 
differed significantly at baseline (at p < 0.05). Adjusted analysis was expected to 
result  in  reduction  of  number  of  patients,  owing  to  missing  data  for  certain 
                                                
8  I published Chapter 6 in Neurology (N.K.Mishra, N.Ahmed   A.Davalos  H.K.Iversen  L.Soinne   
N.Wahlgren    K.R.Lees  Post  thrombolysis  outcomes  amongst  patients  with  prior  stroke  and 
diabetes:  controlled  comparison  of  SITS  international  registry  (SITS-ISTR)  versus  Virtual 
International Stroke Trials Archive (VISTA) Neurology, 2011;77:1866-1872.) Permissions were 
obtained from Wolters Kluwer Health, License Number 2790960994499. 
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variables. Hence, when reporting results, I also quote the corresponding sample 
size. 
In addition to calculating the proportional odds ratios (that express the common 
odds  of  an  improved  distribution  of  outcome  in  association  with  alteplase 
treatment),  I  also  undertook  an  interaction  test  between  the  alteplase  and 
presence  of  diabetes,  previous  stroke  or  both.  Reliable  information  on 
symptomatic haemorrhage was not available since post treatment imaging was 
not  routinely  applied  in  neuroprotection  trials  to  patients  who  had  not  been 
treated with alteplase.  
 
6.3 Results 
6.3.1 Baseline demographics 
The data comprised 29500 patients for this analysis. Data on baseline NIHSS for 
another  272  patients  were  missing  and  had  to  be  excluded  leaving  29228 
patients  whilst  undertaking  the  baseline  severity  adjusted  analysis  (Figure 
2.1).
271  The baseline characteristics of the patients included for this analysis are 
shown in Table 6.1. 
6.3.2 Analysis 
I undertook comparison of outcomes for patients who suffered from diabetes, 
previous stroke or both concomitantly. The findings are shown in figures.  
I found no interaction of variables prior stroke (t PA * PS, p=0.9), diabetes (t 
PA*DM, p=0.19). I also found no interaction of use of alteplase with presence of 
diabetes and previous stroke (t*PA*DM*PS, p=0.5).  
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Table   6-1 Baseline characteristics of the patients.  
 
 
    Thrombolysis  Control  P-values 
Age  All  67.1 (12.5),N=23062  70.1(12.2), N=6166  <0.0001 
  DM  69.9(9.5), N=3905  70.5(10.4),N=1449  0.06 
  No DM  66.5(12.9),N=18799  70.1(12.6),N=4447  <0.0001 
  PS  70.1(10.5),N=2972)  72.9(10.8), N=2014  <0.0001 
  No PS  66.6(12.7),N=19782  69(12.5),N=3979  <0.0001 
  DM+PS  71.0(9.4), N=602  71.6(9.7), N=534  0.31 
  Neither DM nor PS  65.9(13.1), N=16275  68.7(13), N=3064  <0.0001 
Gender (Male)  All  13437/23062(58.3%)  3271/6166(53.1%)  <0.0001 
  DM  2355/3905(60.3%)  781/1449(53.9%)  <0.0001 
  No DM  10873/18799(57.8%)  2351/4447(52.9%)  <0.0001 
  PS  1748/2972(58.8%)  1059/2014(52.6%)  <0.0001 
  No PS  11521/19782(58.2%)  2121/3979(53.3%)  <0.0001 
  DM+PS  363/602(60.3%)  285/534(53.4%)  0.02  
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  Neither DM nor PS  9410/16275(57.8%)  1625/3064(53.0%)  0.001 
Baseline NIHSS*  All  12[0-42],N=23062  12[2-37],N=6166  0.14 
  DM  13[0-40],N=3905  11[2-29], N=1449  0.04 
  No DM  12[0-42], N=18799  12[2-37],N=4447  0.002 
  PS  12[0-42],N=2972  11[2-37],N=2014  0.75 
  No PS  12[0-40],N=19782  12[2-31],N=3979  0.02 
  DM+PS  12[0-40],N=602  11[2-29],N=534  0.08 
  Neither DM nor PS  12[0-40],N=16275  12[2-31], N=3064  0.002 
Hypertension  All  14163/23062(61.4%)  4170/5896(70.7%)  0.001 
  DM  3235/3878(83.4%)  1170/1449(80.8%)  0.02 
  No DM  10736/18509(58%)  3000/4447(67.5%)  0.001 
  PS  2247/2936(76.5%)  1491/1917(77.8%)  0.31 
  No PS  11711/19414(60.3%)  2679/3979(67.3%)  0.001 
  DM+PS  538/600(89.7%)  441/534(82.6%)  0.0005 
  Neither DM nor PS  8918/16018(55.7%)  1950/3064(63.6%)  0.001 
Atrial  Fibrillation  All  5753/22493(25.6%)  1712/5896(29%)  0.001  
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  DM  1130/3814(29.6%)  365/1449(25.2%)  0.001 
  No DM  4533/18397(24.6%)  1347/4447(25.2%)  0.001 
  PS  799/2893(27.6%)  624/1917(32.6%)  0.0002 
  No PS  4853/19353(25.1%)  1088/3979(27.3%)  0.003 
  DM+PS  179/591(30.3%)  141/534(26.4%)  0.15 
  Neither DM nor PS  3850/15948(24.1%)  864/3064(28.2%)  0.001 
Congestive Heart Failure  All  1914/22583(8.5%)  277/3167(8.8%)  0.61 
  DM  538/3802(14.2%)  79/800(9.9%)  0.001 
  No DM  1349/18503(7.3%)  198/2367(8.4%)  0.06 
  PS  312/2898(10.8%)  70/711(9.8%)  0.47 
  No PS  1567/19444(8.1%)  207/2456(8.4%)  0.53 
  DM+PS  92/584(15.8%)  19/222(8.6%)  0.008 
  Neither DM nor PS  1108/16044(6.9%)  147/1878(7.8%)  0.14 
Prior use of antithrombotic agents  All  8672/22543(38.5%)  1267/2968(42.7%)  0.001 
  DM  1920/3795(50.6%)  367/751(48.9%)  0.39 
  No DM  6649/18430(36.1%)  900/2217(40.6%)  0.001  
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  PS  2140/2863(74.7%)  442/687(64.3%)  0.001 
  No PS  6397/19413(33%)  825/2281(36.2%)  0.002 
  DM+PS  442/574((77%)  141/213(66.2%)  0.002 
  Neither DM nor PS  4888/15998(30.6%)  599/1743(34.4%)  0.001 
Systolic Blood  Pressure  All  151.3(21.1),N=22 736  156.6(26.9),N= 6156  0.001 
  DM  154.6(20.7), N=3848  159.7(27.5),N=1446  <0.0001 
  No DM  150.5(21.1),N=18540  155.9(26.8),N=4440  <0.0001 
  PS  152.1(20.4), N=2925  160.3(27.1),N=2013  <0.0001 
  No PS  151.1(21.2), N=19510  155.1(26.7), N=3970  <0.0001 
  DM+PS  154.0(20.5),N=589  163.2(27.8),N=534  <0.0001 
  Neither DM nor PS  150.3(21.2), N=16052  154.3(26.6),N=3058  <0.0001 
Diastolic Blood Pressure  All  82.6(13.5),N=22710  84.0(16.1),N=6156  <0.0001 
  DM  81.9(13.4), N=3841  83.4(15.7),N=1446  0.0007 
  No DM  82.7(13.4),N=18521  84.3(16.3),N=4440  <0.0001 
  PS  82.4(13.4),N=2921  84.9(15.7),N=2014  <0.0001 
  No PS  82.6(13.5),N=19489  83.6(16.3),N=3969  <0.0001  
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  DM+PS  81.7(13.6),N=587  84.2(15.8),N=534  0.005 
  Neither DM nor PS  82.7(13.5),N=16036  83.8(16.5),N=3057  <0.0001 
 
Numbers do not add to a total of 29228 due to missing data for some of the variables. () records standard deviation and  [] the range, * p statistics were calculated by 
employing Wilcoxon non  parametric test. 
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Figure    6-1    Bar  Diagrams  showing  the  distribution  of 
patients in each risk factor category.  
The  numbers  in  the  box  denote  percentage.  Colour  codes 
refer to modified Rankin Scale. 
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Figure    6-2  Forest  Plot  showing  outcomes  for  various 
analyses in affected patients’ population.  
 
 
Unadjusted, and age and baseline adjusted analyses refer 
to ordinal regression analysis. Odds Ratio refers to common 
odds  for  improved  outcomes  at  each  Rankin  category. 
Favourable  outcomes  refer  to  Rankin  0-2  whereas  the 
Excellent  outcomes  refer  to  the  Rankin  score  0-1.  All 
adjusted  analyses  refer  to  an  adjusted  analysis  in  which 
adjustments were made  for all variables  that  differed at 
baseline.  
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Figure    6-3 Forest Plot showing outcomes for various analyses in 
unaffected patients’ population.  
 
Unadjusted and age and baseline adjusted analyses refer to ordinal 
regression  analysis.  Odds  refer  to  common  odds  for  improved 
outcomes at each Rankin category. Favourable outcomes refers to 
Rankin 0-2 whereas the Excellent outcomes refers to the Rankin 
score 0-1. All adjusted analyses refers to an adjusted analyses in 
which  adjustments  were  made  for  all  variables  that  differed  at 
baseline. 
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6.4 Discussion  
The patients who suffer from the concomitant presence of diabetes and previous 
stroke are currently recommended for exclusion from receiving thrombolysis for 
acute  ischaemic  stroke.  Employing  a  robust  analytical  methodology  [shift 
analysis] and a large number of patients [N=29500], I have again shown improved 
outcomes across patients having diabetes, previous strokes or both who received 
thrombolytic therapy compared to those who were excluded from receiving this 
therapy.  
I  have  first  shown  improved  outcomes  amongst  patients  who  did  not  have 
diabetes and prior stroke, each having adjusted odds of 1.7 and 1.6 respectively, 
each of which is comparable to the odds for a similar time window obtained 
from the analysis of pooled data from all of the large trials conducted to date. 
131 This concordance of odds anchors my findings from patients having diabetes 
and  previous  stroke  to  established  randomised  control  trial  results.
29  In  the 
populations  of  patients  with  diabetes,  prior  stroke  or either  condition,  this 
better outcome amongst the group who received thrombolysis with intravenous 
alteplase  versus  untreated  comparators  is  maintained.  I  confirm  the  finding 
using both ordinal and dichotomised analysis approaches, and whether or not the 
analyses are adjusted for baseline variables known to associate with prognosis. I 
find  no  interaction  between  diabetes and  prior  stroke  with  the  effect  of 
alteplase to justify further subgroup analysis. However, in the small group of 
patients  having  both  diabetes  and  prior  stroke,  I  no  longer  confirm  a  better 
distribution  of  outcome  with  alteplase  [OR  1.2,  95%  CI:  0.996 1.5] 
though dichotomisation reveals favourable outcomes [m RS 0 2], OR=1.3(95% CI 
1.008 1.8)]. This discordance may arise from the smaller sample size, N=1141, 
which yields less precise point estimates and may be associated with a type II 
error. The point estimates remain consistent with those from the more reliable 
main analyses. This could also be explained by the fact that I did not account for 
the baseline disability amongst patients who had a previous stroke, and one does 
not  expect  the  patients’outcomes  would  shift  and  get  better  than  their  pre 
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In the present chapter, I have analysed a large dataset, N=29500. The findings 
are reassuring because these patients have a clinical profile similar to the one 
often  seen  in  clinical  practice.  More  patients  in  the  diabetic  group  had 
hypertension, history of previous stroke, atrial fibrillation, and heart failure and 
used  antithrombotic  agents.  Here  the  patients  who  received  treatment  had 
suffered a severe stroke at baseline compared to the untreated patients [NIHSS: 
13 vs. 11]. Similarly, more patients having previous stroke(s) had hypertension, 
diabetes, atrial fibrillation, and heart failure, and use of antithrombotic agents 
before stroke.  
In addition, this analysis supports the findings obtained from VISTA only analysis 
[N=5817] reported in chapter 5, where employing a similar approach I compared 
the patients in VISTA who received thrombolytic therapy against those who did 
not.  That  analysis  reported  similar  odds:  patients  having  diabetes,  OR=  1.3 
[95%CI:  1.05 1.6];  patients  having  previous  stroke,  OR=  OR:  1.3  [95%CI:  1.04 
1.6], and both together, OR= p OR: 1.5 [95%CI: 0.98 2.3].  
A  limitation  of  this  study  is  that  the  data  are  non randomised.  However,  I 
adjusted the analysis for age and baseline NIHSS scores. 
278,279,347,348    (and then 
also for other variables that differed at baseline) and employed robust statistical 
tools [Cochran Maentel Haenszel Test, proportional odds logistic regression; and 
analysis by dichotomisation of Rankin scores]. I believe that I have attained a 
reliable statistical result.  One may anchor the findings on the fact that the odds 
in the group of patients who did not have DM or PS were comparable with the 
published  randomised  trial  data  [In  NINDS,  OR  1.6  (95%CI  1.2 2.1)]
269,  while 
acknowledging  the  caveat  that  there  are  no  analyses  of  RCT  data  that 
specifically examined outcomes after excluding those patients that had diabetes 
or  prior  stroke.  Next,  although  prior  stroke  patients  who  were  offered 
thrombolysis may have had higher premorbid mRS than patients who had no prior 
stroke, it is known that patients with premorbid mRS >1 were excluded from the 
VISTA trials from which comparators for analysis are derived.  This potential bias 
would be expected to lead to underestimation of any benefit from alteplase in 
that subgroup of patients.  
Hyperglycaemia after stroke occurs in about 60% of  patients and only 20% of 
these patients report a history of diabetes mellitus.
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the Chapter 5, hyperglycaemia and diabetes are overlapping but two different 
conditions.  Hyperglycaemia  at  baseline  may  be  associated  with  diabetes 
(uncontrolled or unrecognised diabetes or poor glucose tolerance) or it can be a 
response  to  the  acute  stress  (stress  hyperglycaemia).  The  EMEA  recommends 
that patients suffering from blood glucose levels at baseline <50 and > 400 mg/dl 
should  be  excluded  from  receiving  therapy.  The  purpose  of  analysis  that  I 
present in this chapter was to examine outcomes amongst patients who already 
had diabetes and prior stroke as these are distinct exclusion criteria specifically 
mentioned in the EMEA document. I realise that denominators in my analyses 
(“non diabetic patients”) might be having hyperglycaemia (due to unmasking of 
diabetes,  poor  glucose  tolerance,  unknown  case  of  diabetes  or  stress 
hyperglycaemia) at baseline. What proportions of non diabetics had raised blood 
sugar levels in this dataset is unknown. Examination of outcomes for different 
levels of hyperglycaemia (with or without presence of diabetes/previous stroke) 
would  require  another  analysis.  In  summary,  the  analysis  shows  improved 
outcomes  amongst  patients  with  diabetes,  or  prior  stroke.  The  magnitude  of 
benefit is comparable to that in other patient groups. This finding contrasts with 
EMEA’s justification for restricting use of intravenous alteplase. The analysis did 
not confirm  a  significant  benefit  in  the  small  subgroup  of  patients  who 
had concomitant  diabetes  and  prior  stroke  but  here  the  confidence  intervals 
were wide, and there was no interaction between these two risk factors with the 
treatment effect of alteplase. Hence, I find no justification to exclude patients 
from receiving alteplase for acute ischaemic stroke if they suffer from a previous 
stroke and also have diabetes mellitus.   171 
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7  Should patients having mild or severe stroke 
receive alteplase? 
 
7.1 Introduction 
Intravenous thrombolysis with alteplase is a proven therapy for acute ischaemic 
stroke patients presenting within 4.5 hours of symptom onset.
122,129,131 However, 
some  patients  are  denied  therapy  for  fear  of  poor  outcomes.  European 
guidelines recommend that patients with baseline stroke severity NIHSS >/=25 
and minor/rapidly improving strokes should not be given alteplase.
23 But, there 
is a lack of consensus on what defines a “mild stroke”.
349 Heinrich Mattle and 
colleagues
349 undertook a Medline search to look for papers published between 
1950  and  2009  by  using  a  search  term  “  Minor  Stroke”.  They  extracted  670 
papers and found that most of these had not defined a minor stroke.
349 However, 
some of the definitions have been used to define mild stroke are: 
 
1.  Definition A:  baseline NIHSS score of 0 or 1 in each NIHSS component 
except the items 1a, 1b and 1c that deal with the level of 
consciousness.
349 350 
2.  Definition B: lacunar strokes at baseline.
349 350 
3.  Definition C: presence of motor symptoms (including dysarthria or ataxia 
+/ sensory symptoms).
349 350 
4.  Definition D: NIHSS Score </=9), excluding all patients with extinction or 
neglect, aphasia or having level of consciousness.
349 350 
5.  Definition E:  maximum NIHSS score of 9.
349 350 
6.  Definition F: NIHSS </=3.
349 
7.  Definition G: NIHSS <5. 
 
 
Employing  definition  A  to  E  NINDS  investigators  examined  outcomes  in  624 
patients that were enrolled in the NINDS trial.
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based on a logistic model to examine patients who had favourable outcome on 
day 90. In addition, they also examined the rates of symptomatic intracerebral 
haemorrhages.    Data  comprised  N=28  patients  as  per  definition  A,  N=81  per 
definition  B,  N=439  per  definition  C,  N=173  per  definition  D  and  N=177  per 
definition E.  Based on an Intention to treat analysis, investigators showed that 
the odds for better outcomes ≈ 2 for all the definitions (p<0.05) (lower limit of 
confidence  interval  between1.4  to  1.5;  upper  limit  between  2.7  and  2.9). 
Symptomatic  Intracerebral  Haemorrhage  occurred  in  0 4%  of  patients  per 
definition.
350   
 
Employing the definitions A to F, Fischer et al
349 reported analysis of Bernese 
Stroke Registry data (N=760) and examined short term outcomes (patient goes 
home)  and  a  favourable  medium  term  outcomes  (m RS  0 2  on  day  90)  for 
patients. In addition, they also analysed data for various subgroups of patients 
defined  by  their  sex,  age,  laterality  of  lesions  (left right)  or  circulation 
(anterior posterior) and temporal profile of admissions (early versus late). This 
study  reported  that  median  NIHSS  were  lowest  for  the  definitions  A  and  F. 
Definition A and definition F were associated with most favourable short and 
medium  term  outcomes.  Per  definition  C,  more  numbers  of  patients  with 
anterior  circulation  infarction  were  discharged  home  compared  to  posterior 
circulation stroke (p=0.02). Rankin  scores  on  day 90 were less  favourable for 
elderly  patients  per  definition  E  (p<0.05).  Definitions  A,  D  and  F  were  not 
associated  with  differences  on  outcomes  across  the  subgroups.    Authors 
recommended for the need of a consensus definition of a mild stroke.
349 
 
Several stroke trials explicitly exclude patients with NIHSS of 5 or less (definition 
G).
46,247,351,352 9 
 
Patients having rapidly improving stroke symptoms are also recommended for 
exclusion because these patients are assumed to have improved outcomes.
122 But 
                                                
9 I published Chapter 7 in Stroke (Mishra NK, Lyden P, Grotta JC, Lees KR; VISTA Collaborators. 
Thrombolysis  is  associated  with  consistent  functional  improvement  across  baseline  stroke 
severity:  a  comparison  of  outcomes  in  patients  from  the  Virtual  International  Stroke  Trials 
Archive (VISTA). Stroke. 2010 Nov;41(11):2612-7.). Permissions were obtained from Wolters 
Kluwer Health, License Number: 2783790313323. 
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data indicate that this may not always be the case.
142,353 356  Nedeltchev et al
357 
show  that  about  75%  of  patients  that  present  with  mild  or  rapidly  improving 
stroke symptoms achieve a Rankin score of </=1 by day 90. Those that have 
persistent proximal vessel occlusion and a baseline NIHSS of >/=10 suffer 7 times 
the excess risk of unfavourable outcomes.
357 Persistent occlusion of blood vessels 
was shown to be associated with poor outcomes in patients.
356,358 360 Additional 
data are needed so that one can reliably select phenotypes of those patients 
that would either undergo spontaneous recovery or need thrombolysis. 
 
t PA guidelines were framed under an assumption that  many patients who show 
rapid improvement/ have minor strokes would not display residual deficit, but 
treatment with thrombolytic therapy would expose them to risk of complications 
such  as  cerebral  haemorrhage.
23  Similarly,  those  patients  who  present  with 
baseline  NIHSS  >/=25  are  also  supposed  to  have  poorer  outcomes  because  of 
excess symptomatic haemorrhages.
23 Baseline stroke severity (b NIHSS) is known 
to  affect  outcomes  amongst  thrombolysed  patients,  and  was  therefore 
incorporated for patients’ selection in ECASS III trial.
23 Though the regulatory 
authorities  have  recommended  withholding  thrombolytic  therapy  amongst 
patients with minor/rapidly improving strokes and for those with severe stroke 
at  baseline,  poorer  response  to  therapy  in  these  subgroups  has  never  been 
demonstrated in randomised controlled trials.
23 Indeed, post hoc analyses of the 
NINDS and ECASS III trials suggest equal efficacy across severity ranges, though 
power to examine subgroups is inevitably lower than that chosen for the primary 
analyses and patients at extremes of severity were under represented.
361 363 The 
logistical challenges involved in generating randomised trial evidence for these 
limited subgroups militate against any prospect for producing a definitive answer 
in  the  foreseeable  future.  Therefore  one  must  turn  to  alternative  sources  of 
evidence.  
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7.2 Methods 
7.2.1 Data Source and patients 
As  discussed  in  Chapter  2,  I  collated  the  demographics,  clinical  data  and 
measures of functional outcome from neuroprotection trials conducted in the 
period 1998 to 2007, held within the Virtual International Stroke Trials Archive, 
VISTA (www.vista.gla.ac.uk).   
 
7.2.2 Statistical analysis 
I compared outcomes between patients who received thrombolysis and patients 
who did not receive thrombolysis (controls) amongst categories of baseline NIHSS 
scores (below 4, 5 8, 9 12, 13 16, 17 20, 21 24 and >/=25). For each contrast, I 
compared the overall distribution of all seven categories of day 90 mRS scores of 
the two groups, i.e. from 0 (asymptomatic) through 5 (bedbound and completely 
dependent),  to  6  (dead).  For  analysis  of  the  supporting  endpoint,  NIHSS,  I 
grouped the adjacent scores into categories: 0 (no measurable deficit), 1 4, 5 8, 
9 12, 13 16, 17 20, 21 24, ³25 (most severe neurological deficit) or dead. The 
distribution of patients across these categories was then compared between the 
groups as for mRS.    
 
To test for a significant association of outcome distribution with thrombolysis 
exposure I used the Cochran Mantel Haenszel [CMH] statistic, adjusting for both 
age  and  baseline  NIHSS  as  continuous  variables.  Further,  I  applied  logistic 
regression analysis, also adjusted for age and baseline (b ) NIHSS, to estimate 
the odds ratio under the assumption of proportional odds and its associated 95% 
confidence interval. Reliable information on symptomatic haemorrhage was not 
available  since  post  treatment  imaging  was  not  routinely  applied  in 
neuroprotection trials to patients who had not been treated with alteplase.  
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7.3 Results 
7.3.1 Patient sample 
Complete data were available for analysis of mRS in 5817 patients and on NIHSS 
in 5715 (see chapter 2 for details of VISTA data). Of the 5817 patients with mRS 
outcome data, 1585 (27.2%) received thrombolysis. 
 
7.3.2 Does baseline stroke severity influence stroke outcomes?  
In  an  ordinal  logistic  regression  analysis,  I  found  that  baseline  severity 
(p<0.0001), use of rt PA and age were significant predictors of outcomes. Then, 
in  an  age  adjusted  ordinal  logistic  regression  analysis,  I  found  that  baseline 
stroke  severity  (p<0.0001)  and  the  interaction  between  severity  and  use  of 
alteplase (p=0.04) were associated with outcome from stroke, but I did not see 
an independent effect of alteplase (p=0.65). 
 
Supported by this interaction test, I classified the baseline stroke severity into 
seven baseline NIHSS score categories:1 4,5 8,9 12,13 16,17 20,21 24,and>/=25, 
and undertook tests of association for thrombolysis with outcomes in each of 
these categories. 
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Figure    0-1  7-1  Figure  showing  details  of 
selection of patients from VISTA for this 
analysis. 
 
VISTA data (1998-2007)
N=9665 patients
Ischaemic Stroke patients
N=9058
VISTA analysis
N=6092
Exclude missing m-RS 
data: 5817 patients for 
analysis
Exclude missing NIHSS 
data: 5711 patients for 
analysis
Potential SITS MOST Overlap 
N=2789
Patients with unknown 
nationality N=177
Intracerebral haemorrhage
N=571
Undetermined
N=36 
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Table   0-1 7-1 Baseline characteristics of the patients studied in VISTA.  
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7.3.3 Are  there  improved  outcomes  across  all  baseline  stroke 
severity categories? 
7.3.3.1  Primary analysis: functional outcome by modified Rankin Scale.  
I report the findings in figure 7 2 below. 
 
 
 
Figure   0-2 7-2 Forest plot showing age and baseline stroke severity adjusted outcomes across 
categories of baseline severity level 
 
7.3.4 Secondary analysis: neurological outcomes by NIHSS. 
Findings are shown in figure 7.3. 
 
7.3.5 Sensitivity analysis  
I  also  performed  unadjusted  analysis,  and  analysis  in  which  I  adjusted  for 
additional factors.  Results are shown in figure 7.3 
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Figure   0-3  7-3 Findings from secondary and sensitivity analyses 
  
Nishant Kumar Mishra, 2011.            Chapter 7, 181 
 
 
I could not adjust for onset to treatment [OTT] time because time to initiation 
of  thrombolytic  therapy  was  not  recorded  within  the  source  neuroprotection 
trials.  
Fifty nine per cent of records lacked coding for the variable “antithrombotic” 
(i.e.  antiplatelet  and  anticoagulants)  (N=3432),  4.8%  for  atrial  fibrillation 
(N=278) and 3.2% for patients with prior strokes (N=186). Because the analyses 
were to  be conducted within each  stratum of  baseline stroke  severity,  these 
differences were more pronounced limiting the analyses of data controlled for 
all  variables  that  differed  at  baseline:  age,  baseline  NIHSS,  prior  use  of 
antithrombotic drugs, previous stroke and atrial fibrillation). 
 
7.4 Discussion  
Patients with mild and severe strokes are under represented in randomised trials 
and post marketing analyses. The  EMEA marketing authorisation for alteplase in 
acute  ischaemic  stroke  lists  minor  neurological  deficit  or  symptoms  rapidly 
improving before start of infusion, and severe stroke as assessed clinically (e.g. 
NIHSS>25)  and/or  by  appropriate  imaging  techniques,  as  contraindications.
23  
Such  patients  do  present  to  hospital  services,  however,  and  this  places  the 
physicians in a dilemma whether or not to offer treatment. Some experienced 
physicians treat  such patients.  For example, 12%  of  patients in  the SITS ISTR 
thrombolysis registry had a baseline NIHSS score in the range 0 to 4 and 4% had 
severe stroke with NIHSS >/=25. Many more patients were probably not included 
for thrombolysis treatment: a Canadian series found that 31% of patients were 
considered too mild or improving too rapidly for treatment.
142 About 20 46% of 
patients  that  present  in  emergency  departments  do  not  receive  thrombolytic 
therapy because of presence of mild or rapidly improving stroke.
142,364 367   This 
cannot  be  justified  on  the  basis  of  observed  outcome.  In  dataset  of  93517 
patients  that  suffered  stroke,  29200  patients  had  mild  or  rapidly  improving 
stroke. Of these, 28 % of the patients failed to go home on discharge. A similar 
proportion was unable to move around without assistance.
368  Randomised trials 
to establish the existence or extent of benefit at extremes of baseline severity  
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may be difficult to conduct and delayed in execution. Other sources of evidence 
must be examined, and high quality registry data are the obvious choice. 
 
In the present non randomised comparison of data held in VISTA, outcomes after 
thrombolysis  were  significantly  better  than  in  untreated  comparators  across 
baseline  NIHSS  scores  5  to  24.  This  significant  association  was  lost  only  at 
extremes of b NIHSS (i.e. 1 4 and >/=25). Although the point estimates for both 
adjusted and unadjusted odds ratios remain favourable in the extreme groups, 
they  are  lower  than  those  observed  at  other  levels  of  stroke  severity  and 
confidence intervals include the possibility of significant harm as well as benefit. 
In these extreme groups the small sample size seriously undermines the power of 
the statistical tests and with wide confidence intervals the true point estimate is 
not reliably indicated. There is a second statistical issue to consider, relating to 
the  outcome  measure  that  I  used.  By  examining  the  full  distribution  of  the 
modified Rankin scale I have used a test that is less dependent on case mix than 
dichotomisation:  I was able to use the same test for patients with mild stroke as 
severe stroke and still detected benefit. 
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Figure   0-4 7-4 Distribution of outcomes in patients with baseline severity NIHSS score of 0-4  
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Figure   0-5 7-5  Outcomes in patients having baseline severity NIHSS >/=25 
3.1 
1.7
1.6
3.4
7.8 
3.4  8.9 19 
7.8 21.9  14.1 
17.3 
43.8 
46.4 
TPA
Control
0 1 2 3 4 5 dead 
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Even so, at the extremes of baseline severity, outcomes are generally so good or 
so  poor  that  only  a  few  mRS  categories  are  well  represented  in  the  control 
groups.    Both  the  Cochran Mantel Haenszel  test  and  the  proportional  odds 
estimations will be compromised if some categories are not contributing to the 
analysis:  effectively, the test of treatment effect will be diluted by the non 
contributing  groups.  For  CMH  this  means  that  it  becomes  harder  to  reach 
statistical significance but for the proportional odds tests, the basic assumption 
has been breached:  the effect is not proportional. There is no easy solution to 
this problem:  if case mix is altered to deliver a significant result then patients 
with mild or severe stroke must be excluded – the solution used by the trials.  
Conversely if the outcome measure is varied according to the sample case mix 
(the sliding dichotomy approach discussed by Murray et al)
283 then interpretation 
is rendered difficult:  is an odds ratio for achieving mRS 0 versus 1 6 equivalent 
to  an  odds  ratio  for  achieving  mRS  0 5  versus  6,  i.e.  is  survival  free  from 
symptoms equivalent to survival at any cost? 
Here, I have chosen to present one analytic approach for all severities of stroke 
but I also illustrate the range of outcomes at extremes of severity. From these, 
although  the  summary  statistics  show  only  a  non significant  but  favourable 
trend,  I  can  draw  further  conclusions.  Amongst  patients  with  severe  stroke, 
there appears to be a trend towards benefit across almost all boundaries of mRS 
(Figure 7 5). Amongst patients with mild stroke, all boundaries except 0 1 versus 
2 6  show  benefit  but  four  of  the  mRS  categories  are  entirely  unrepresented 
(Figure 7 4).  Findings derived from the VISTA data show no reason to withhold 
treatment  from  either  group  of  patients  but  are  not  in  themselves  sufficient 
evidence to justify treatment. 
My findings draw validity from the fact that the source clinical trials rigorously 
reported  outcomes,  and  had  strict  on site  data  verification  procedures. 
However,  the  non random  allocation  to  treatment  versus  control  groups  is  a 
significant weakness of our design. One cannot determine the degree and cause 
of exclusion of patients from our database; one can only consider factors known 
to  associate  with  prognosis.    Further,  information  on  variables  like  do not  
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resuscitate order for severe strokes or complete list of concomitant treatments 
were not captured in the VISTA datasets. These could have introduced bias as 
well. 
I have adjusted statistically for factors that have a large influence on outcome. 
One can also ‘anchor’ the findings by comparison of treatment associations for 
patients with moderate  stroke severity in  our  study against  known  treatment 
effects in comparable patients from randomised trials. For example, I found an 
OR for favourable outcome of 1.3 – 1.6 for patients with b NIHSS 9 12 and 13 16;  
the comparable estimate from treatment within 3 hours of stroke onset in RCT 
would  be  1.64  and  for  3 4.5  hours  would  be  1.34.
131  The  estimates  are 
comparable and perhaps conservative.  
The decay of benefit across later onset to treatment times raises a second issue. 
I do not have information on the onset to treatment delay for alteplase in the 
current analysis. Since the patients were permitted only one investigational drug 
in the participating VISTA trials, alteplase being used as standard of care, and 
since these trials were closely monitored by their sponsors, one can assume that 
patients were largely treated within 3 hours of stroke onset. I also assume that 
the onset to treatment time is comparable to those from the CASES and SITS 
MOST  registries  (155  (130 175)  minutes  and  140  (115 165)  minutes  [n=6483] 
respectively).
146,369    Unfortunately,  the  latency  between  stroke  onset  and 
recording of initial severity differed between the treatment group (3.7 hours) 
and controls (5.1 hours) in the VISTA data. Severity is associated with onset to 
hospital  arrival  time:  patients  with  more  severe  stroke  present  earlier.
370  I 
adjusted the analyses for stroke severity but it is conceivable that residual bias 
persists.  Such  a  bias  would  cause  underestimation  of  true  initial  severity 
amongst the controls and through the baseline adjustment would have led to 
overestimate treatment effect. It will influence all patients across the severity 
range but may be less evident at extremes of severity: the NIHSS criterion will 
be  responsible  for  discouraging  use  of  alteplase,  and  so  the  proportion  of 
patients who are treated with alteplase will fall at extremes of NIHSS.  
I lacked data on symptomatic haemorrhages, since patients who are not treated 
with  thrombolysis  generally  do  not  undergo  follow up  cerebral  imaging  for  
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routine  detection  of  haemorrhagic  transformation.  However,  the  outcome 
measure that I used takes into account effects of haemorrhage or other adverse 
events on function. 
I  adjusted  for  age  and  baseline  severity  as  these  are  the  established  most 
important variables known to influence outcomes.
265 I could not adjust for all   
age, baseline NIHSS, prior use of antithrombotic drugs, previous stroke and atrial 
fibrillation together   as one of the contributing trial programs did not record 
pre treatment  medications.  However  I  was  able  to  undertake  an  adjusted 
analysis  for  the  variables  that  were  found  significant  in  ECASS  III,  namely 
diabetes and prior stroke, and the estimates remained consistent.  
 
Some of the patients in this study received an investigational medicinal product. 
Each  contributing  trial  has  already  tested  for,  and  excluded,  a  significant 
interaction of that product with alteplase, both in vitro and in vivo. 
 
Individual patient data analyses from pooled randomised data
131 could be the 
most informative method to assess the influence of baseline severity on outcome 
response to alteplase.  Unfortunately, the pooled data have a median baseline 
NIHSS of 11 and interquartile range of 7 to 16, that would weaken analyses to 
guide use of t PA in the patients at the extremes of baseline NIHSS categories.  
Enrolment  to  extreme  subgroups  is  generally  limited.
41  Pooja  Khatri  and 
colleagues have applied for funding to seek support a placebo controlled trial of 
alteplase in patients suffering mild stroke. The trial would be called Potential of 
rtPA for Ischaemic Strokes  with Mild Symptoms (PRISMS) (International Stroke 
Conference, Los Angeles, 2011).  
 
Analyses of VISTA data imply that patients at extremes of NIHSS scores recorded 
at  baseline  may  still  benefit  from  treatment  but  the  supporting  evidence 
remains weak.  
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8  Mismatch based delayed thrombolysis: a meta-
analysis 
8.1 Introduction 
Thrombolysis is the principal therapy for acute stroke patients in the early hours 
after symptom onset
 but has a short treatment window.
122,129 In a meta analysis 
of  data  derived  from  2775  patients  (pooled  from  the  ATLANTIS,  ECASS,  and 
NINDS  trials),  there  was  a  gradually  diminishing  benefit  toward  6  hours from 
stroke onset [(odds ratio [OR]=2.8; 95% CI, 1.8 to 4.5) for 0 to 90 minutes, 1.6 
(95% CI, 1.1 to 2.2) for 91 to 180 minutes, 1.4 (95% CI, 1.1 to 1.9) for 181 to 270 
minutes, and 1.2 (95% CI, 0.9 to 1.5) for 271 to 360 minutes].
130 Recently, the 
ECASS III trial (N=821; treatment vs. placebo 1:1; median time for administration 
of alteplase=3 hours, 59 minutes) confirmed clinical benefit within 4.5 hours of 
stroke onset. (OR=1.34; 95% CI, 1.02 to 1.76; P=0.04). 
129 However, the wider 
95% CI at 6 hours (0.9 to 1.5 for 271 to 360 minutes in the meta analysis
130) have 
suggested  that  there  may  still  be  patients  able  to  benefit  from  thrombolysis 
even beyond 4.5 hours. Conversely, others may be at increased risk from late 
treatment. The use of imaging approaches to select patients who have remaining 
salvageable  tissue  for  delayed  treatment  has  been  proposed,  most  notably 
approaches that include magnetic resonance imaging (MRI) perfusion/diffusion 
“mismatch.”
371,372  
 
Several trials have tested thrombolysis in patients selected after MRI. Even some 
centres have incorporated mismatch imaging and delayed thrombolysis into their 
routine clinical practice.
45,373 Safety and efficacy data were reported for those 
patients that received thrombolysis beyond 3 hours of symptoms onset in a MR 
based selection paradigm (n=180) and also CT or MR based patients thrombolysis 
within 3 hours of their symptoms onset (714 and 316 respectively). These were 
pooled data from four German and one Spanish centres (N=1210). These data  
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showed that the rates of symptomatic haemorrhages or mortality were similar 
10 
between  the  three  groups  (p=0.2  and  0.7  respectively).
45  Symptomatic 
haemorrhages were significantly reduced in case of patients selected by MRI. 
(p=0.5).
45  
 
I undertook a meta analysis of data in the public domain to examine whether 
extension of the treatment window among patients selected according to the 
presence of mismatch can be recommended for routine clinical practice.  
 
8.2 Methods 
8.2.1 Selection of Trials 
I  planned  to  include  only  relevant  papers  that  described    findings  of  studies 
which  either  undertook  prospective  enrolment  of  consecutive  stroke  patients 
with mismatch profile for delayed thrombolysis [beyond 3 hours of stroke onset] 
or had studied mismatch based, delayed thrombolysis in a randomised controlled 
design. I excluded case reports, case series and studies restricted to specific 
anatomical  brain  locations.
374  I  defined  (1)  mismatch  profile  as  a  perfusion 
volume  at  least  1.2  times  that  of  the  infarction  core  utilising  the  imaging 
methodology  available  with  the  concerned  trial  centre,  (2)  Symptomatic 
Intracerebral  Haemorrhage  (SICH)  as  radiologically  confirmed  cerebral 
haemorrhage  in  association  with  clinical  worsening  following  thrombolytic 
therapy [within 36 hours in case of t PA and 72 hours in case of desmoteplase]   
(3)  reperfusion  and/or  recanalisation    according  to  the  respective  studies’ 
definitions (4) favourable clinical outcome as an NIHSS improvement of 8 points 
from the baseline or attainment of NIHSS of 0 or 1 and / or m RS of 0 or 1 and 
(5) Mortality as death (m RS 6) in the 90 days following thrombolytic therapy.  
 
I  considered  the  rt PA  and  desmoteplase  together  as  both  are  thrombolytic 
agents.
70,106 108,375,376  These differ in some features: desmoteplase lacks the 2
nd 
                                                
10 I published Chapter 8 in Stroke (Mishra NK, Albers GW, Davis SM, Donnan GA, Furlan AJ, 
Hacke  W,  Lees  KR.  Mismatch-based  delayed  thrombolysis:  a  meta-analysis.  Stroke.  2010 
Jan;41(1):e25-33.) Permissions were obtained from Wolters Kluwer Health, License Number:  
2783790733330 
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kringle site in its molecular structure; does not need to be cleaved by plasmin; is 
active  in  its  single  chain  form;  has  reduced  neurotoxicity;  limited  passage 
through the blood brain barrier.
 70,106 108,375,376   Desmoteplase has a theoretical 
advantage  over  rt PA  as  it  is  almost  non functional  if  fibrin  is  absent.
  70,106 
108,375,376   Alteplase is already a proven therapy for treating stroke patients in 
the  early  hours  of  its  onset  [NINDS,  ECASS  III]
122,
129  and  doses  that  carry 
acceptable  safety  and  efficacy  have  been  identified
109 111.  Both  desmoteplase 
and  alteplase  remain  investigational  for  delayed  thrombolysis.  However,  I 
undertook  a  sensitivity  analyses  for  any  differential  effect  between 
desmoteplase versus alteplase.  
 
Until the DIAS II study the identification of ischaemic penumbra was based on 
magnetic  resonance  perfusion diffusion  weighted  imaging  (MR  PI DWI) 
mismatch.
111 For the first time, the DIAS II investigators were permitted to select 
patients based on the visual appreciation of mismatch on perfusion CT images as 
an alternative to MR perfusion studies depending upon the local expertise of the 
imaging centre. I included data from either method as reported in the DIAS II 
publication.
111  
 
I included all trials that defined the mismatch profile as the perfusion volume 
being 1.2 times of the infarction core. I placed no restriction on the manner in 
which  perfusion  was  measured  in  these  trials.  For  example,  in  DIAS  2,  the 
mismatch  population  was  identified,  based  on  either  CT  perfusion  or  MR 
perfusion  according  to  centre  preference.  The  determination  of  mismatch  in 
DEFUSE  and  EPITHET  was  based  on  post processed  PWI  data  that  included 
correction for arterial input and thresholding. In contrast, in the desmoteplase 
studies mismatch was determined “real  time”  without  post processing  by the 
investigator using the “eyeball” technique.   
 
 
8.2.2 Endpoints 
Endpoints  of  interest  for  our  meta analysis  were  comparisons  between 
thrombolysed  and  non thrombolysed  patients  in  (1)  favourable  outcome  (2) 
reperfusion and/or recanalisation (3) mortality and (4) SICH.  I also examined Nishant Kumar Mishra, 2011.                                                                                       Chapter 8, 192 
 
 
the  rates  of  favourable  versus  unfavourable  clinical  outcome  amongst 
successfully reperfused patients. 
 
8.2.3 Search 
I first searched the “Web of Knowledge” for ten broad terms [“Clinical Trial*”, 
“Prospective  Study”, “stroke  trial*”, “thrombolytic agent”,  “desmoteplase”,  
“tissue  plasminogen  activator”,  “recanalisation  in  stroke”,    “  reperfusion 
therapy in stroke”, “penumbra in stroke”, and “mismatch hypotheses”]. Then, I 
refined the search by combining these with terms that underline the mismatch 
hypotheses and thrombolysis. My last search was undertaken on 19
th December, 
2008. From review of the title and abstract I selected for further examination all 
relevant  papers  describing  the  original  findings  of  studies  that  used  the 
mismatch  hypotheses  and  selected  patients  for  thrombolysis  despite  delay 
beyond 3 hours of stroke onset. I checked whether any later paper or abstract 
offered supplemental data. Once selected, each paper was read completely and 
the relevant data extracted. I also searched the bibliography of each of these 
papers for further articles.  
 
  
8.2.4 Statistical Analysis 
For this meta analysis, I retrieved “estimate(s) of effect” from the abstract(s). 
When  relevant  data  were  missing,  I  searched  the  full  text  and  any 
supplementary articles.
377 Primarily, I wished to analyse data derived from the 
patients with mismatch profile on an intention to treat (ITT) basis but where the 
ITT data were unavailable we accepted ‘per protocol’ data and described the 
underlying limitations. The comparisons were mainly planned between patients 
offered any dose of any thrombolytic agent against the corresponding placebo 
treated patients.
377  
 
I  performed  sub group  analysis  amongst  patients  who  were  treated  with 
thrombolytics at doses approved or still under clinical investigation, i.e. 90 g/kg 
desmoteplase  or  0.9mg/kg  of  rt PA.  Comparisons  (summary  estimates)  are 
expressed as odds ratio [OR] and their 95% confidence interval [CI]. Whereas I 
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calculate  the  summary  estimate  [adjusted  OR  (a OR)],
377  I  report  only  the 
findings of  fixed method here. But, I have indicated the instances where the 
results have diverged. I assessed the heterogeneity using the tests statistics for 
the  heterogeneity  and  I
2  for  inconsistency  supported  by  the  examination  of 
L’Abbé’s plots.  
 
The analysis included data derived from those patients who were selected (or 
could  have  been  selected)  based  on  mismatch  profile.  In  order  to  assess  if 
favourable outcomes (clinical outcomes at day 90) were more common amongst 
the patients who had successful reperfusion, I retrieved data on 242 patients for 
whom  the  reperfusion  findings  were  available  [the  DIAS  I  trial
109  (N=97),  the 
DEDAS trial
110 (N=34), the EPITHET trial
181 (N=77; “Good Neurological Outcome” 
with reperfusion : 30 and without reperfusion : 47 (for mismatch patients only) 
and the DEFUSE trial
183 (N=34; mismatch  with early reperfusion: 18 patients, 
mismatch  without  early  reperfusion:  16  patients)].  Corresponding  information 
was not reported in the DIAS II trial.
111 Similarly, in order to answer if favourable 
clinical  outcome  occurred  more  frequently  in  the  thrombolysed  group  of 
patients, information on 410 patients was available [DIAS I
 trial (N= 102), DIAS II 
trial (186), DEDAS trial (N=37) and the EPITHET trial (N=85; mismatch patients 
with/without “Good Neurological Outcome” in the thrombolysis group: 42; and 
placebo  group:  43)]  in  which  the  patients  were  thrombolysed  with  any 
thrombolytic  agent  at  any  dosage.  Next,  to  answer  if  reperfusion  or 
recanalisation occurred more frequently amongst those who were thrombolysed, 
I retrieved data on 211 patients who received thrombolytic therapy at any dose 
[DIAS  I:  97  patients;  DEDAS  (ITT):  37  patients,  [Target  Population,  (TP)  =  23 
patients]; EPITHET: 77 patients]. To assess mortality between thrombolysed and 
non thrombolysed patients, I extracted data on 410 patients [DIAS I=102, DIAS 
II=186,  DEDAS=  37,  EPITHET  =  85  (mismatch  only)].  To  assess  SICH  between 
thrombolysed and non thrombolysed patients, I extracted data on 405 patients 
[DIAS I=102, DIAS II=186, DEDAS= 37, EPITHET =80 (mismatch group only)]. Owing 
to mathematical difficulties involved in calculating OR when the numerator is 
zero, I combined the DEDAS data with DIAS I data for mortality analysis.  
 
I undertook sensitivity (subgroup) analyses in which I compared the data after 
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further evaluation. I also analysed differences in clinical outcome between the 
patients who were thrombolysed within 3 6 hours of stroke onset versus beyond 
6 hours. Finally, I compared and contrasted the attributes of the studies and 
assessed their quality based on the manner in which patients were enrolled and 
the resulting baseline characteristics.  
 
 
 
8.3 Results 
8.3.1 Literature search 
The  literature  search  (Table  1)  led  to  13  citations  on  the  DEFUSE  trial  (6 
articles),
183,378-385 two on the DEDAS trial (1 article),
110 6 on the DIAS trial,
109 9 on 
the EPITHET trial (three articles)
181,386 388 and 2 on DIAS II(1 article).
111,389 The 
information on 502 patients was obtained from the five main articles
109 111,181,183 
describing the relevant trials [(DIAS (104 patients), DIAS II(186 patients), DEDAS 
(37  patients),  DEFUSE (74  patients)  and  EPITHET (101  patients)]  and  the  data 
corresponding  to  the  patients  with  mismatch  profile  were  retrieved  for 
subsequent analysis.  
 
8.3.2 Comparative analysis of the “Mismatch” Trials: 
I  compared  the  attributes  that  differed  between  the  trials  to  highlight  the 
underlying heterogeneity in the manner the selected trials were conducted DIAS 
II  enrolled  the  least  severely  affected  stroke  patients  (median  NIHSS  9)  and 
EPITHET the most severe (median NIHSS 14 in the treatment arm and 10 in the 
placebo arm). Median baseline NIHSS scores were 11.5 and 12 respectively in the 
DEFUSE  and  DIAS  I  trials.    I  also  compared  the  time  since  stroke  onset  until 
thrombolysis  [OTT]  and  we  assessed  qualitatively  the  proportion  of  patients 
treated  in  each  trial  after  4.5  hours.  Detailed  analysis  of  OTT  could  not  be 
undertaken without raw data. Nishant Kumar Mishra, 2011.                                                                                       Chapter 8, 195 
 
 
Table   8-1  Characteristics of the trials included for the meta-analysis 
 
Attributes  DIAS I
109  DIAS II
111  DEFUSE
183  DEDAS
110  EPITHET
181 
Drug   Desmoteplase  Desmoteplase  t-PA  Desmoteplase  t-PA 
Doses   Fixed doses: 25mg, 37.5 
mg,  50  mg  and  later 
weight adjusted doses of 
62.5µg/kg, 90 µg/kg and 
125 µg/kg. 
90 µg/kg and 125µg/kg; 
permissible  maximal 
dose: equivalent to 100 
kg. 
0.9mg/kg; 10% dose bolus, rest over 
one hour; no upper limit to dose. 
90µg/kg  and  125  µg/kg; 
no  upper  limit  to  the 
maximal dose. 
0.9mg/kg;10% dose bolus, rest 
in  1  hour;  permissible  upper 
limit 90mg. 
Age (years)  18 to 85   18 to 85  18 +  18 to 85  18+ 
NIHSS 
Eligibility 
criteria  
8 TO 20  4 TO 24  ≥5  4 T0 20  ≥5 
Method used 
to  evaluate 
mismatch 
Mean  Transit  Time 
(MTT) 
CT&MRI;  selection 
based  on  visual 
impression  of  the 
Tmax  MTT;  based  on  visual 
impression 
Tmax Nishant Kumar Mishra, 2011.                                                                                       Chapter 8, 196 
 
 
investigator. 
Primary 
Endpoints of 
the study  
Reperfusion
†  in  4  to  8 
hours post treatment and 
clinical  outcome  at  day 
90.  
8  points  improvement 
or  score  of  0-1  on  the 
NIHSS scale; a score of 
0 to 2 on mRS and BI 
score of 75-100. 
8 points improvement or score of 0-1 
on the NIHSS scale; a score of 0 to 2 
on mRS and BI score of 75-100. 
Reperfusion
†  in  4  to  8 
hours post treatment and 
clinical  outcome  at  day 
90. 
Infarct  growth  attenuation  in 
mismatch  patients  between 
alteplase  and  placebo 
analysed. 
SICH 
definitions 
Any ICH associated with 
a  worsening  of  4  points 
or  more  on  the  NIHSS 
and  confirmed  by  CT 
within  72  hours  of 
treatment. 
ICH  confirmed  by 
“appropriate  imaging 
tool  and  clinical 
worsening of 4 or more 
points on NIHSS at 72 
hours 
Any  degree  of  brain  haemorrhage 
identified  along  with  worsening  on 
NIHSS greater than or equal to 2 with 
in  36  hours  of  t-PA  [major  SICH  if 
NIHSS deterioration is 2 or 3 points 
on  NIHSS  and  major  SICH  if  the 
deterioration on NIHSS is 4 or more] 
Any ICH associated with 
a  worsening  of  4  points 
or  more  on  the  NIHSS 
and  confirmed  by  CT 
within  72  hours  of 
treatment 
(As per SITS-MOST criterion) 
Clinical  deterioration  of  4  or 
more  on  NIHSS  scale  within 
36  hours  of  thrombolysis, 
parenchymal  haemorrhage  of 
grade 2 on CT scans. 
 
 
Legend: 
†Reperfusion defined as either  30% reduction of MTT volume of abnormality
 or 2 points improvement on the adapted Thrombolysis In Myocardial
 Infarction 
(TIMI) grading scheme using MRA. Nishant Kumar Mishra, 2011.                                                                                       Chapter 8, 197 
 
 
Table   8-2: Baseline characteristics of Onset-to-Treatment time in the Mismatch Trials  
 
Clinical 
Trial 
                                 OTT data 
DIAS II  ·  43 patients thrombolysed in 3-6 hours against 26 in placebo arm. 
·  80 patients thrombolysed in 6-9 hours against 37 in placebo arm.  
DEDAS  ·  OTT (median) for treatment group (n=29): 7 h 29 min [Range: 3 h 42 min 
– 9 h 28 min] 
·  OTT (median) for placebo group (n=8): 7 h 23 min [Range:  3 h 40 sec – 8 
h 36 min].  
DIAS I  ·  OTT (median) for treatment group (n=75) : 5 h 24 min  
·  OTT (median) for placebo group (n=27) : 5 h 25 min 
·  OTT (median) for total population : 5 h 25 min.  
EPITHET  ·  OTT (mean) for the treatment group: 4 h 57 min [standard deviation (SD) 
= 42 min]  
·  OTT (mean) for the placebo group: 4 hours 54 minutes [SD=50 min]  
·  OTT (mean) mismatch profile group: 4 h 53 min. SD= 45 minute 
·  OTT (mean) mismatch profile placebo group : 4h 51 min, SD = 51 min. 
 
 
 
8.3.3 Statistical Analyses 
 
8.3.3.1  Did reperfusion or recanalisation occur more frequently in the 
patients who were thrombolysed?  
The  data  from  211  patients  showed  greater  individual  odds  for  reperfusion 
and/or recanalisation amongst the patients who received thrombolytic therapy 
[statistically  significant  in  the  DIAS  I  trial  (OR  =  4.1,  95%  CI  =  1.3 15.2)  the Nishant Kumar Mishra, 2011.                                                                                       Chapter 8, 198 
 
 
EPITHET trial (OR = 3.7, 95% CI = 1.3 – 10.8) but non significant in DEDAS trial 
[(OR=0.9, 95% CI =0.1 6.9]. Here, the combined data gave a greater adjusted 
odds  for  reperfusion  /  recanalisation  for  the  patients  who  had  thrombolytic 
therapy (at any dosage) [a OR: 3.0; 95% CI = 1.6 5.8; P<0.05, P for heterogeneity 
=0.26 and I
2: 25.7%]   
 
I  repeated  the  analysis  after  excluding  desmoteplase  doses  that  have  been 
abandoned  for  clinical  development:    the  sub analysis  restricted  to 
desmoteplase  90   g/kg  or  rt PA  gave  a OR=2.28;  95%CI  =0.7 7.3,  P=0.165 
[Random Method] and a OR=2.65, 95%CI = 1.3 5.5, P=0.007 [Fixed Method], P for 
clinical  heterogeneity  =0.13  and  I
2:  50.5%].  I  examined  the  underlying 
heterogeneity by L’Abbé plot. Nishant Kumar Mishra, 2011.                                                                                       Chapter 8, 199 
 
 
 
 
 
Figure    8-1Did  reperfusion  or  recanalisation  occur  more  frequently  in  patients  who  were 
thrombolysed?  
Findings  are  shown  from  the  fixed-method  analysis  of  combined  data  (a)  after  exclusion  of 
abandoned doses by fixed (b) and random-method (c) analyses.  
 
 
 
Nishant Kumar Mishra, 2011.                                                                                                     Chapter 8, 200 
 
 
 
 
Figure   8-2 Did reperfusion or recanalisation occur more frequently in patients who were thrombolysed?  
L’Abbé plot shows (a) the complete data set and (b) the abandoned doses excluded for heterogeneity. The circle size denotes the sample size; DIAS, grey circles; DEDAS 
open circles; and EPITHET, black circles. Nishant Kumar Mishra, 2011.            Chapter 8, 201 
 
 
8.3.3.2  Are favourable outcomes more common in the patients who had 
reperfusion?  
The individual odds for favourable clinical outcome in the four studies reporting 
this endpoint were greater in the patients who had reperfusion as compared to 
those who did not reperfuse (DIAS I : OR = 3.4, 95% CI = 1.3 – 8.8;  DEDAS : OR = 
9.6, 95% CI = 1.5 – 64.6; EPITHET : OR=7.2, 95% CI :2.3 to 23.2; DEFUSE : OR = 
5.4,  95%  CI  =  0.94  –  38.1).  For  all  trials  combined,  the  adjusted  odds  were 
greater for the patients who had successful reperfusion as compared to those 
who did not [a OR = 5.2, 95% CI = 3 to 9.1], P for clinical heterogeneity = 0.60, I
2 
:0%]  
 
In a sensitivity analyses in which the DEFUSE trial data were excluded [as the 
DEFUSE was (unlike others) a non randomised prospectively conducted study], 
the a OR remained greater amongst patients with successful reperfusion (a OR = 
5.2, 95% CI = 2.8 to 9.5, P =0.00; heterogeneity statistics p: 0.4 and I
2:0% )  Nishant Kumar Mishra, 2011.            Chapter 8, 202 
 
 
 
 
Figure   8-3 Are favourable outcomes more common in patients who underwent reperfusion?  
Findings  are  shown  from  the  fixed-method  analysis  of  combined  data  (a)  and  after  excluding 
DEFUSE data (b). Nishant Kumar Mishra, 2011.            Chapter 8, 203 
 
 
 
8.3.3.3  Did favourable clinical outcome occur more frequently in the 
thrombolysed group of patients?   
With the exception of DIAS II, all trials had reported non significantly improved 
odds of favourable clinical outcome in the thrombolysis group of patients. (DIAS 
I:  OR  =  2.2,  95%  CI  =  0.7  –  7.44;  DEDAS 
(19):  OR  =  2.4,  95%  CI =  0.4  – 28.0; 
EPITHET:  OR  =  1.7,  95%  CI=  0.7 4.4;  DIAS  II:  OR=0.8,  95%  CI  =0.4 1.6).  The 
combined data analysis failed to show significant benefit (a OR = 1.28 95% CI = 
0.84 1.97), P for clinical heterogeneity = 0.28 and I
2=20.9%. On excluding the 
DIAS II data, a OR: 1.96, 95%CI: 1.06 3.63 and for clinical heterogeneity the I
2:0% 
and P=0.89. 
   
 
I  repeated  the  analysis  after  excluding  desmoteplase  doses  that  have  been 
abandoned for clinical development: with 90ug/kg desmoteplase and rt PA 0.9 
mg/kg  data  alone,  I  found  a OR  =  1.4;  95%  CI  =  0.9 2.3,  P=0.16;  for  clinical 
heterogeneity p=0.56 and, I
2:0%.On excluding the DIAS II data, OR=1.88, 95% CI: 
0.95 3.72 and heterogeneity statistics: I
2= 0%; and p=0.69. L’Abbé’s plots were 
examined for the underlying heterogeneity in these analyses. 
 
Under sensitivity analysis, no differential effect of desmoteplase versus alteplase 
was found, with the ratio of OR=. 0.7 [95%CI: 0.24 to 1.920; P: 0.46]. Nishant Kumar Mishra, 2011.            Chapter 8, 204 
 
 
 
   
 
Figure    8-4 Did a favourable clinical outcome occur more frequently in the thrombolysed 
group of patients? 
Findings are shown from the fixed method analysis of combined data (a), after exclusion of DIAS II 
data (b), and after exclusion of abandoned doses (c). Nishant Kumar Mishra, 2011.            Chapter 8, 205 
 
 
 
 
 
Figure    8-5 Did a favourable clinical outcome occur more frequently in the thrombolysed 
group of patients?  
 
L’Abbé plot examining heterogeneity in the analysis (a) for complete data, (b) for DIAS II data 
excluded,  (c)  for  complete  data  but  abandoned  doses  excluded,  and  (d)  for  DIAS  II  data  and 
abandoned-dose  data  excluded.  The  size  of  the  square  denotes  the  sample  size.  1  indicates 
DEDAS; 2, DIAS I; 3, EPITHET; and 4, DIAS II (black rectangle). Nishant Kumar Mishra, 2011.            Chapter 8, 206 
 
 
 
8.3.3.4  Was there a greater probability of mortality in thrombolysed patients 
compared to those not thrombolysed?   
Here, the individual odds for mortality were non significant in the thrombolysis 
group.  [DIAS  II:OR=  2.4,  95%  CI  =0.7 10.1)  ;  DIAS  I:  OR=  3.6,  95%CI  =  0.5 
161.3;EPITHET trials (OR: 2.7, 95% CI: 0.8 10.9) and the DEDAS
  trial (OR: 0.5, 
95% CI=0.0 34.9)].  The  combined data  analysis  found  a  significant  increase  in 
mortality in the thrombolysis group of patients compared to the placebo group 
[a OR =2.4, 95% CI =1.2 4.9; P=0.02 and P for heterogeneity =0.67 and I
2:0%]. 
 
Repeating  the  analysis  after  excluding  data  from  abandoned  desmoteplase 
doses,  i.e.  restricting  the  analysis  to  patients  treated  with  90   g/kg  of 
desmoteplase or 0.9 mg/kg rt PA, then a OR= 1.6 [ 95%CI: 0.7   3.7 ], P = 0.28 ; 
P for heterogeneity = 0.56 and I
2:0%. 
 
Under sensitivity analysis, no differential effect of desmoteplase versus alteplase 
was found, with the ratio of OR=. 0.8 [95%CI: 0.2 to 3.5; P:0.8] Nishant Kumar Mishra, 2011.            Chapter 8, 207 
 
 
 
 
 
Figure   8-6 Was there a greater probability of mortality in thrombolysed patients compared 
with those not thrombolysed?  
 
 
Findings are shown from the fixed-method analysis of combined data (a) and after exclusion of the 
abandoned-dose data (b). 
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8.3.3.5  Was there a greater probability of SICH in thrombolysed patients 
compared to those not thrombolysed?  
The individual odds for SICH were non significant for the combined data (DIAS I: 
OR=7.9, 95%CI =0.7 infinity; DIAS II: OR=5.9, 95%CI: 0.5 infinity; EPITHET: OR= 
152.6, 95%CI: 15.9 infinity) but the combined odds for SICH were significantly 
greater for the group that underwent thrombolytic therapy (a OR: 24.7, 95%CI : 
5.2 118.2.  Heterogeneity  statistics:  I
2:35.4%,  and  P=0.2].  On  combining  data 
from DEDAS with DIAS I, the findings remained non significant for the individual 
odds (DIAS I + DEDAS: OR=7.1, 95%CI=0.7 infinity) but were significant for the 
combined  analysis  [a OR:  6.5,  95%CI:  1.2 35.4  and  for  clinical  heterogeneity 
p=1.0 and I
2:0%]  
 
Repeating the analysis by excluding the data of abandoned doses, the  findings 
were non significant both for individual odds (DIAS I+DEDAS OR=3.7, 95%CI: 0.03 
infinity;  DIAS  II:  OR=5.7,  95%CI:  0.2 infinity;  EPITHET:  OR=6.5,  95%CI:  0.4 
infinity)  and by combining it with the DIAS I data (a OR 5.4, 95%CI  0.9 31.8), P 
for heterogeneity = 0.97 and I
2:0%  but attained a marginal significance of the 
adjusted  odds  derived  by  excluding  DEDAS  trial  (a OR:  6,  95%CI  1.00 35.8; 
heterogeneity statistics: p:1 and I
2 : 0%). 
 
There occurred no SICH in placebo arms and therefore a sensitivity analysis to 
assess  any  differential  effect  of  desmoteplase  versus  alteplase  could  not  be 
undertaken. Nishant Kumar Mishra, 2011.            Chapter 8, 209 
 
 
 
 
 
Figure   8-7 Was there a greater probability of SICH in thrombolysed patients compared with 
those not thrombolysed?  
Findings are shown from the fixed-method analysis for all studies combined but with DEDAS data 
excluded (a), DEDAS combined with DIAS I data (b), and after exclusion of the abandoned-dose 
data (c). Nishant Kumar Mishra, 2011.                                                                                       Chapter 9, 210 
 
 
 
8.3.3.6  Were there better clinical findings (outcomes or reperfusion) if 
treatment commenced within 3 to 6 hours versus 6 to 9 hours?  
 
Limited data were available to examine OTT and neither the DIAS I 
(20) nor DIAS II 
individually suggested significantly greater odds (DIAS I: OR= 1.07, 95%CI = 0.4 
2.9, P= 0.9; DIAS II: OR= 0.8, 95%CI: 0.4  1.8, P= 0.7). When combined, the a OR 
= 0.9, 95%CI: 0.5  1.7, p=0.8) 
 
 
 
 
 
Figure   8-8:  Were there better clinical findings (outcomes or reperfusion) when treatment 
was commenced within 3 to 6 hours vs. 6 to 9 hours? 
 
 
8.3.4 Analysis of Mortality 
In DIAS I trial, one placebo and two desmoteplase deaths occurred due to cardiac 
causes. In the DIAS II trial, only one of three deaths in the 90  g/kg group and 
three of 14 deaths in125 ug/kg were considered related to the trial medication. 
In the DEDAS trial, the sole death in the 90  g/kg groups was due to aspiration 
pneumonia while that in the 125  g/kg groups was due to evolving neurological 
deterioration of a left MCA infarct, leading to pneumonia.  
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8.4 Discussion  
I undertook a meta analysis of all previous studies that evaluated the principle 
of physiological selection for delayed thrombolysis, based on the presence of 
potentially viable tissue in the ischaemic penumbra.
29,390,391 These trials utilised 
the mismatch hypothesis using either MRI (perfusion/diffusion mismatch) or CTP 
(perfusion/cerebral  blood  volume  mismatch)  as  a  signature  of  the  putative 
penumbra.
109 111,181,183  Apart  from  the  recent  DIAS II  trial
111,  these  trials  had 
supported the physiological basis of the mismatch concept. The disappointing 
findings of the DIAS II trial have been attributed to limitations of the study and 
to  chance.
111,389  To  test  for  consistency,  I  undertook  a  meta analysis  of  the 
studies that studied the mismatch hypothesis to select and thrombolyse patients 
despite delays beyond 3 hours. Five trials (DIAS I, DIAS II, EPITHET, DEFUSE and 
DEDAS)
 109 111,181,183 were available for inclusion.  
 
It  was  a  priori  decided  that  those  studies  would  be  excluded  which  did  not 
undertake prospective enrolment of consecutive stroke patients with mismatch 
profile (for treatment in delayed time window, i.e., beyond 3 hours of stroke 
onset) or did not study mismatch based delayed thrombolysis in a randomised 
controlled design. Hence, I did not include the study by Schellinger et al
45 as it 
was  based  on  pooled  data  (and  not  a  pre planned  prospective  trial)  from  5 
different  centres  and  lacked  in  a  control  arm  that  would  have  prevented 
calculation  of  odds  ratio  in  the  absence  of  a  denominator.  DEFUSE  trial  was 
included in this meta analysis because it was a prospectively conducted clinical 
trial.  Further,  it  reported  reperfusion  data  that  could  be  considered  for  the 
analysis.   
 
The  results  from  this  metaanalysis  indicate  that  reperfusion  and/or 
recanalisation is more common with thrombolysis when all doses are considered 
together but the significance is lost with the exclusion of data on abandoned 
doses of desmoteplase that reduced the power of this analysis through effects on 
sample size.  
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Furthermore,  favourable  clinical  outcome  is  more  common  amongst  patients 
with successful reperfusion of the ischaemic parenchyma, despite delays beyond 
three hours from stroke onset. This conclusion is not influenced by inclusion of 
the  non randomised  DEFUSE
  trial  data.  The  DIAS  II  trial  did  not  report 
reperfusion findings.   
 
However,  I  did  not  find  evidence  from  the  current  analysis  that  favourable 
clinical  outcome  was  significantly  improved  in  the  group  that  underwent 
thrombolysis.  Neither  did  I  find  a  significant  benefit  if  I  excluded  doses  of 
desmoteplase  that  have  been  abandoned  for  clinical  development.  The 
confidence interval around the estimate of effect remains wide and would be 
consistent  with  a  doubling  of  odds  for  favourable  outcome,  though  in  this 
respect DIAS II suggests that the likely upper limit may be 1.5.  Even so, odds of 
1.5 remain greater than those achieved in unselected patients treated with rt PA 
in the ECASS III trial and have been regarded as sufficient to influence national 
and European stroke treatment guidelines (SIGN or ESO
 )
392.   
 
Late treatment even among selected patients may carry some risk. I found a 
marginally significant increase in the odds of death among all treated patients, 
with a point estimate of 2.4. When I restricted the analysis to rt PA 0.9 mg/kg 
and to the dose of desmoteplase that remains under development (90  g/kg), 
the odds ratio for mortality fell to 1.6 and the risk was not significant. Higher 
doses  of  desmoteplase  were  clearly  linked  to  excessive  SICH  and  were 
abandoned for this reason. The current analysis does not take into account the 
attributed  cause  of  death.    Many  deaths  in  DIAS II  and  in  EPITHET  were 
considered  unrelated  to  treatment.  The  attribution  may  be  important  for 
understanding of the mechanism of effect but caution is required when drawing 
conclusions from subjective assessments such as these.  Treatment failure can 
contribute to late death, just as unrecognised excitotoxic damage may represent 
a  potential  mechanism.  Regardless,  if  mortality  is  increased,  this  may  be 
mediated via haemorrhagic transformation.  
 
Despite lack of significance in the individual odds for the SICH in the patients 
given thrombolytic therapy, the adjusted OR indicates a statistically significant 
increase in SICH after delayed thrombolysis. Similarly, an increased risk of sICH Nishant Kumar Mishra, 2011.                                                                                       Chapter 9, 213 
 
 
has long been recognised for time based tPA in the established clinical windows, 
but this is offset by the improved clinical outcomes in the treated patients. On 
excluding  doses  of  desmoteplase  that  have  been  abandoned  for  clinical 
development, the adjusted odds for SICH again lost significance.  
 
Caution is required in interpreting these post hoc sub group analyses. Although 
the inclusion of data from all doses may give a falsely pessimistic view of the 
risk/benefit  profile  after  mismatch based  thrombolysis,  post hoc  exclusion  of 
doses  that  have  been  abandoned  in  clinical  development  is  a  data driven 
decision  and  raises  statistical  concerns  of  bias  that  can  only  be  assuaged  by 
further prospective trials. 
 
I find no evidence that relatively  earlier (3 6h) versus later (6 9h) treatment 
influence  my  findings.    This  is  of  particular  relevance,  since  ECASS III  has 
recently shown unselected patients benefit from alteplase given within 4.5 h of 
stroke onset, and a small proportion of patients in the mismatch trials would 
now be considered eligible for such treatment:  I cannot exclude the possibility 
that  some  of  the  potential  benefit  amongst  mismatch  patients  may  be  time 
dependent but it appears unlikely that this is sufficient to explain all effects.  
 
Now that ECASS III results are known, a further meta analysis using individual 
patient data from the trials studied here should be undertaken to assess clinical 
and radiological outcomes for the patients who were thrombolysed beyond 4.5 
hours of the stroke onset. Similarly, an additional analysis comparing outcomes 
in patients with mismatch versus without mismatch is desirable but was beyond 
the scope of our meta analysis. 
 
The  current  meta analysis  included  data  from  five  different  trials  of  which 
DEFUSE could be considered only in the analysis of favourable clinical outcome 
amongst patients with reperfusion vs. no reperfusion. DIAS II did not report the 
reperfusion findings and had to be excluded where these data were needed. The 
L’Abbe plot
393,394 suggests that DIAS II contributes to the heterogeneity in the 
combined analysis of favourable outcomes in all thrombolysed patients, and the 
DEDAS  trial  to  the  analysis  of  reperfusion  and  recanalisation  in  patients 
thrombolysed  with  the  abandoned  doses  excluded.  Both  these  sources  of Nishant Kumar Mishra, 2011.                                                                                       Chapter 9, 214 
 
 
heterogeneity appeared to affect the results by virtue of the effects of sample 
size on the power of a study. 
 
We  know  that  the  number  needed  to  treat  to  achieve  enhanced  favourable 
outcome with alteplase may be as few as seven within 3h but that this has risen 
by 3 4.5 h to approximately fourteen. When treatment with alteplase is started 
between 4.5 hours and 6 hours OTT the number needed to treat rises to 25. 
Hence, the challenge is to establish whether any patients benefit or donot based 
on multimodal imaging approaches and delayed time wondow. The use of either 
MR imaging to identify perfusion/diffusion mismatch or a CT based alternative is 
attractive.  It  is  clear  from  current  data  that  delayed  thrombolysis  amongst 
patients selected according to mismatch imaging is  associated  with increased 
reperfusion and/or recanalisation and that recanalisation and/or reperfusion is 
associated  with  improved  outcomes.  At  present,  whilst  the  data  remain 
consistent  with  improved  functional  outcome  from  delayed  thrombolysis 
amongst  mismatch  patients,  statistically  significant  benefit  on  functional 
outcomes  has  not  been  confirmed.  Although  the  pooled  results  suggest  that 
mortality may be higher, the retention of excessive doses of desmoteplase in the 
analysis is likely to lead to overestimation of any risk.   
 
It should be noted that existing methods for defining mismatch may be optimised 
in future resulting in greater power of the mismatch based thrombolysis studies. 
For  example,  in  this  analysis,  I  considered  1.2  as  the  cut off  for  defining  a 
mismatch profile. However, a post hoc analysis of the DEFUSE study has recently 
shown that highest sensitivity and specificity occur at a mismatch ratio of 2.6; 
suggesting that the previous studies were probably underpowered and lacked a 
sufficiently  rigorous  definition  for  mismatch  ratio.
182  Further,  the  2 second 
threshold for T max is likely also suboptimal, as a post hoc analysis of DEFUSE 
data have shown a significantly better correlation between infarct growth and 
penumbra salvage volume for PWI lesions defined by Tmax > 6 seconds.
383 The 
EPITHET investigators have reported similar findings.
386 It is now clear that both 
trials  included  significant  volumes  of  benign  oligemia  in  their  mismatch 
assessments.  Recently,  automated  online  analysis  of  MR  mismatch  has  been 
described that facilitates the rapid selection for delayed treatment. In summary, Nishant Kumar Mishra, 2011.                                                                                       Chapter 9, 215 
 
 
the continued refinement in the definitions of different perfusion parameters 
would result in better choice of the best measure of perfusion [T max, TTP, 
MTT, CBV or CBF] and correction for arterial input functions.  
 
Thus, the definitions used in the published trials to date have been generous, 
including many patients who had limited penumbral tissue and limited prospect 
of clinical improvement in response to thrombolysis. The recently formed Stroke 
Imaging Repository (STIR) collaboration has initiated a detailed examination of 
this  topic.
395  The  diversity  of  mismatch  definitions  and  large  number  of 
investigators involved in these studies weaken conclusions about the potential 
value of mismatch in future clinical management of patients with stroke.
198,199  
However, these weaknesses do not extend to our conclusions about the status of 
existing evidence for use of thrombolysis amongst mismatch patients:  patients 
were  selected  according  to  the  best  intentions  of  the  investigators  under 
protocols which were state of the art when written, though they have already 
been  overtaken.    Prospective  phase  III  trials  are  required  to  test  whether 
thrombolysis is associated with a favourable risk/benefit ratio when used under 
modified circumstances.  In Australia, the Extending the Time for Thrombolysis 
in Emergency Neurological Deficits (EXTEND) trial,
396 which will use a phase III 
design  and  randomisation  of  patients  4.5 9  hours  alteplase  or  placebo,  using 
automated mismatch selection, will test this hypothesis.  
 
These data show that delayed thrombolysis amongst patients selected according 
to mismatch imaging is associated with increased reperfusion/recanalisation and 
that recanalisation/reperfusion is associated with improved outcomes. But, not 
all patients that receive alteplase improve in their outcomes. From an analysis 
of combined DEFUSE and EPITHET dataset, treatment effect of t PA was shown 
to be greater amongst those patients that had vessel occlusion at baseline.
46,397  
Further, in a meta analysis, Rha and Saver have also shown strong  association of 
recanalisation  with  improved  outcomes  and  reduced  mortality  in  a  meta 
analysis.
151  It appears logical that the target of thrombolytic therapy should be 
to  achieve  recanalisation.  Hence  trialists  now  aim  to  select  patients  with  
“Vessel  occlusion  or  high grade  stenosis  in  proximal  cerebral  arteries”  for 
treatment until 9 hours of symptoms onset.
46    
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Meantime, while the concept of selection of patients based on their individual 
pathophysiology  rather  than  a  rigid  time  window  remains  attractive,  delayed 
treatment according to mismatch selection cannot be recommended as part of 
routine care until or unless further trials show benefit.  
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Conclusions and future directions       
 
 
9   Conclusions and future directions 
Thrombolytic  therapy  is  the  therapy  of  proven  efficacy  for  the  treatment  of 
acute  ischaemic  stroke.
131  However,  it  has  not  yet  made  a  significant  public 
health impact; very few patients receive this therapy.
228  Many physicians fail to 
administer t PA because they adhere strictly to the stroke guidelines and fear 
that any deviation would increase the risk of haemorrhage. It is known that most 
of the exclusion criteria are based not on negative evidence (showing harm from 
t PA use), but on absence of data from the original trials. Many of the exclusions 
were based on expert opinion which was originally framed to assist recruitment 
of a homogeneous patient population for the trial. Soon after the NINDS trial was 
published,  showing  better  outcomes  in  a  3  hour  time  window,  the  drug  was 
approved in the USA.
24 The European Medicines Agency was reluctant to approve 
its use  (because ECASS I, ATLANTIS and ECASS II failed to confirm the NINDS 
findings), but later did, subject to the fulfilment of conditions that the SITS 
MOST study and  ECASS III trials would be conducted  by  the sponsors.
23 While 
SITS MOST showed that the outcomes from the t PA use in 3 hours window were 
similar  to  the  pooled  RCT  data  (and  can  also  be  used  by  less  experienced 
centres), the ECASS III trial showed that t PA use improved outcomes even in a 
3 4.5 hour time window.
129,146,147 After it was shown that t PA is efficacious until 
a 4.5 hours’ time window, there was a felt need to answer other exclusions that 
were listed in the EMEA document.
23  
 
The  purpose  of  this  thesis  was  to  examine  those  exclusion  criteria,  and 
therefore, I decided to examine the following questions: (a) Whether the benefit 
from t PA use extends to those older than 80 years? (b) Whether those suffering 
from concomitant diabetes and previous stroke have improved outcomes after 
the use of alteplase? (c) Whether the patients having a mild stroke or a severe 
stroke should be treated with alteplase? In addition, I also planned to examine 
whether  use of  thrombolytic therapy  beyond 3  hours  and  based  on mismatch 
criteria could be recommended for routine clinical practice?   
 
So in Chapter 3, I examine Virtual International Stroke Trials Archive (VISTA) 
data to test whether current European recommendation suggesting exclusion of       
 
 
elderly  patients  (older  than  80  years)  from  thrombolysis  for  acute  ischaemic 
stroke  is  justified.  Employing  non randomised  controlled  comparison  of 
outcomes, I show better outcomes amongst all patients (P < 0.0001; OR, 1.39; 
95% CI, 1.26 to 1.54), young patients (P < 0.0001; OR, 1.42; 95% CI, 1.26 to 1.59) 
and the elderly patients (P = 0.002; OR, 1.34; 95% CI, 1.05 to 1.70). Odds Ratios 
are consistent across all age deciles > 30 years. Outcomes assessed by National 
Institutes of Health Scale (NIHSS) score and dichotomised modified Rankin Scale 
score are consistently similar.  
 
In  Chapter  4,  I  compare  thrombolysed  patients  in  Safe  Implementation  of 
Thrombolysis  in  Stroke  International  Stroke  Thrombolysis  Register  (SITS ISTR) 
with  VISTA  non thrombolysed  patients  ("comparators"  or  "controls")  and  test 
exactly  similar  question  as  in  Chapter  3.    Distribution  of  scores  on  modified 
Rankin scale are better amongst all thrombolysis patients than controls (odds 
ratio 1.6, 95% confidence interval 1.5 to 1.7; Cochran Mantel Haenszel P<0.001). 
Association occurs independently amongst patients aged ≤80 (0R 1.6, 95%CI1.5 to 
1.7;  P<0.001;  n=25,789)  and  in  those  aged  >80  (OR  1.4,  95%  CI  1.3  to  1.6; 
P<0.001; n=3439). Odds ratios are consistent across all 10 year age ranges above 
30, and benefit is significant from age 41 to 90; dichotomised outcomes (score 
on modified Rankin scale 0 1 v 2 6; 0 2 v 3 6; and 6 (death) versus rest) are 
consistent with the results of ordinal analysis. These findings are consistent with 
results from VISTA reported in Chapter 3. Age alone should not be a criterion for 
excluding patients from receiving thrombolytic therapy. 
 
In Chapter 5, I employ VISTA data to examine whether patients having diabetes 
and  previous  stroke  have  improved  outcomes  from  use  of  alteplase  in  acute 
ischaemic  stroke.  Employing  a  non randomised  controlled  comparison,  I  show 
that  the  functional  outcomes  are  better  for  thrombolysed  patients  versus 
nonthrombolysed comparators amongst non diabetic (P < 0.0001; OR 1.4 [95% CI 
1.3 1.6])  and  diabetic  (P  =  0.1;  OR  1.3  [95%  CI1.05 1.6])  patients.  Similarly, 
outcomes  are  better  for  thrombolysed  versus  nonthrombolysed  patients  who 
have not had a prior stroke (P < 0.0001; OR 1.4 [95% CI1.2 1.6]) and those who 
have (P = 0.02; OR 1.3 [95% CI1.04 1.6]). There is no interaction of diabetes and 
prior  stroke  with  treatment  (P  =  0.8).  Neurological  outcomes  (NIHSS)  are 
consistent with functional outcomes (mRS).        
 
 
 
In Chapter 6, I undertake a non randomised controlled comparison of SITS ISTR 
data  with  VISTA  controls  and  examine  whether  patients  having  diabetes  and 
previous  stroke  have  improved  outcomes  from  use  of  alteplase  in  acute 
ischaemic  stroke.  I  show  that  adjusted  mRS  outcomes  are  better  for 
thrombolysed  versus  non thrombolysed  comparators  amongst  patients  with 
diabetes  mellitus  (OR  1.45[95%  CI1.30 1.62],  N=5354),  previous  stroke  (OR 
1.55[95% CI1.40 1.72], N=4986), or concomitant diabetes mellitus and previous 
stroke (OR 1.23 [95% CI 0.996 1.52], P=0.05, N=1136), all CMH p<0.0001. These 
are  comparable  to  outcomes  between  thrombolysed  and  non thrombolysed 
comparators amongst patients suffering neither diabetes mellitus nor previous 
stroke: OR=1.53(95%CI 1.42 1.63), p<0.0001, N=19339. There are no interaction 
between  diabetes  mellitus  and  previous  stroke  with  alteplase  treatment  (t 
PA*DM*PS, p=0.5). Present data supports results obtained from the analyses of 
VISTA data in chapter 5. There is no statistical evidence to recommend exclusion 
of patients with diabetes and previous stroke from receiving alteplase.  
 
In Chapter 7, I examine VISTA data to test whether exclusion of patients having a 
mild or severe stroke at baseline would be justified. Stratifying baseline stroke 
severity  for  quintiles  of  NIHSS  scores,  I  observe  that  there  are  significant 
associations  of  use  of  alteplase  with  improved  outcomes  for  baseline  NIHSS 
levels from 5 to 24 (p<0.05). This association lose significance for baseline NIHSS 
categories 1 to 4 (P = 0.8; OR, 1.1; 95% CI, 0.3 4.4; N = 8/161) or ≥ 25 (P = 0.08; 
OR,  1.1;  95%  CI,  0.7 1.9;  N  =  64/179)  when  sample  sizes  are  small  and 
confidence  interval  wide.  These  findings  fail  to  provide  robust  evidence  to 
support  the  use  of  alteplase  in  the  mild  or  severe  stroke  patients,  though 
potential for benefit appears likely. 
 
In  Chapter  8,  I  present  a  meta analysis  of  trials  that  investigated  mismatch 
criteria for patients’ selection to examine whether present evidence supports 
delayed thrombolysis amongst patients selected according to mismatch criteria. 
I collate outcome data for patients who were enrolled after 3 hours of stroke 
onset  in  thrombolysis  trials  and  had  mismatch  on  pre treatment  imaging.  I 
compare favourable outcome, reperfusion and/or recanalisation, mortality, and 
symptomatic  intracerebral  haemorrhage  between  the  thrombolysed  and  non       
 
 
thrombolysed groups of patients and the probability of a favourable outcome 
among patients with successful reperfusion and clinical findings for 3 to 6 versus 
6 to 9 hours from post stroke onset. I identify articles describing the DIAS, DIAS 
II, DEDAS, DEFUSE, and EPITHET trials, giving a total of 502 mismatch patients 
thrombolysed beyond 3 hours. The combined adjusted Odds Ratios (a ORs) for 
favourable outcomes are greater for patients who had successful reperfusion (a 
OR=5.2; 95% CI, 3 to 9; I
2=0%). Favourable clinical outcomes are not significantly 
improved  by  thrombolysis  (a OR=1.3;  95%  CI,  0.8  to  2.0;  I
2=20.9%).  Odds  for 
reperfusion/recanalisation  are  increased  amongst  patients  who  received 
thrombolytic  therapy  (a OR=3.0;  95%  CI,  1.6  to  5.8;  I
2=25.7%).  The  combined 
data show a significant increase in mortality after thrombolysis (a OR=2.4; 95% 
CI,  1.2  to  4.9;  I
2=0%),  but  this  is  not  confirmed  when  I  exclude  data  from 
desmoteplase doses that are abandoned in clinical development (a OR=1.6; 95% 
CI, 0.7 to 3.7; I
2=0%). Symptomatic intracerebral haemorrhage  is significantly 
increased  after  thrombolysis  (a OR=6.5;  95%  CI,  1.2  to  35.4;  I
2=0%)  but  not 
significant after exclusion of abandoned doses of desmoteplase (a OR=5.4; 95% 
CI,  0.9  to  31.8;  I
2=0%).  Delayed  thrombolysis  amongst  patients  selected 
according  to  mismatch  imaging  is  associated  with  increased 
reperfusion/recanalisation.  Recanalisation/reperfusion  is  associated  with 
improved outcomes. However, delayed thrombolysis in mismatch patients was 
not confirmed to improve clinical outcome, although a useful clinical benefit 
remains  possible.  Thrombolysis  carries  a  significant  risk  of  symptomatic 
intracerebral haemorrhage and possibly increased mortality. Criteria to diagnose 
mismatch are still evolving. Validation of the mismatch selection paradigm is 
required with a phase III trial. Pending these results, delayed treatment, even 
according  to  mismatch  selection,  cannot  be  recommended  as  part  of  routine 
care. 
 
In summary, by employing rigorous analysis techniques, I provide some data that  
would serve as a useful source of evidence to the practicing physicians.
398  
 
However,  there  are  challenges  that  are  associated  with  the  use  of  historical 
controls (like VISTA non thrombolysed patients as used in chapters 3 7). In some 
cases, it is possible to adjust for potential sources of bias or to interpret findings 
through internal controls. For example, in assessing effects of thrombolysis on       
 
 
age, the results in the elderly could be compared to those in younger patients 
for whom RCT data are available to support the effect size estimate. Bias is less 
easy to control in the analyses for which comparable RCT data are unavailable. 
Owing to differences in population characteristics, one may observe excessive 
heterogeneity between patients’ subgroups. If the contributing VISTA controls 
data used entry criteria for severity that did not fully encompass those of the 
thrombolysed  group,  then  a  systematic  bias  in  outcomes  would  be  likely. 
Further, geographical or temporal variation in management can generate bias as 
well. Although the historical outcomes in VISTA were rigorously collected, the 
SITS ISTR  data  (Chapters  4  and  6)  are  open  to  bias  through  knowledge  of 
treatment. Further, because SITS ISTR is a registry, one cannot guarantee its 
completeness.  
 
Bias may manifest as overly estimated point estimate: bigger treatment effect 
(point estimates > 1.6 for improved outcomes)
269 for patients with moderate b 
NIHSS  may  indicate  an  imbalance  in  case  mix  (possibly  leading  to  large 
heterogeneity between  each subgroup) rather  than  a  strong treatment  effect 
from  the  use  of  t PA.  I  undertook  analyses  adjusting  for  age  and  baseline 
severity, and then for those covariates that differed at baseline ( if data were 
completely  available),  but,  numerous  other  potential  confounders  remain 
unmeasured or unknown.  For example, the time from stroke onset to use of t 
PA could not be considered in these analyses. The onset to treatment time was 
known for SITS ISTR but an equivalent value was not available in VISTA, where 
onset to randomisation for an investigational product was instead recorded (and 
was different between the t PA and control groups).  Further, these analyses did 
not  control  for  the  centre  effect  which  may  have  influence  on  patients’ 
outcomes.
399  Baseline NIHSS accounts for about 80% of variance in outcomes of 
acute ischaemic strokes, and together with age should normally control for the 
variability in the adjusted analysis.
265,280 The most compelling bias arises from 
the fact that the control patients were not given thrombolysis through clinician 
choice, implying that they may have been ‘unsuitable’ in an immeasurable or 
unrecorded  way.  The  magnitude  of  these  biases  is  unknown  in  these  present 
analyses. Methods employed to adjust for differences at baseline do not confirm 
bias removal.
400  Despite  availability  of  good  prognostic  data,  residual       
 
 
confounding may  still persist.
400  Even  alternative methods like  the  propensity 
scores method do not guarantee removal of bias.  
 
I  based  my  adjusted  analyses  on  CMH  test  and  proportional  odds  logistic 
regression analyses. This approach to data analyses were applied by Lees et al in 
the SAINT trial
271 and have been tested and shown to give reliable estimates on 
other datasets.
269 These also add to the power of the study.
401  The CMH test is 
limited by sample size, and if data on covariates are missing, it may not be able 
to  stratify  beyond  a  limit.  For  example,  in  chapter  7,  fifty nine  per  cent  of 
records lacked coding for the variable “antithrombotic” (i.e. antiplatelet and 
anticoagulants) (N=3432). If the analyses were to be done within each stratum of 
the baseline stroke severity level, there would occur further diminution of the 
available data per stratum. Hence, an adjusted analysis for several covariates 
would be difficult within the stratum. In chapter 3, prior use of antiplatelet and 
anticoagulants was not used for adjusted analyses along with other co variates 
that  had  differed  at  baseline,  because,  by  including  antithrombotic  in  the 
analyses, the effective size of dataset reduced from 4620 to 1930 for the non 
elderly and from 1152 to 454 for the elderly. In chapter 4, adjusted analyses 
were possible for all variables that differed at baseline: the effective sample 
size reduced from 26028 patients to 22148 patients for the non elderly age group 
and  from  3472  to  2593  patients  for  the  elderly  age  group.  Adjustment  by 
regression  analysis  relies  on  assumptions  that  there  is  a  linear  relationship 
between  the  covariates  measured  at  baseline  and  outcomes  at  a  later  time 
point;  and  these  can  be  expressed  by  regression  equation.  However,  the 
assumption that the relationship is linear between the baseline stroke severity 
and outcomes may not always be true.
280,402  
 
Despite these limitations, and pending randomised data, evidence presented in 
this thesis may be found useful by stroke physicians to guide therapy in their 
patients. International Stroke Trial (IST 3) has been enrolling patients in 0 6 hour 
time window for about a decade and will report subgroup analyses on some of 
the  patients  that  are  currently  excluded  from  European  drug  label  (like  the 
elderly). Subgroup analysis of an open label trial spanning a period of >10 years 
will require careful scrutiny. These will be selected patients who may have been 
treated by centres that may have had doubts about their capability to deliver       
 
 
alteplase  safely  or  about  treatment  efficacy.  Owing  to  dismal  prospects  of 
conducting  large  randomised  trials  that  specifically  test  a  hypothesis  of 
outcomes  in  the  specific  subgroups  of  patients  for  which  data  are  currently 
lacking (e.g. concomitant diabetes and previous stroke), data like those that are 
presented  in  this  thesis  may  have  relevance  to  the  routine  clinical  practice. 
Clinicians  should  individualise  the  stroke  therapy  based  on  their  clinical 
judgement.  
 
In the future, I intend to expand this work by examining outcomes in remaining 
exclusion  subgroups.  In  order  to  do  this,  I  have  initiated  collaborations  with 
colleagues  at  various  centres.  Working  together,  I  will  undertake  systematic 
reviews and meta analysis of data. Also, where sufficient data are available, I 
will compare outcomes between thrombolysed and non thrombolysed groups for 
improvement in patients’ outcomes. Whereas in this thesis, I employed adjusted 
analyses  technique,  adjusting  for  age  and  baseline  stroke  severity,  for  any 
further work, I may also consider matching procedures like propensity scores, 
the Mahalanobis method or Kent’s method when dealing with non random data 
like these.
280 
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Appendix 
SAS 9.2 Codes for statistical analyses 
A  PROC  FREQ  function  was  employed  to  run  CMH  test.  In  SAS  9.2  software, 
analyses  employing  a  code  “proc  freq;  tables  A*B*C*D  /  cmh;  run;”  was 
undertaken. Here, the analysis examines association of C with D when adjusted 
by stratification for covariates A and B. 
A  PROC LOGISTIC function was used to fit the proportional odds model.  
 
SITS and VISTA steering committee members 
 
SITS  steering  committee  members  comprised  A  Davalos,  Department  of 
Neurosciences  Hospital  Universitari  Germans  Trias,  Universitat  Autònoma  de 
Barcelona  Ctra  Canyet  s/n  08916  Badalona,  Barcelona,  Spain,  G.  Ford, 
Department  of  Clinical  Pharmacology,  New  Castle  University,  Level  6  Leazes 
Wing  Royal  Victoria  Infirmary,  Newcastle  NE1  4LP;  M.  Grond,  Department  of 
Neurology,  Kreisklinikum  Siegen,  Siegen,  Germany,  W.  Hacke,  Neurologische 
Klinik, Universität Heidelberg ,Im Neuenheimer Feld 400 , 69120 Heidelberg; M. 
Hennerici, Department of Neurology University Hospital Mannheim University of 
Heidelberg  68167  Mannheim;  M.  Kaste  Department  of  Neurology,  Helsinki 
University Central Hospital, University of Helsinki, Finland; V. Larrue, Dept of 
Neurology,  Toulouse  University  Hospital,  Toulouse,  K.R.  Lees,  Institutes  of 
Cardiovascular  and  Medical  Sciences,  University  of  Glasgow,  UK;  R.O.  Roine, 
Turku University Central Hospital, Turku, Finland, D. Toni, Dept of Neurological 
Sciences, University 'La Sapienza', Rome,Italy; N. Wahlgren (Chair), Department 
of Neurology, Karolinska University Hospital, Stockholm, Sweden. VISTA Steering 
Committee  members  comprised  K.R.  Lees  (Chair),  MD,  Institutes  of 
Cardiovascular  and Medical Sciences, University  of  Glasgow, UK;  L. Claesson,        
 
 
AstraZeneca LLP,  Södertälje, Sweden; E. Bluhmki, PhD, Boehringer Ingelheim, 
Biberach, Germany; B. Gregson, Dept. of Neurosurgery, Newcastle University, 
Newcastle  General  Hospital,  UK;  G.  Donnan,  MD,  Neurology,  University  of 
Melbourne,  Australia;  H.  C.  Diener,  MD-PhD,  Department  of  Neurology, 
University  Duisburg Essen,  Hufelandstrasse,  Essen,  Germany;  J.  Grotta,  MD, 
Department of Neurology, University of Texas, Houston Medical School, USA; J. 
Marler,  MD,  Food  and  Drug  Administration  ,  USA;  P.  Teal,  MD,  Professor  of 
Stroke Neurology, University  of  British Columbia, Vancouver.;  M.G. Hennerici  
MD-PhD,  Department  of  Neurology,  University  of  Heidelberg,  Germany;  N.G. 
Wahlgren,  MD  PhD,  Karolinska  Hospital,  Stockholm,  Sweden;  P.  Lyden,  MD 
Cedars Sinai  Medical  Center,  Los  Angeles,  USA;  P.W.  Bath,  MD  Institute  of 
Neuroscience,  University  of  Nottingham,  UK;  R.  Sacco,  MD  Miller  School  of 
Medicine, University of Miami, USA; S.M Davis, MD Department of Neurology, 
Royal Melbourne Hospital, University of Melbourne, Australia; W. Hacke, MD PhD 
Department of Neurology, University of Heidelberg, Germany; S. Warach, MD 
National  Institute  of  Neurological  Disorders  and  Stroke,  USA;  M.  Fisher,  MD, 
Dept  of  Neurology,  University  of  Massachusetts  Medical  School,  USA;  M. 
Hommel,  MD  Joseph  Fourier  University,  Grenoble,  France;  M.  Kaste,  MD 
Department  of  Neurology,  Helsinki  University  Central  Hospital,  University  of 
Helsinki, Finland; K. Muir, MD, Division of Clinical Neurosciences, University of 
Glasgow, Glasgow, UK; A. Shuaib, MD, Director, Stroke Program, University of 
Alberta, Canada; C. Weimar, MD Department of Neurology, University Hospital 
Essen,  University  of  Duisburg Essen,  Essen,  Germany;  A.  Alexandrov,  MD 
University of Alabama Hospital, Birmingham, AL, USA. Once the approval was 
obtained, request for data was made to the VISTA co ordinator, Dr Myzoon Ali 
and the SITS ISTR co ordinator, Dr Niaz Ahmed.  
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